Molecular characterization and optimization of enzymes involved in glycosaminoglycan biosynthesis by Raedts, J.G.J.
  
Molecular characterization and 
optimization of enzymes involved in 
glycosaminoglycan biosynthesis 
 
J.G.J. (John) Raedts 
  
 
 
 
 
 
 
 
 
 
 
 
Thesis committee 
 
Thesis supervisor 
Prof. dr. J. van der Oost 
Personal Chair at the Laboratory of Microbiology 
Wageningen University 
 
Thesis co-supervisor 
Dr. S.W.M. Kengen 
Assistant Professor at the Laboratory of Microbiology 
Wageningen University 
 
Other members 
Prof. dr. G. Eggink, Wageningen University 
Prof. dr. ir. H. Gruppen, Wageningen University 
Prof. dr. W.J.H. van Berkel, Wageningen University 
Dr. M.H.M. Eppink, Synthon B.V., Nijmegen 
 
This research was conducted under the auspices of the Graduate School VLAG 
  
 
Molecular characterization and 
optimization of enzymes involved in 
glycosaminoglycan biosynthesis 
 
J.G.J. (John) Raedts  
 
 
 
 
 
 
 
 
 
Thesis 
submitted in fulfillment of the requirements for the degree of doctor 
at Wageningen University 
by the authority of the Rector Magnificus 
Prof. dr. M.J. Kropff, 
in the presence of the 
Thesis Committee appointed by the Academic Board 
to be defended in public 
on Friday 21 October 2011 
at 1.30 p.m. in the Aula. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
J.G.J. (John) Raedts 
 
Molecular characterization and optimization of enzymes involved in            
glycosaminoglycan biosynthesis (160 pages). 
 
PhD thesis, Wageningen University, The Netherlands (2011) 
With propositions and summaries in English and Dutch 
 
ISBN: 978-94-6173-019-0
  
Contents 
 
 Aim and outline 1 
Chapter 1 Introduction                                                                         
Heparin and heparin-like glycosaminoglycans 
5 
Chapter 2 Occurrence of L-iduronic acid and putative D-glucuronyl C5-
epimerases in prokaryotes 
31 
Chapter 3 Evidence for D-glucuronyl C5-epimerase activity in the 
bacterium Bermanella marisrubri sp. RED65 
51 
Chapter 4 Microbial production of the murine heparan sulfate D-
glucuronyl C5-epimerase 
71 
Chapter 5 Improved production of Pasteurella multocida hyaluronan 
synthase in Escherichia coli 
91 
Chapter 6 Correlated mutation analysis as a tool for smart library 
design to improve Pyrococcus furiosus phosphoglucose 
isomerase activity 
103 
Chapter 7 Summary and general discussion 117 
 Nederlandse samenvatting 143 
 Dankwoord 147 
 Curriculum Vitae 151 
 List of Publications 152 
 Overview of completed training activities 153 
 
 
  Aim and outline  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 2 
Aim and outline 
The research described in this thesis is part of B-Basic project 3.5 entitled “Directed 
evolution of glycosaminoglycan synthases and glycosaminoglycan modifying enzymes”. 
During this research project we explored alternative ways of controlled chemo-enzymatic 
synthesis of monodisperse and uniform glycosaminoglycans for pharmaceutical applications, 
with a main focus on heparin. The D-glucuronyl C5-epimerase was recognized as a key 
enzyme in heparin biosynthesis. Two alternative approaches were taken to get closer to an 
industrial applicable enzyme; improvement of the murine (mouse) C5-epimerase and 
identification and characterization of novel candidate C5-epimerases isolated from 
prokaryotes. 
 
Chapter 1 is an introduction to the work presented in this thesis. It gives an overview on 
glycosaminoglycans, mainly concentrating on hyaluronan and heparin. Their biological roles 
and biosynthesis are discussed, with main focus on the C5-epimerization of D-glucuronic acid 
into L-iduronic acid in heparin biosynthesis. This reaction is facilitated by heparan sulfate D-
glucuronyl C5-epimerase. 
 
Chapter 2 is an overview of prokaryotic candidate D-glucuronyl C5-epimerases. The 
occurrence of L-iduronic acid in microorganisms is reviewed, and candidate C5-epimerases 
are identified by in silico screening using animal heparan sulfate D-glucuronyl C5-epimerases 
as a query. Potential physiological implications of these candidate C5-epimerases are 
discussed. 
 
Chapter 3 describes the cloning, expression and purification of a selection of prokaryotic 
candidate C5-epimerases using Escherichia coli BL21(DE3) as a host. All candidate C5-
epimerases could be expressed successfully, some have been purified and used to initiate 
crystallization trials. The candidate C5-epimerase have been tested for activity using an 
HPLC-PAD method optimized for hexuronic acid analysis. Hydrolyzed reaction mixture of de-
O-sulfated heparin and the candidate C5-epimerase from the bacterium Bermanella 
marisrubri sp. Red65 shows conversion of L-iduronic acid to D-glucuronic acid. This implies 
the first experimental proof of D-glucuronyl C5-epimerase activity in a prokaryote. 
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Chapter 4 presents the attempts of the heterologous expression of the murine D-glucuronyl 
C5-epimerase gene in an industrially applicable expression system. Two different expression 
hosts have been tried; both expression in Pichia pastoris (yeast) as Escherichia coli. No 
protein production has been observed in P. pastoris. Gene expression in E. coli only results in 
the production of soluble protein when the enzyme is N-terminally fused to maltose binding 
protein (MBP). Truncation studies indicate increased solubility upon N-terminal truncations. 
Activity has been confirmed indication functional heterologous expression of the murine D-
glucuronyl C5-epimerase in E. coli. 
 
Chapter 5 describes a comparison study of Pasteurella multosida hyaluronan synthase 
(pmHAS) production. This enzyme has been functionally expressed in the past. However, 
limitations exist in expression levels, protein purification and protein stability. Fusion of this 
protein to a protein tag possibly helps overcome some of these problems. In this chapter we 
compare pmHAS expression and activity when fused to an polyhistidine-tag and fused to 
maltose binding protein (MBP). 
 
Chapter 6 gives an example of protein improvement by “smart library design”. We screened 
a mutant library of Pyrococcus furiosus phosphoglucose isomerase (PfPGI) for differences in 
PGI activity. The mutations are based on Comulator predictions, a computational method to 
identify correlated amino acid residues. Two conserved and correlated amino acid residues 
are varied in PfPGI. By enzyme kinetics we indicate a correlation between amino acid 
prevalence and elevated PGI activity. This higher activity is specific for manganese as 
cofactor, which might indicate changes in metal affinity. 
 
Chapter 7 summarizes and discusses the results described in the previous chapters of this 
thesis. Three bottlenecks to overcome are discussed; ways to improve glycosaminoglycan 
modifying enzyme stability are discussed, suggestions are made on usable methods to assay 
D-glucuronyl C5-epimerase activity and potential key residues and the protein fold of the 
heparan sulfate D-glucuronyl C5-epimerases are discussed. 
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Introduction 
Carbohydrates are key building blocks ubiquitously found in all forms of life. The self-
explanatory name already suggests the chemical nature of these molecules. Being hydrated 
carbon based molecules, the structure generally exists of carbon, hydrogen and oxygen 
atoms. Although all carbohydrates are almost exclusively composed of these elementary 
atoms, an enormous variety exists. Most of this diversity reflects the combination of distinct 
building blocks (monosaccharides), leading to long linear or branched polysaccharides. 
Many different polysaccharide structures exist. Glycosaminoglycans (GAGs) are a 
highly abundant type of biological active polysaccharides predominantly found in animals. 
Glycosaminoglycans are long linear anionic hetero-polysaccharide chains, also referred to as 
mucopolysaccharides, that consist of repeating disaccharide units consisting of a hexuronic 
acid and a hexosamine. The latter is either a D-glucosamine (GlcN) or a D-galactosamine 
(GalN). The hexuronic acid is a D-glucuronic acid (GlcA) or its C5-epimer L-iduronic acid 
(IdoA). The GAG keratan sulfate is an exception, it has the hexose D-galactose (Gal) instead 
of a hexuronic acid. The disaccharide composition differs per type of GAG, and can vary both 
in sugar content and glycosidic linkage. The main classification of all described GAGs is based 
on these differences. The most common glycosaminoglycans are chondroitin sulfate, 
dermatan sulfate, heparan sulfate, heparin, hyaluronan and keratan sulfate (Table 1). 
 
Table 1 – Overview of most common glycosaminoglycans 
Glycosaminoglycan  Main disaccharide Sulfation pattern Localization 
Chondroitin sulfate -4)-GlcA-β(1,3)-GalNAc-β(1- GalNAc at C4 / C6,        
GlcA at C2 
cartilage, bone, heart 
valves 
Dermatan sulfate -4)-IdoA-α(1,3)-GalNAc-β(1- GalNAc at C4 / C6,        
IdoA at C2 
skin, blood vessels, 
heart valves 
Heparan sulfate -4)-GlcA-β(1,4)-GlcNAc-α(1- GlcA(IdoA) at C2, 
GlcNAc(NS) at C6 / C3 
cell surface 
membranes, ECM 
Heparin -4)-IdoA-α(1,4)-GlcNS-α(1- like heparan sulfate    
but heavier sulfated 
mast cells (e.g. lungs, 
liver, skin) 
Hyaluronan -4)-GlcA-β(1,3)-GlcNAc-β(1- completely unsulfated 
chain 
synovial fluid, eye, 
ECM, skin 
Keratan sulfate -3)-Gal-β(1,4)-GlcNAc-β(1- Both Gal and GlcNAc     
at C6 
cornea, bone, 
cartilage 
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Glycosaminoglycans are often sulfated at various positions, resulting in another 
differentiating feature apart from differences in disaccharide composition. The fact that this 
sulfation pattern can vary within any given type of GAG, implies that the heterogeneity of 
GAGs is enormous. Additional consequence of these sulfate additions, is the highly negative 
charge of glycosaminoglycans. Together with the carboxyl group of the hexuronic acids, this 
results in the GAG heparin being the most negatively charged biological macromolecule 
known (Lindahl, 1997). 
Most glycosaminoglycans can be found in large quantities in specific cell structures 
called proteoglycans. These large structures consist of a linear core protein with many 
glycosaminoglycans covalently linked to it. Each glycosaminoglycan is linked to the core 
protein via a Gal-Gal-Xyl sugar linker, where the xylose (Xyl) is attached to a serine residue of 
the core protein and the glycosaminoglycan is linked to the galactose (Gal) residue. Also 
proteoglycans are highly diverse; variations occur both in the type of core protein and in 
type, size and number of glycosaminoglycans. 
 
Overview common heparin-like glycosaminoglycans 
A wide variety of glycosaminoglycans have been characterized to date. In this thesis the 
focus is on [GlcNAc – GlcA/IdoA] containing GAGs. An overview of these glycosaminoglycan 
structures can been found in Figure 1. A more detailed description of each individual 
glycosaminoglycan is given in this paragraph. 
 
Heparin | The first report of heparin was nearly a century ago (Howell and Holt, 1918). It 
took another twenty years before the relevance of heparin as a pharmaceutical application 
became clear, when in 1935 heparin was first described as a clinical anticoagulant (Linhardt, 
1991). Even though an application was found, it lasted until the 1960s before L-iduronic acid 
was identified as the major uronic acid residue (Cifonelli and Dorfman, 1962; Perlin et al., 
1968). Subsequently, a general structure of heparin could be elucidated, and more insight in 
the molecular mechanism behind the anticoagulation effect was obtained. 
Heparin is widely distributed among animals, including mammals, birds, fish. Also 
from invertebrates like insects, worms, lobsters and clams, heparin-like structures have been 
isolated (Linhardt and Toida, 1997; Luppi et al., 2005; Im et al., 2010). Also these heparin-like 
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compounds can have anticoagulant activities, even though not all these organisms have a 
blood coagulation system (Nader et al., 1999; Medeiros et al., 2000). To date (clinical) 
heparin is still most efficiently obtained by isolation as a polydisperse mixture from animal 
tissue that is rich in mast cells. Initially a frequently used source was liver (hepatos in Latin), 
resulting in the name heparin. Nowadays, heparin is isolated from highly vascularized tissue 
derived as side-product from livestock. Examples of such tissue include (porcine) intestine 
tissue and (bovine) lung tissue, although the latter is banned from US and European markets 
since the outbreak of bovine spongiform encephalopathy (BSE) in the 1990’s. The extraction 
of heparin requires rather large quantities of animal tissue; one kg of tissue typically results 
in as little as 150 mg of isolated heparin (Alban, 1997). 
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Figure 1 – Chemical structure of the repetitive disaccharide unit of the described glycosaminoglycans. 
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Many proteins have been described that can bind heparin. Binding is mainly due to the large 
number of negatively charged residues present in these GAGs, which highly contribute to 
electrostatic interactions based binding. Two well-studied examples of heparin protein 
interactions are fibroblast growth factor 2 (FGF-2) and antithrombin. For both proteins the 
minimal binding structure is a pentasaccharide, although both pentasaccharides have a 
dissimilar chain modification motif (Fig.2). Binding of heparin by FGF-2 requires an N-
sulfated-D-glucosamine and an L-iduronic acid that is 2-O-sulfated (Lindahl, 1997). Structural 
data of heparin bound to basic fibroblast growth factor is available and amino acid residues 
involved in heparin binding have been characterized. However these residues are found not 
to be conserved throughout the FGF family (Faham et al., 1996). 
Structural data also is available of antithrombin-heparin interactions (Lindahl et al., 
1979). The pentasaccharide sequence required for binding (Thunberg et al., 1982) is 
depicted in Figure 2. Binding of heparin by the serine protease inhibitor antithrombin leads 
to inactivation of several members of the coagulation cascade including thrombin (Factor II) 
and Factor Xa (Bourin and Lindahl, 1993). The coagulation activity of thrombin, which is a 
serine protease, is based on the conversion of soluble fibrinogen into insoluble strands of 
fibrin. Thrombin can be released from prothrombin by prothrombinase (Factor Xa), the 
activated form of the serine endopeptidase Factor X. 
 
Heparan sulfate | A glycosaminoglycan highly similar to heparin is heparan sulfate. For some 
time heparan sulfate was mainly an unwanted by-product of heparin purification. However, 
as more insight in its biological distribution and roles became known, heparan sulfate is now 
recognized as a large group within the family of glycosaminoglycans. Consequently, heparin 
now is regarded as just one of the members within the family of heparan sulfate (Casu and 
Lindahl, 2001). 
Heparan sulfate is structurally closely related to heparin. Similar to heparin, the 
polysaccharide backbone consists of repetitive dimers of D-glucosamine 1-4 linked to D-
glucuronic acid (Fig.1). The number of modifications on the backbone, however, is less than 
for heparin, especially the degree of sulfation and C5-epimerization. Heparan sulfate 
generally has less than one sulfate group per disaccharide, while heparin on average has 
three (Linhardt et al., 1992). The same holds true for the hexuronic acid content; while 
heparan sulfate predominantly consists of D-glucuronic acid, hexuronic acid residues in 
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heparin are up to 90% L-iduronic acid. Also the chain length of heparan sulfate is typically 
longer and more polydisperse than that of heparin (Griffin et al., 1995). 
Heparan sulfate is believed to be ubiquitously present in the animal kingdom, with an 
exception of sponges (Nader et al., 1999; Medeiros et al., 2000). Although structurally 
related to heparin, it differs in topology and biological roles (Conrad, 1998). Heparan sulfate 
is located at the external surface of cell membranes and the extracellular matrix (ECM) as 
part of a proteoglycan. It has a role in multiple specific cell-cell and cell-protein interactions. 
Heparan sulfate is involved in many processes, mostly related to regulation of cell growth 
and development, proliferation and cell adhesion (Wight et al., 1992; Perrimon and 
Bernfield, 2000). Numerous compounds have been found to interact with heparan sulfate 
proteoglycans, e.g. signaling molecules like growth factors, cytokines, morphogens, enzymes 
and extracellular matrix proteins. These binding properties result in involvement of heparan 
sulfate in diseases like viral invasions e.g. herpes simplex virus 1 (Shukla et al., 1999). Tumor 
metastasis involves the deregulated release of heparan sulfate due to enhanced heparanase 
activity (Hulett et al., 1999; Vlodavsky et al., 1999). Another disorder based on deregulation 
of glycosaminoglycan-acting enzymes is mucopolysaccharidosis (MPS), which is the inability 
to degrade glycosaminoglycans due to an inherited mutation, resulting in accumulation of 
glycosaminoglycans in lysosomes. As much as ten different forms are described, two of 
which are a result of deficiencies in α-L-iduronic acid acting enzymes; a mutation in the α-L-
iduronidase gene results in MPS I (Hurler syndrome) while MPS II (Hunter syndrome) is the 
result of a mutation in the iduronate sulfatase gene. 
 
Hyaluronan | Hyaluronan, also referred to as hyaluronic acid, is a glycosaminoglycan with a 
rather simple structure. Although the polymer consists of the same building blocks as 
heparin and heparin sulfate, it differs in that the disaccharides are connected via different 
glycosidic bonds. In addition hyaluronic acid is the only GAG that is completely unsulfated. 
The polymer generally is a very long molecule, that is built from as many as 2,000-25,000 
disaccharide repeats, resulting in molecules of up to 107 Da (Chong et al., 2005). The 
polymer consists of D-glucuronic acid β(1-3) linked to N-acetyl-D-glucosamine β(1-4) (Fig.1) 
(Weissmann and Meyer, 1954). Like all GAGs, hyaluronic acid has a large number of anionic 
residues, resulting in a large water binding capacity. Even at low concentration it has viscous 
hydrated gel forming properties. Even though the primary structure is rather simple, a wide 
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variety of secondary structures can occur, resulting in different biological functions. It is 
believed that high molecular weight hyaluronan molecules adopt an anti-parallel β-sheet like 
tertiary structure, stabilized by specific H-bonds and hydrophobic bonds (Scott and Heatley, 
1999). Low molecular weight molecules do not adopt this structure.  
Hyaluronic acid is involved in various biological processes, and can be found in 
various kinds of tissue (Laurent et al., 1996; George, 1998). Hyaluronan plays important roles 
in the extracellular matrix (ECM). For example, hyaluronic acid is found in abundance in the 
ECM of load-bearing joints. Hyaluronan absorbs significant amounts of water providing a 
turgor pressure, crucial for its structural role in connective tissue (Fraser et al., 1997). This 
water binding capacity also is crucial in the hydration balance. Additionally, hyaluronan has a 
regulatory effect since it can be bound by various cell surface receptors. It has a role in 
various stages of cell growth including embryonic development, cell migration, cell 
proliferation, inflammations, healing processes and tumor growth (Sherman et al., 1994). 
The first isolation of hyaluronan was from the vitreous body of the eye, hyaloid in 
Greek, hence the name hyaluronan (Meyer and Palmer, 1934). Other tissues in vertebrates 
being rich in hyaluronic acid include the umbilical cord, the synovial fluid in joints and the 
dermis. The highest concentration of hyaluronic acid reported in animal tissue, is in rooster 
combs, making it a commonly used source for industrial hyaluronan isolation. 
 
Acharan | Acharan sulfate is a non-canonical glycosaminoglycan, whose structure has high 
resemblance with heparin. This polysaccharide has been isolated from the giant African snail 
Achtina fulica (Kim et al., 1996). The major repeating disaccharide structure is determined 
(Fig.1) as [→4)-α-D-GlcNAc-(1→4)-α-L-IdoA2S-(1→], although to a lesser extent also 
unsulfated disaccharides can be present (Kim et al., 1998). The hexuronic acid in acharan 
sulfate is 100% L-iduronic acid (Chi et al., 2006). However, the most remarkable difference 
compared to heparin, is the acetylation of the D-glucosamine residues. In heparin 
biosynthesis C5-epimerization of D-glucuronic acid is only possible when the GlcNAc is de-N-
acetylated and subsequently re-N-sulfated. The acetylated amine group in acharan sulfate 
might indicate either a heparan sulfate D-glucuronyl C5-epimerase that is less substrate 
specific or an additional and alternative D-glucuronyl C5-epimerase. Unfortunately no 
genome data is available for this species to date, and therefore putative differences in the 
C5-epimerases remain unclear. 
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Glycosaminoglycan biosynthesis 
The variation in glycosaminoglycan chain complexity is a result of essential differences in 
their biosynthesis. While the biosynthesis of hyaluronan is restricted to only a few steps, the 
biosynthesis of heparin / heparan sulfate is a rather complex multistep process. An overview 
of the biosynthesis of both types of glycosaminoglycans is given below. 
 
Biosynthesis of hyaluronic acid 
Hyaluronan is synthesized in the plasma membrane by one specific glycosyltransferase called 
hyaluronan synthase (HAS). This enzyme is an integral membrane protein containing 
multiple membrane domains present throughout the protein sequence. One single 
glycosyltransferase domain (GT2) is responsible for the transfer of the two different UDP-
sugars; UDP-GlcNAc and UDP-GlcA (Weigel et al., 1997). These UDP-sugars are placed either 
at the reducing end (e.g. in mouse; MmHAS and human; HsHAS) or at the non-reducing end 
(e.g. frog; XlHAS) of the growing hyaluronan molecule (Wiegel and DeAngelis, 2007). The 
hyaluronan chain polymerizes on the cytoplasmic side of the plasma membrane. In 
vertebrates the chain growth is in a processive way. This means that upon release from the 
hyaluronan synthase, the growing hyaluronan chain cannot be further elongated. In 
vertebrates as much as three isoforms (HAS1, HAS2, HAS3) of the hyaluronan synthase exist; 
in both human and mouse these have been identified and characterized (Spicer et al., 1997). 
All three isoforms have HAS activity, but differ in the chain length of the hyaluronan 
molecules that they produce and the ease with which produced hyaluronan molecules are 
released from the cell surface (Itano and Kimata, 2002). 
 
Biosynthesis of heparin and heparan sulphate 
Unlike hyaluronan biosynthesis, the biosynthesis of heparin and heparan sulfate is a 
multistep process. The wide variation in the different heparan sulfate sequences is caused by 
the many enzymes involved in the biosynthesis of these glycosaminoglycans (Lindahl et al., 
1998). Over thirty different enzymes are involved, including multiple glycosyltransferases, 
multiple sulfotransferases and a single C5-epimerase (Esko and Selleck, 2002). Most of these 
enzymes are so-called type II transmembrane proteins and are believed to be localized in the 
Golgi apparatus. The whole biosynthesis can be divided into three parts: (1) chain initiation, 
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(2) chain polymerization and (3) chain modification. A schematic representation is provided 
in figure 2 (Sasisekharan and Venkataraman, 2000; Esko and Lindahl, 2001; Habuchi et al., 
2004; Mizumoto et al., 2005; Lindahl and Li; 2009). 
 
Xyl transferase
Gal transferase I
Gal transferase II
GlcA transferase I
α-GlcNAc transferase I
α-GlcNAc transferase II
β-GlcA transferase II
GlcNAc N-deacetylase/ N-
sulfotransferase
GlcA C5-epimerase
2-O-sulfotransferase
6-O-sulfotransferase
3-O-sulfotransferase
FGF-1/FGF-2 antithrombin
Chain  
initiation
Chain 
polymerization
Chain 
modification
= xylose
= galactose
= glucuronic acid
= iduronic acid
= glucosamine
= sulfate group
 
Figure 2 – Schematic representation of heparin / heparan sulfate biosynthesis. The epimerization step is the 
second step in the chain modification, and only possible upon the N-deacetylation / N-sulfation step of the N-
acetyl-D-glucosamine residue attached at the C4 of that specific D-glucuronic acid residue (Jacobsson et al., 
1984). Subsequent O-sulfatation steps of the hexuronic acid or flanking D-glucosamine residues results in the 
protection of the hexuronic acid residue for further epimerization. Picture based on (Esko and Lindahl, 2001). 
 
Chain initiation | Most glycosaminoglycans contain the common GAG-protein linkage 
tetrasaccharide D-GlcA-β(1→3) – D-Gal-β(1→3) – D-Gal-β(1→4) – D-Xyl- β(1→O) – Ser. The 
chain initiation of the glycosaminoglycan starts with the xylosylation of a Serine (Ser) residue 
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of the core protein, catalyzed by a Xylosyltransferase (XylT). Subsequently, two 
galactosyltransferases (Gal-I and Gal-II) are responsible for the attachment of two D-
galactose-residues (Gal) to the xylose-residue (Xyl). The linkage tetrasaccharide is completed 
after addition of a D-glucuronic acid (GlcA) residue to the Gal-residue, catalyzed by a 
glucuronyltransferase (GlcAT-I). All sugars are added at the non-reducing end of the chain, 
and originate from UDP-sugar, with UDP being released upon sugar-transfer. 
 
Chain polymerization | The polymerization of heparin / heparan sulfate is mediated by a 
hetero-oligomeric complex of two glycosyltransferases; EXT1 and EXT2 (McCormick et al., 
2000). In vivo this complex is localized in the Golgi apparatus (McCormick et al., 1998; Lind et 
al., 1998). It is responsible for the polymerization by alternating addition of D-glucuronic acid 
(GlcA) and N-acetyl-D-glucosamine (GlcNAc) linked by a 1→4 glycosidic bond. The residues 
are added to the non-reducing termini of the growing chain, leading to a homogeneous non-
sulfated glycosaminoglycan called heparosan. 
 
Chain modification | The polymerization reactions result in the heparin backbone 
(heparosan), a uniformly repetitively polysaccharide of GlcNAc and GlcA. To obtain heparin 
and heparan sulfate, up to six different modifications of the heparosan molecule are 
required. 
The first two modifications are catalyzed by a single enzyme. The bifunctional enzyme 
N-deacetylase / N-sulfotransferase (NDST) is responsible for replacement of most N-acetyl 
groups of the GlcNAc residues by N-sulfated groups (Kjellén, 2003). As much as four different 
isoforms have been described in human and mouse (Aikawa et al., 2001). Each isoform has 
its unique preference in the acetylation : sulfation ratio of the GlcNAc residue. This 
difference contributes to the large variation in N-acetylation / N-sulfation patterns of D-
glucosamine in heparin and heparin sulfate. N-sulfation is essential determining the overall 
extent of modification of the polymer chain, as some of the subsequent modification steps 
recognize only N-sulfated glucosamine.  
The next modification step is the conversion of D-glucuronic acid (GlcA) residues into 
L-iduronic acid (IdoA) catalyzed by a D-glucuronyl C5-epimerase. In mammals only one single 
isoform of this enzyme is present. It has been demonstrated that GlcA is recognized as a 
substrate, when it is linked at C-1 to an N-acetyl-D-glucosamine and at C-4 to an N-sulfated-
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D-glucosamine (Lindahl et al., 1984). The reverse structure is not recognized as a substrate, 
but a GlcA residue between two N-sulfated residues is recognized as substrate as well. 
Different than other described heparin modifying enzymes, the C5-epimerization of D-
glucuronic acid in heparin biosynthesis is the only step that cannot be done chemically to 
date and therefore completely depends on enzymatic catalysis (Li, 2010). 
The last three polymer modifying steps are all O-sulfation steps, catalyzed by three 
different O-sulfotransferases. All these sulfotransferases use adenosine 3’-phosphate 5’-
phosphosulfate (PAPS) as a sulfate donor. The first O-sulfation step involves the sulfation of 
the C2 of the hexuronic acid. The responsible enzyme uronosyl-2-O-sulfotransferase (2-OST) 
both reacts on GlcA and IdoA, although it prefers the latter (Rong et al., 2001). GlcA is only 
sulfated occasionally while IdoA is sulfated ranging from 50 to 90% (Safaiyan et al., 2000). 
The 2-OST is likely to be physically associated to the C5-epimerase in vivo. Both enzymes co-
localize in the Golgi-apparatus (Pinhal et al., 2001). Enzyme stability and activity of both, is 
enhanced by this physical association. However, the subsequent 2-O-sulfation is not a 
prerequisite for the formation of IdoA residues, as the C5-epimerase is active without 2-OST. 
The other two sulfation steps both act on the D-glucosamine-residues. A D-
glucosamine-6-O-sulfotransferase is responsible for sulfation at C-6 of a GlcN, while the C-3 
of GlcN can be sulfated by a D-glucosamine-3-O-sulfotransferase. In contrast to 2-OST, there 
are multiple isoforms identified of both 6-OST (three isoforms) and 3-OST (at least five 
isoforms). These isoforms are expressed in a tissue and developmental stage dependent way 
(Habuchi et al., 1999; Shworak et al., 1999). In parallel to the C5-epimerization step, also the 
2-O-sulfation and 6-O-sulfation steps occur frequently, although sulfation-levels are tissue 
specific (Safaiyan et al., 2000). The number of 3-O-sulfated residues are relatively low in 
heparin sulfate / heparin. 
 
Hexuronic acid C5-epimerization 
The previous paragraph describes all reaction steps involved in heparin / heparan sulfate 
biosynthesis. The C5-epimerization of hexuronic acids, being part of a glycosaminoglycan, 
cannot be performed chemically and therefore is considered as a bottleneck in controlled in 
vitro synthesis of heparin. The next paragraph focuses on this specific reaction and the 
involved enzyme. Three distinct types of C5-epimerases have been described to be able to 
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catalyze the C5-epimerization of hexuronic acids (Valla et al., 2001); one polymannuronic 
acid C5-epimerase and two distinct D-glucuronyl-C5-epimerases (Fig.3). Each of these 
enzymes has a very limited substrate acceptance and only acts on specific polysaccharides. 
There is no apparent sequence homology between these enzymes. 
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Figure 3 – Schematic representation of reactions catalyzed by the three described hexuronic acid C5-
epimerases. (A) Alginate D-mannuronan C5-epimerases catalyze the conversion of D-mannuronic acid into L-
guluronic acid. (B) Chondroitin D-glucuronyl C5-epimerase converts D-glucuronic acid into its C5-epimer L-
iduronic acid. (C) Heparan sulfate D-glucuronyl C5-epimerase mediated catalysis also results in L-iduronic acid 
formation. The epimerase reaction is expected to occur via carbanion intermediate by abstraction and re-
addition of the C5 proton. Water is used as the proton acceptor / donor. 
 
Polymannuronic acid C5-epimerases 
Polymannuronic acid C5-epimerases do not act on D-glucuronic acid in a glycosaminoglycan 
but on D-mannuronic acid in alginate. These C5-epimerases are the best described hexuronic 
acid C5-epimerases, involved in the biosynthesis of alginate. Alginate is an unbranched linear 
polysaccharide consisting of (1-4) linked β-D-mannuronic acid residues, some of these D-
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mannuronic acid residues are converted to their C-5 epimer L-guluronic acid by a 
polymannuronic acid C5-epimerase (Fig.3A). The ratio between these two hexuronic acids 
are variable and depend on the source of isolation. Discovered in the late 19th century 
alginate was originally extracted from brown seaweed. Nowadays it is also identified in the 
two bacterial genera Pseudomonas (Franklin et al., 1994) and Azotobacter (Haug and Larsen, 
1970). Alginate has a high water binding capacity, which makes it a widely used product with 
multiple industrial applications. 
Much research has been done on the bacterial polymannuronic acid C5-epimerases 
(Remminghorst and Rehm, 2006). All genes involved in the alginate biosynthesis are 
clustered in an operon, both in P. aeruginosa and A. vinelandii. The corresponding enzymes 
reside in the periplasm including the polymannuronan C5-epimerase (AlgG). However A. 
vinelandii has a set of seven additional polymannuronan C5-epimerases (AlgE1-7) that are 
secreted by the cell and whose genes are not located in the alginate biosynthesis gene 
cluster (Ertesvåg et al., 1999). Alg1-7 have a Ca2+ dependency and do not share similarity at 
amino acid sequence level with AlgG. Most likely these additional epimerases are crucial for 
the high variability in the epimerization pattern. 
The ease of working with these extracellular alginate C5-epimerases has led to 
extensive research of these enzymes. It has been shown that all seven extracellular alginate 
C5-epimerases are composed of varying amounts of two types of structural modules. Each 
type of C5-epimerase has one or two copies of the catalytically active A-module, which is 
about 385 amino acids long. In addition up to seven copies of the much smaller R-module 
(155 amino acids) are present per enzyme. A crystal structure is available for the smallest 
epimerase AlgE4, which has one single A-module and one single R-module. The A-module 
alone is both catalytically active, and can bind calcium (Ertesvåg and Valla, 1999). X-ray 
crystallography data (2.1-Å resolution) have revealed a right-handed β-helix with 4 parallel 
sheets, where the active site is positioned in a highly basic groove (Rozeboom et al., 2008). 
The R-module has a right-handed parallel β-roll subunit (NMR data) that is likely to be 
involved in additional calcium binding. Linkage of a R-module to an A-module enhances 
overall activity substantially (Aachmann et al., 2005). 
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D-glucuronyl C5-epimerases 
The other two hexuronic acid C5-epimerases both act on β-D-glucuronic acid linked to a 
hexosamine in a polymer. In either case α-L-iduronic acid is the reaction product. However 
although the result of the reaction of both enzymes is identical, no significant sequence 
homology exists between them at amino acid level. Also biochemically both epimerases are 
dissimilar, since they differ in pH optimum and the requirement for cations (Malmström and 
Åberg, 1982). Both enzymes can only accept their natural substrate.  
 
Dermatan sulfate D-glucuronyl C5-epimerase | The dermatan sulfate D-glucuronyl C5-
epimerase (EC 5.1.3.19) converts D-glucuronic acid to L-iduronic acid (Fig.3B) in chondroitin 
biosynthesis (Malmström and Fransson, 1975). The gene responsible for the expression of 
this C5-epimerase has been identified only a few years ago, and was renamed from its 
original name SART2 (squamous cell carcinoma antigen recognized by T-cell 2) (Maccarana et 
al., 2006). Different than the heparosan D-glucuronyl C5-epimerase, the chondroitin D-
glucuronyl C5-epimerase requires a divalent metal ion, with manganese as the most 
effective one. Based on several bacterial lyases a structural model of the epimerase has been 
proposed. The catalytic site is expected to comprehend three putative catalytic residues, 
two Histidines (His-205 and His-450) and one Tyrosine (Tyr-261). Site directed mutagenesis 
of any of these conserved residues results in complete loss of epimerase activity (Pacheco et 
al., 2008). 
 
Heparan sulfate D-glucuronyl C5-epimerases | Also the heparan sulfate C5-epimerase (EC 
5.1.3.12) catalyzes the conversion of D-glucuronic acid into L-iduronic acid, however it only 
accepts N-sulfated heparosan as substrate (Fig.3C). Unlike the other two hexuronic acid C5-
epimerases, no structural data is available of heparosan C5-epimerases, nor has the catalytic 
site been identified. However, a reaction mechanism is proposed based on activity 
measurements. The C5-epimerase reaction occurs via a carbanion intermediate by 
abstraction and re-addition of the C5-proton derived from water (Hagner-McWhirter, 2000). 
The re-addition can occur at both sides of the pyranose ring, in such a way that it can give an 
inversion of configuration; the carboxy group shifts across the plane of the pyranose ring. In 
vitro the reaction is freely reversible, with a slight preference for D-glucuronic acid over L-
iduronic acid. However, in vivo the C5-epimerization step is irreversible; possibly because the 
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L-iduronic acid is blocked for the C5-epimerase by the subsequent 2-O-sulfation step 
(Hagner-McWhirter, 2004). 
Although the exact catalytic mechanism still is unclear, the biological importance of 
D-glucuronyl C5-epimerase activity in early vertebrate development has been shown in 
previous research. Animals lacking D-glucuronyl C5-epimerase activity either die perinatally 
or have very early embryonic patterning defects. In zebra fish it has been shown that dorso-
ventral axis formation and patterning is highly affected in the absence of D-glucuronyl C5-
epimerase activity (Ghiselli and Farber, 2005). Similar findings have been reported for axonal 
development of neurons in a null allele mutant of the nematode Caenorhabditis elegans 
(Bülow and Hobert, 2004). Also the development of some organs requires D-glucuronyl C5-
epimerase activity. Mouse mutants having a disrupted D-glucuronyl C5-epimerase have also 
been demonstrated to lack L-iduronic acid, resulting in a neonatal lethality with 
malformations in kidney, lung and skeletal development (Li et al., 2003; Jia et al., 2009). 
The catalysis of D-glucuronic acid into L-iduronic acid is typically mediated by a single 
epimerase. As mentioned, an exception is reported in zebra fish, where two genes have 
been identified (glce-A and glce-B). Both genes are expressed, and the gene products both 
are homologous to the D-glucuronyl C5-epimerase gene present in mammals, like human 
(Ghiselli and Farber, 2005). Examination of the genome data of Branchiostoma floridae 
(Florida lancelet fish) reveals another example of two distinct heparan sulfate D-glucuronyl 
C5-epimerase genes present in one single organism. Examination of other (fish) genomes did 
not reveal other examples, indicating that such recent gene duplication is not a general 
feature in fish. 
 
L-iduronic acid 
As described in the previous paragraph the lack of a heparan sulfate D-glucuronyl C5-
epimerase results in severe disturbance in early embryonic patterning and morphogenesis, 
stressing the importance of L-iduronic acid as a substituent in heparin. Much research has 
been done to study this rather unusual hexuronic acid. 
The first report of an L-iduronic acid containing glycosaminoglycan, was by Hoffman 
and co-workers. They showed its presence in dermatan sulphate (Hoffman et al., 1956). 
Initially the L-iduronic acid was considered to be incorporated in heparin biosynthesis as a 
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UDP-sugar. Jacobson & Davidson reported catalytic activity of rabbit skin extracts, in which 
L-iduronic acid seemed to be formed from UDP-D-glucuronic acid (Jacobson and Davidson, 
1963). However, later research demonstrated that L-iduronic acid is formed via C5-
epimerization of D-glucuronic acid, only after UDP-D-glucuronic acid is incorporated in the 
polymer. This process is identical for the biosynthesis of both dermatan sulfate (Malmström 
et al., 1975) and heparin (Lindahl et al., 1972; Höök et al., 1974). UDP-L-iduronic acid has 
never been isolated from any natural source and is considered as an unnatural sugar. 
As a C5-epimer of D-glucuronic acid, L-iduronic acid only differs with respect to the 
orientation of the carboxyl group at the C5 position. Even though this might seem only a 
small change, glycosaminoglycans that contain L-iduronic acid generally do have stronger 
binding properties resulting in elevated biological activities, compared to structures that 
only contain D-glucuronic acid. The reason for this can be found in the nature of both 
hexuronic acids. While D-glucuronic acid is restricted to only a 4C1 conformation, L-iduronic 
acid has three stable conformations and can occur additionally also in the other boat 
conformation 1C4 and in a skew-boat conformation 2S0 (Fig.4). 
 
 
Figure 4 – Structural conformation of D-glucuronic acid (GlcA), and its C5-epimer L-iduronic acid (IdoA). Three 
stable conformations are possible for L-iduronic acid; the most stable form is 4C1 with a calculated energy of 
67.66 kcal/mole (a). The other boat conformation (b) (1C4; 73.80 kcal/mole) and a skew boat (c) (
2S0; 76.66 
kcal/mole). The theoretical energy value of 1C4 D-glucuronic acid (d) is 63.97 kcal/mol. Theoretical energy 
values are calculated by Chembio 3D. 
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Lower calculated energy values correspond to less tension on the ring, and thus result in a 
more stable conformation. Theoretically, the most stable conformer is the most abundant 
one. All three conformers of L-iduronic acid are rather stable and therefore do occur. 
However, the occurrence highly depends on the position and modifications of L-iduronic acid 
in the polymer (Ferro et al., 1990). Still, L-iduronic acid has a greater conformational 
flexibility which results in a more flexible structure, and therefore in less (electrostatic) 
stress in a polymer chain (Casu et al., 1988). It has been suggested that this increased chain 
flexibility is crucial for the binding capacity of L-iduronic acid containing glycosaminoglycans 
like heparin (Jia et al., 2009). 
 
In vitro synthesis of heparin – Needed: improved D-glucuronyl C5-epimerase 
Heparin is extracted rather inexpensively from animal derived tissue. However, several 
(potential) limitations of this methods exist. Firstly, like all animal-derived materials, there is 
a potential risk of contamination of the product with either allergens or pathogens. 
Secondly, there is a potential shortage of crude material since for the European and U.S. 
market only heparin isolated from porcine material is allowed since the outbreak of BSE in 
the 1990’s. A third and major drawback of these extraction methods is that isolated heparin 
is always a heterogeneous mixture of polymers. For pharmaceutical purposes polydispersity 
should be reduced to a minimum, resulting in defined product size and product 
modifications. Also limiting is the restricted natural variety of heparin. Non-natural heparin 
analogs that have potentially better therapeutic characteristics, cannot be obtained using 
the existing isolation methods. 
Much effort has been taken to reach chemical synthesis of heparin-like oligomers, 
leading to successful chemical synthesis methods. Several synthetic heparin derivatives have 
been described (De Kort et al., 2005). The first synthetic antithrombotic pentasaccharide 
(Fondaparinux) is available on the world-market as Arixtra® (Petitou and van Boeckel, 2004). 
These completely chemical ways of synthesis require, mainly due to the many protection 
and de-protection events, over 60 steps. On the contrary, the absolute strength of this 
process is the degree of control of the process; the end-product is very well defined. 
Despite the success of these chemical synthesis approaches on relatively small scale, 
these methods are not applicable to bulk-scale production processes, as typical yields are 
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less than 0.5% (Kuberan et al., 2003). Alternatively, also a more feasible enzymatic 
biosynthesis approach has been described. This shows the modification of a relatively cheap 
and largely available starter material, generating a heparin-like product (Kuberan et al., 
2003; Lindahl et al., 2005). Modification of the capsular polysaccharide of a bacterium (E. coli 
K5), results in a heparin-like polymer (neoheparin) that has similar anticoagulant properties 
as heparin. Compared to the chemical synthesis, higher yields can be achieved, in largely 
reduced synthesis time. 
Most heparin modifications can be done in a chemical way (Casu et al., 1994), 
however the epimerization of D-glucuronic acid towards L-iduronic acid is an exception. An 
enzyme for C5-epimerization therefore is crucial when aiming for controlled synthesis of 
heparin. Two alternative ways to reach controlled enzymo-chemical heparin synthesis could 
be (1) controlled heparin chain building via incorporation of UDP-IdoA or (2) obtaining a D-
glucuronyl C5-epimerase that is easily produced in large quantities and robust enough to use 
in an industrial process. 
(1) The controlled chain elongation using UDP-sugars would give the highest degree 
of control, and therefore the most defined end-product. However, UDP-L-iduronic acid is 
considered as an unnatural sugar that only is proven to exist when produced chemically, and 
its limited availability implies high costs. Additionally, there is a bottleneck in the UDP-IdoA 
incorporation. Previous attempts have been made to incorporate chemically synthesized 
UDP-L-iduronic acid by glucuronyl-transferases (Weïver et al., 2008). Until now this was not 
successful, suggesting that specific glycosyltransferases will be required for the 
incorporation of L-iduronic acid. The lack of natural UDP-IdoA and the disability of L-iduronic 
acid incorporation via an UPD-sugar means the requirement of two novel types of enzymes; 
a glycosyltransferase that accepts UDP-IdoA and a C5-epimerase that can convert UDP-GlcA 
to UDP-IdoA. 
(2) Alternatively the potential of the mouse D-glucuronyl C5-epimerase (MmC5) as an 
industrial tool can be improved by increasing its robustness and production levels. The D-
glucuronyl C5-epimerase as described in the heparin / heparan sulfate biosynthesis has been 
cloned and heterologously expressed (Li et al., 2001). Unfortunately the enzyme has serious 
limitation for use in (large scale industrial) in vitro processes in terms of protein stability and 
protein production. Protein engineering of the MmC5 would be an option to improve the 
enzyme for industrial purposed. Another approach would be the identification and 
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production of robust D-glucuronyl C5-epimerases orthologs that can efficiently catalyze the 
same reaction.  
 
Conclusions 
Glycosaminoglycans are a specific class of biological active polysaccharides. As described 
above, a small number of glycosaminoglycans is involved in numerous biological processes. 
Most of these glycosaminoglycans can vary in their degree of polymerization, D-glucuronic 
acid epimerization and acetylation / sulfation pattern, each can have major impact on 
biochemical / biophysical features and as such on their biological functionality. Many 
different enzymes are involved in glycosaminoglycan biosynthesis, and many of them exist in 
multiple isoforms, allowing the variations as seen for glycosaminoglycans. Altogether this 
can lead to the large variation in chain modification as seen in glycosaminoglycans like 
heparin / heparan sulfate. 
Traditionally glycosaminoglycans are isolated from animal tissue, however this brings 
some undesired side-effects. Not only there is a risk of immunogenic reactions upon co-
isolation of animal derived antigens, also the isolated fractions are typically highly 
polydisperse and show a large variability in degree of sulfation and epimerization. To obtain 
monodisperse and uniform glycosaminoglycans is a major challenge when starting from such 
sources, especially when aiming for pharmaceutical applications. Chemical synthesis of these 
structures is rather complex and thus economically not feasible for bulk-scale production. 
The use of heparosan as a starting material for heparin production is an alternative 
approach. Such chemo-enzymatic approaches have been tested previously on small scale, 
however there is ample room for improvement at the level of enzyme optimization. A key 
enzyme required to move the chemo-enzymatic production process to a cost effective level 
concerns a D-glucuronyl C5-epimerase. Most steps in heparin chain modification can be 
done chemically. Although the C5-epimerization step can be done chemically at 
disaccharide-level (Chiba et al., 1988), it is not possible to C5-epimerize GlcA at a polymer 
level. This implies the requirement for a industrial applicable D-glucuronyl C5-epimerase 
when aiming for chemo-enzymatic synthesis of heparin.  
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Abstract 
Glycosaminoglycans (GAGs) are polysaccharides that are typically present in a wide diversity 
of animal tissue. Most common GAGs are well-characterized and pharmaceutical 
applications exist for many of these compounds, e.g. heparin and hyaluronan. In addition, 
also bacterial glycosaminoglycan-like structures exist. Some of these bacterial GAGs have 
been characterized, but until now no bacterial GAG has been found that possesses the 
modifications that are characteristic for many of the animal GAGs such as sulfation and C5-
epimerization. Nevertheless, the latter conversion may also occur in bacterial and archaeal 
GAGs, as some prokaryotic polysaccharides have been demonstrated to contain L-iduronic 
acid. However, experimental evidence for the enzymatic synthesis of L-iduronic acid in 
prokaryotes is as yet lacking. We therefore performed an in silico screen for D-glucuronyl C5-
epimerases in prokaryotes. Multiple candidate C5-epimerases were found, suggesting that 
many more microorganisms are likely to exist possessing an L-iduronic acid residue as 
constituent of their cell wall polysaccharides. 
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Introduction 
Glycosaminoglycans (GAGs) are long linear negatively charged hetero-polysaccharides, 
consisting of repeating disaccharide residues usually of a hexuronic acid linked to a 
hexosamine. Glycosaminoglycans are ubiquitously found throughout the animal kingdom, 
where they are involved in a wide variety of biological processes. The most common 
glycosaminoglycans are chondroitin sulfate, dermatan sulfate, heparan sulfate, heparin, 
hyaluronan and keratan sulfate (Chapter 1). 
The glycosaminoglycan hexuronic acid residue is either D-glucuronic acid or its C5 
epimer L-iduronic acid. The latter is a rather unique hexuronic acid that is typically found in 
glycosaminoglycans, while D-glucuronic acid is a very common compound in nature. The 
epimerization of D-glucuronic acid towards L-iduronic acid is mediated by a D-glucuronyl C5-
epimerase acting at a polysaccharide level after D-glucuronic acid incorporation (Lindahl et 
al., 1972; Höök et al., 1974). The C5-epimerization of D-glucuronic acid is essential for 
specific binding properties of versatile glycosaminoglycans like heparin and heparan sulfate. 
Another D-glucuronyl C5-epimerase does exist responsible for dermatan sulfate 
biosynthesis, as well as a C5-epimerase involved in alginate biosynthesis. These epimerases 
do not show sequence homology to the heparin D-glucuronyl C5-epimerase (Valla et al., 
2001). 
Glycosaminoglycans traditionally are isolated from animal tissue. A major drawback is 
the great polydispersity of animal-derived material, both in chain length and degree of 
epimerization/sulfation. Large scale chemical synthesis of heparin is not feasible, because of 
the C5-epimerization of D-glucuronic acid being one of the major bottlenecks. L-iduronic acid 
can be synthesized chemically, however C5-epimerization of D-glucuronic acid as part of a 
polymer only can be done enzymatically. The C5-epimerase in animal heparin biosynthesis 
has been identified and characterized, and has some major limitations to use in large scale 
biotechnological production processes. 
Novel D-glucuronyl C5-epimerases that have less restrictions in substrate acceptance, 
better stability and easier production methods would have great potential in controlled 
chemo-enzymatic synthesis of L-iduronic acid containing polymers like heparin and heparin-
analogs. In this review we discuss putative novel C5-epimerases that might convert D-
glucuronic acid to L-iduronic acid with less restrictions. 
Chapter 2 
 
34 
Glycosaminoglycan-like structures in bacterial capsules 
Traditionally, GAGs were considered as polymeric structures only to be found in 
(in)vertebrate animals. However, in the past decades, some polyanionic bacterial cell wall 
polysaccharides have been described, of which the structure has resemblance to some well-
characterized animal glycosaminoglycans. Microorganisms possessing GAGs generally are 
pathogenic bacteria in which the surface exposed capsular polysaccharides are likely to serve 
as a virulence factor. The resemblance between the bacterial capsule and the animal GAG 
results in very limited or no response of the hosts’ immune system. GAG-containing 
pathogens, including serotypes of both Escherichia coli and Pasteurella multocida, are 
discussed below. 
 
E. coli GAGs | Many different serotypes of E. coli have been described. Discrimination 
between these strains is generally based on antigenic studies. Mostly differences can be 
found in a specific part of the bacterial lipopolysaccharide (LPS), the so-called O-antigen. To 
a lesser extent differences are seen in antigenic properties of the flagella (H-antigen) and the 
bacterial capsule (K-antigen). The latter is a protective layer of polysaccharides that generally 
can be easily observed by light microscopy. Over 70 different K-antigens have been 
described (Ørskov et al., 1977). As discussed below, two of them are analogous to 
glycosaminoglycans as found in animals. 
A chondroitin-like glycosaminoglycan has been isolated from E. coli O5 : K4 : H4 
(Rodriguez et al., 1988). Identical to chondroitin this “K4 capsular polysaccharide” consists of 
equimolar amounts of β-D-glucuronic acid and β-N-acetyl-galactosamine. Unlike chondroitin 
an additional fructose is β(1,3) linked as a substituent to each GlcA residue. However, this 
modification can easily be removed by mild acidification, resulting in a chondroitin 
backbone. Upon removal of the fructose residue, the immune response against the K4 
polysaccharide decreases considerably. 
Another glycosaminoglycan-like structure has been described for the K5 antigen of E. 
coli O10 : K5 : H4. This capsular polysaccharide has an identical structure to heparosan, the 
unsulfated and non-epimerized backbone structure of heparan sulfate and heparin. The K5 
capsule is a linear polysaccharide containing α-N-acetyl-glucosamine and β-glucuronic acid in 
equimolar amounts, linked by an (1-4) glycosidic bond (Vann et al., 1981). In contrast to 
Occurrence of L-iduronic acid and putative D-glucuronyl C5-epimerases in prokaryotes 
 
35 
animals, no post-polymerization modifications occur on the heparosan molecule. This makes 
the K5 polysaccharide a useful substrate to study the enzymes in heparin biosynthesis 
(Kusche et al., 1991; Hagner-McWhirter et al., 2000), and a potential precursor for chemo-
enzymatic synthesis of heparin. 
 
P. multocida GAGs | Similar glycosaminoglycans have been isolated from several serotypes 
of another pathogenic gamma-proteobacterium, namely Pasteurella multocida. The capsules 
of P. multocida type A, D and F could be removed upon treatment with different 
glycosaminoglycan hydrolases (Rimler, 1994). A more detailed analysis of the capsular 
polysaccharides of P. multocida type D and F has revealed similarity with the K-antigens of E. 
coli K5 and K4 respectively. The P. multocida type D polymer is identical to heparosan, the 
type F polymer is unmodified chondroitin (DeAngelis et al., 2002). 
Additionally, another P. multocida capsular polysaccharide has been described to be 
analogous to a vertebrate glycosaminoglycan. The extracellular capsule of P. multocida type 
A is chemically identical to the animal GAG hyaluronan (Rosner et al., 1992). In addition, 
multiple species of Streptococci have been described to have such a hyaluronan capsule. All 
these strains are pathogenic to human or other mammals, the hyaluronan capsule having an 
important role in preventing an immune response. Since these molecules are identical to 
mammalian hyaluronan, bacterially produced hyaluronic acid has substantial commercial 
value. In addition to animal derived hyaluronan, it is nowadays widely commercially 
available for numerous existing applications. 
 
Although multiple examples of bacterial GAGs do exist, for none of these 
glycosaminoglycans modifications have been observed similar to those in the GAG 
biosynthesis pathways in animals. A key modification step in these pathways is the C5-
epimerization of D-glucuronic acid towards L-iduronic acid, catalyzed by a D-glucuronyl C5-
epimerase. No bacterial counterpart of this enzyme has been experimentally characterized 
to date. However, the presence of L-iduronic acid in extracellular polysaccharides of several 
microorganisms, suggests that D-glucuronyl C5-epimerases do exist in prokaryotes. 
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Identification of iduronic acid in microbes 
While being a well-known component of (animal) glycosaminoglycans, the presence of L-
iduronic acid in prokaryotes is rather uncommon. For some time it was believed that L-
iduronic acid could only be found in multicellular eukaryotes. However, as discussed below, 
in the last decades multiple examples of microbial L-iduronic acid have been published. 
 
Bacteria 
The first case of L-iduronic acid being present in a prokaryote was reported in a study of the 
gram-positive bacterium Clostridium perfringens NCTC 10578 (Darby et al., 1970). L-iduronic 
acid was identified in a purified “type-specific” polysaccharide from Clostridium perfringens 
strain Hobbs 10. The exact polysaccharide structure is still unknown but the L-iduronic acid 
level in the isolated polysaccharide is estimated to be 7%. Most likely this “type-specific” 
polysaccharide is part of a bacterial capsular polysaccharide (Lee and Cherniak, 1974). 
Another report on the presence of L-iduronic acid in a prokaryote concerns the 
analysis of specific extracellular polysaccharide (EPS) of Butyrivibrio fibrisolvens strain X6C61 
(Stack et al., 1988). As much as 37 strains of B. fibrisolvens were screened in total, but only a 
single strain appeared to contain L-iduronic acid. This indicates that L-iduronic acid is part of 
a type-specific EPS. The exact composition of the EPS remains to be characterized, although 
it has been proposed that L-iduronic acid is associated to a galactosamine residue. 
In addition, several reports exist in which L-iduronic acid is identified as a compound 
of an O-specific polysaccharide. An O-antigen is the highly variable part of a 
lipopolysaccharide (LPS), which is present in the outer membrane of gram-negative bacteria. 
The first report of L-iduronic acid being present in an O-antigen was after structure 
elucidation of the O-antigen of the marine bacterium Pseudoalteromonas haloplanktis strain 
KMM 223 (44-1) (Hanniffy et al., 1998). The L-iduronic acid residue is part of a 
pentasaccharide (Fig.1) that additionally contains two D-glucuronic acid residues and two 
residues of the uncommon QuiN4N (2,4-diamino-2,4,6-trideoxyglucose). The high amount of 
hexuronic acids results in a highly acidic O-antigen. In addition, the uncommon QuiN4N 
residues and GlcA residues have been found in other serotypes of Pseudoalteromonas 
(Nazarenkoa et al., 2003), however strain KMM 223 remains the only example that has an L-
iduronic acid containing O-antigen. 
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   Organism        Structure           Reference 
 
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------- 
 
     →4)- β-D-GlcA-(1→4)-β-D-GlcA-(1→3)-β-D-QuiNHb4NHb-(1→2)- α-L-IdoA-(→ 
Pseudoalteromonas                  4 
Haloplanktis KMM 223                ↑  Hanniffy et al., 1998 
(44-1)                  1 
                   α-D-QuiNAc4NAc    
 
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------- 
 
      β-D-GlcNAc 
Escherichia coli O112ab   1                   Perepelov et al., 2008 
 &                      ↓ 
Shigella boydii B15     3                     Liu et al., 2008 
→4)-α-D-GalNAc-(1→4)→α-D-Glc-(1→4)-α-L-IdoA-(1→3)-β-D-GalNAc-(1→    
 
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------- 
 
     GlcA-(1→4)-GlcA-(1→4)-GlcA-(1-4)-β-D-Glc-(1→N)-Asn       1/3 of GlcA residues can 
         3                    3                    3                |        be replaced by IdoA 
Halobacterium halobium    ↑       ↑        ↑          X      
                OSO3-            OSO3-            OSO3-               | 
                          Thr / Ser     Wieland et al., 1985 
 
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------  
Figure 1 – Known prokaryotic structures containing L-iduronic acid; bacterial O-antigens and the Halobacterium 
halobium glycoconjugate. GlcA, glucuronic acid; QuiNHb4N, 2,4-diamino-2,4,6-trideoxy-D-glucose (Hb, S-3-
hydroxybutyryl; Ac, acetyl); IdoA, iduronic acid; GlcNAc, N-acetyl-glucosamine; GalNAc, N-acetyl-galactosamine. 
 
More recently, two additional O-antigens have been identified in which L-iduronic acid is one 
of the building blocks (Fig.1). Both Escherichia coli type 112ab and Shigella boydii B15, have 
an identical pentasaccharide structure (Perepelov et al., 2008; Liu et al., 2009). Many more 
O-antigens structures of various serotypes of both E. coli and S. boydii have been resolved to 
date, however L-iduronic acid seems to be restricted to these two reported strains. Just like 
the previous reports dealing with L-iduronic acid identification in bacteria, the occurrence of 
this structure is highly type-specific rather than a general feature. 
 
Archaea 
L-iduronic acid has been reported in archaea only once. There is evidence of the presence of 
iduronic acid in a cell surface lipoprotein of Halobacterium halobium (Wieland et al., 1986). 
The cell wall of this archaeon is a glycoprotein based S-layer. The glycoprotein has two 
specific forms of N-glycosylation. First each polypeptide consists of a single 
glycosaminoglycan-like polysaccharide with a [-4)-GalNAc-(1-4)-GalA-(1-3)-GalNAc-(1-]n10-15 
backbone attached. Apart from that, there are 12 potential glycosylation sites where an Asn-
Glc (asparaginylglucose) linkage unit is extended by two or three β(1-4) bound glucuronic 
acid residues. About 1/3 of these glucuronic acid moieties are replaced by an iduronic acid 
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(Fig.1). An identical glycoconjugate can be found at the organisms’ flagellin (Wieland et al., 
1985). Although archaeal flagellins often undergo posttranslational modification (Jarrell et 
al., 1996), until now this is the only report of iduronic acid presence in such a structure. 
 
Non-canonical L-iduronic acid containing polymers in eukaryotes 
L-iduronic acid traditionally is considered to be a component in many common animal 
glycosaminoglycans. Apart from these well-characterized GAGs, recently L-iduronic acid also 
has been identified in some atypical polymers. The eukaryotic organisms having these non-
canonical polymers usually do not possess the traditional GAGs as found in animals. Possibly 
the formation of L-iduronic acid is the result of another C5-epimerase than the heparosan D-
glucuronyl C5-epimerase. An overview of some of these rare L-iduronic acid containing 
structures is provided below. 
 
Algae | Pleurochrysis haptonemofera is a unicellular coccolithophorid marine alga. It 
produces coccolith, a calcified scale. Apart from carbonate crystals, this scale contains a 
small amount of polysaccharide called “coccolith matrix acidic polysaccharide” (CMAP). The 
structure of CMAP has been determined to be composed of a repeating disaccharide 
structure, of which L-iduronic acid is one of the sugars (Ozaki et al., 2007). In addition there 
are reports of the existence of L-iduronic acid in specific polysaccharides in multicellular 
algae. The cell wall of sea lettuce (genus Ulva) includes four types of polysaccharides, of 
which the water-soluble ulvan is exclusively found in members of the Ulvales. This 
polysaccharide has a repetitive disaccharide of L-iduronic acid that is α(1-4) linked to a C3-
sulfated rhamnose (Lahye and Robic, 2007). 
 
Fungi | Phallic acids are specific glycuronans that can be found in the fruiting-bodies of 
members of the taxon Phallales. Tsuchihashi and colleagues have described the isolation of 
phallic acid of at least ten species, all containing L-iduronic acid. (Miyazaki et al., 1979). The 
exact structural composition is still unknown, but it has been reported that these 
polysaccharides are composed of β-glucuronic acid and α-iduronic acid residues that have an 
(1-4) linkage. The internal ratio of these two hexuronic acids varies around 2:1 to 3:1. The 
polysaccharide is called protuberic acid when the ratio glucuronic acid to iduronic acid is 
equal to 2:1 (Tsuchihashi et al., 1983). 
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Sponges | Citronamides A and B are unique products that have been isolated from the 
Australian sponge Citronia astra. Both are non-canonical tetrapeptides with a linked 3- or 4-
O-(aminocarbonyl)-α-iduronic acid residue. These compounds accidently have been co-
isolated with Dysinosin A, a potential serine protease (thrombin) inhibitor. Citronamides A 
and B are structurally not related to Dysinosin A, and the biological function of these 
products still needs to be clarified (Carroll et al., 2009). 
 
Identification of C5-epimerases in prokaryotes 
The above described polymeric structures are examples of L-iduronic acid containing 
polysaccharides and glycosaminoglycan-like structures in several microorganisms. The 
existence of L-iduronic acid does suggest D-glucuronyl C5-epimerase activity to occur in 
these organisms. The wide diversity of these GAG-like structures suggests the presence of 
candidate C5-epimerases with a different or broader substrate specificity. To date no such 
candidate enzyme has been identified. 
In an attempt to identify candidate C5-epimerases, we screened all available 
prokaryotic genomes for sequences homologous to human D-glucuronyl C5-epimerase by 
Blast analysis (http://blast.ncbi.nlm.nih.gov/Blast.cgi; Altschul et al., 1997). Multiple 
prokaryotic sequences were identified that have homology to the human protein sequence. 
Also Blasts on metagenome data reveal multiple putative prokaryotic C5-epimerases. All 
found candidate C5-epimerases have a well-conserved domain making them members of the 
pfam06662 superfamily (Bateman, et al., 2004) containing the consensus of the C-terminus 
of D-glucuronyl C5-epimerases. An overview of all prokaryotes having one or more candidate 
D-glucuronyl C5-epimerase gene(s) is provided in Table 1. 
 
The occurrences of these candidate C5-epimerases seem to be type-specific rather than 
species-specific. This is in line with the earlier discussed reports on the identification of L-
iduronic acid containing polymers in prokaryotes, that also appear to be type-specific in 
various species. Among the identified candidate C5-epimerases differences in size exist; 
however, this is mainly a result of variation of the N-terminal domain of the protein. 
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Table 1 – Overview candidate C5-epimerases in prokaryotes 
  Organism      Class    Size     Gene ID           e-value. 
Bacteria; Acidobacteria 
 Candidatus Koribacter versatilis Ellin345  Candidatus koribacter 401 aa    94970543 9e-65 
Bacteria; Actinobacteria 
 Sanguibacter keddieii DSM 10542   Actinobacteridae  355 aa    269795908 1e-16 
 Conexibacter woesei DSM 14684   Rubrobacteridae  473 aa    284043115 3e-19 
 Conexibacter woesei DSM 14684   Rubrobacteridae  489 aa    284046741   1e-26 
Bacteria; Bacteroidetes 
 Bacteroides sp. 1_1_6    Bacteroidia  305 aa    253567783 1e-29 
Bacteria; Firmicutes 
 Bacillus cereus R309803    Bacillales   307 aa    229164211 2e-40 
 Clostridium ljungdahlii ATCC 49587   Clostridia   737 aa    300854052   6e-52 
 Clostridium ljungdahlii ATCC 49587   Clostridia   399 aa    300855735 9e-53 
 Clostridium ljungdahlii ATCC 49587   Clostridia   372 aa    300855857 7e-50 
 Clostridium kluyveri DSM 555   Clostridia   411 aa    153953040 1e-35 
 Clostridium kluyveri DSM 555   Clostridia   372 aa    153953635 2e-32 
 Clostridium kluyveri DSM 555   Clostridia   452 aa    153953720 1e-32 
 Clostridium kluyveri NBRC 12016   Clostridia   414 aa    219853696 1e-35 
 Ruminococcus sp. 18P13    Clostridia   302 aa    291544017 6e-34 
 Thermoanaerobacter tengcongensis MB4  Clostridia   312 aa    20807150 3e-58 
Bacteria; Proteobacteria 
 Campylobacter hominis ATCC BAA-381  Epsilonproteobacteria 458 aa    154149157 4e-34 
 Nautilia profundicola AmH    Epsilonproteobacteria 317 aa    224373665 2e-38 
 Bermanella marisrubri sp. RED65   Gammaproteobacteria 448 aa    94501207 2e-76 
 Escherichia coli O112ab    Gammaproteobacteria 323 aa    187880578 1e-23 
 Shigella boydii type 15    Gammaproteobacteria 323 aa    187880569 1e-23 
 Photorhabdus asymbiotica    Gammaproteobacteria 370 aa    253991788 5e-15 
 Photorhabdus luminescens sp. laumondii TTO1  Gammaproteobacteria 368 aa    37528614 4e-12 
 Vibrio cholerae bv. albensis VL426   Gammaproteobacteria 308 aa    229524794 2e-27 
 Vibrio cholerae st. CO845    Gammaproteobacteria 311 aa    295149004 9e-34 
Archaea; Korarchaeota 
 Candidatus Korarchaeum cryptofilum OPF8  Candidatus korarchaeum 337 aa    170290161 3e-28 
Archaea; Euryarchaeota 
Methanothermobacter marburgensis st Marburg Methanobacteria  381 aa    304314521 8e-40 
 Methanothermobacter thermautotrophicus ΔH  Methanobacteria  405 aa    15678358 2e-59 
 Methanocaldococcus fervens AG86    Methanococci  305 aa    241911015 5e-59 
 Methanocaldococcus infernus ME   Methanococci  298 aa    241904910 6e-48 
 Methanocaldococcus jannaschii DSM 2661  Methanococci  308 aa    15669315 5e-61 
 Methanocaldococcus vulcanius M7   Methanococci  305 aa    255051598 2e-51 
 Methanococcus voltae A3    Methanococci  330 aa    163798575 7e-10 
 Thermococcus barophilus MP   Thermococci  367 aa    197628867 3e-22 
 Thermococcus barophilus MP   Thermococci  511 aa    197629016 3e-33 
 Thermococcus onnurineus NA1   Thermococci  520 aa    212224590 3e-32 
 Thermococcus sibiricus MM 739   Thermococci  371 aa    242398189 2e-27 
 Thermococcus sibiricus MM 739   Thermococci  512 aa    242398190 9e-35
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Most prokaryotic sequences show a similar organization as the protein sequence of animal 
D-glucuronyl C5-epimerases. An N-terminal signal peptide is predicted for many sequences 
and at the C-terminus of the protein the conserved pfam06662 domain can be found. This 
architecture resembles that of animal D-glucuronyl C5-epimerases. A multiple sequence 
alignment of the C-terminal domain of the prokaryotic candidate C5-epimerase and a 
selection of animal C5-epimerases is included as supplementary figure 1. 
It is tempting to speculate on the role of those amino acid residues that are 
completely conserved. Residues possibly involved in catalysis are the conserved tyrosines 
and histidines. Structural data of two other types of C5-epimerases, not homologous to the 
heparin C5-epimerase (Valla et al., 2001) and the prokaryotic candidate epimerases, reveal a 
role of conserved histidines and tyrosines in catalysis for both functionally distinct C5-
epimerases (Rozeboom et al., 2008; Pacheco et al., 2008). Although there is no homology at 
amino acid level, a similar catalytic mechanism of the heparin-acting C5-epimerase to these 
distinct C5-epimerases cannot be ruled out and could be feasible. 
 
We constructed a phylogenetic tree (Huson; 2007) containing several eukaryotic D-
glucuronyl C5-epimerases, as well as a selection of prokaryotic homologs (Fig.2). The 
multiple sequence alignment (Notredame et al, 2000; Thompson et al., 1997) is mostly 
based on the C-terminus of the genes as to be seen in supplementary figure 1. 
No remarkable differences were observed when constructing a tree of the full length 
sequences or of the C-terminus only. Phylogenetically, the prokaryotic candidate C5-
epimerase sequences cluster in a domain-specific way (Fig.2). Most deviation is observed in 
bacterial sequences, while archaea and eukaryotes are more alike. Obvious inter-domain 
substitutions can not be observed, and are not expected to have occurred recently. Few 
bacterial sequences do cluster with eukaryotes and archaea but these are close to the root 
and bootstrap values are too low to draw any conclusions. 
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Figure 2 – Phylogenetic analysis candidate C5-epimerases. The coloring of branches is domain specific; 
eukaryotes in red, bacteria in blue and archaea in green. The used bootstrap value is 1000.  
 
 
Vibrio cholerae bv. 
Albensis VL426
Vibrio cholerae strain 
CO845
Thermoanaerobacter 
tengcongensis MB4
Photorhabdus 
luminescens TT01
Photorhabdus 
asymbiotica
pyridoxal phosphate-dependent aminotransferase
UDP-N-acetyl-D-mannosaminuronate dehydrogenase
predicted UDP-Glucose dehydrogenase 
glycosyltransferase group1
predicted C5-epimerase
UDP-N-acetylglucosamine 2-epimerase
predicted (UDP-N-acetylgalactosamine) transferase
predicted acetyl transferase
pyridoxal phosphate-dependent aminotransferase
nucleoside-diphosphate sugar epimerase
protein with no identified homolog
predicted acetyl transferase  
Figure 3 – Neighborhood analysis candidate C5-epimerases. 
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On an intra-domain level one could speculate on the clustering. Considering a confidence 
level of 70% or higher, the archaeal genes cluster in two clades. Surprisingly the two 
Methanothermobacter species do not cluster with the Methano(caldo)cocci. The subset of 
bacterial sequences gives rise to several clades, each not necessarily clustered in a class 
specific way. An example is seen for Thermoanaerobacter, Bacillus and Ruminococcus that 
do cluster with Bacteroides and not cluster with the clostridiae genes, even though they are 
all in the class of firmicutes. Instead the clostridiae genes cluster with an Acidobacterium. It 
is tempting to speculate that these deviations reflect the occurrence of variant enzymes 
(paralogs) with a different substrate specificity. This is expected because of the wide 
diversity that exists in bacterial cell wall polysaccharides. Most likely the candidate C5-
epimerases are involved in the biosynthesis of type-specific polysaccharides. 
The association of the putative candidate C5-epimerases with other (predicted) sugar 
modifying enzymes (e.g. glycosyltransferases) is clearly revealed upon neighborhood analysis 
of the involved prokaryotic genomes (Fig.3). Genes in this gene cluster are likely to be 
involved in strain specific O-antigen production, since some of the sequences have homology 
to the wbb operon (Derzelle et al., 2004), which is known to be involved in the O-antigen 
biosynthesis (Reeves et al., 1996). As LPS do not occur in gram positives, alternatively these 
gene clusters can also be involved in the biosynthesis of a capsular polysaccharide. This cell 
wall structure can occur in gram positive bacteria like T. tengcongensis. The exact gene 
function is hard to distinguish, since genes involved in polysaccharide capsule biosynthesis 
are sometimes embedded in the other cell wall biosynthesis related gene regions (e.g. LPS) 
and vice versa (Chen et al., 2007). 
A remarkable similarity in genomic organization is seen for some of the putative C5-
epimerases. Figure 3 shows the flanking genes up- and downstream the candidate C5-
epimerases of two Vibrio cholerae strains (albensis VL426 and CO845), the thermophilic 
bacterium Thermoanaerobacter tengcongensis MB4 and two Photorhabdus species. Both 
Photorhabdus luminescens TT01 and Photorhabdus asymbiotica are symbiotic pathogens of 
insects, although P. asymbiotica is occasionally found as an opportunistic pathogen of 
humans as well. V. cholera is a well-known human pathogen, causing cholera. No virulence 
activity is reported for T. tengcongensis (Bao et al., 2002). 
For most of these prokaryotic candidate C5-epimerases, the gene is in close proximity 
of various sugar modifying enzymes. The analogy in gene neighborhood organization is 
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remarkably similar for the above mentioned five bacteria. Other bacterial candidate C5-
epimerases have a different organization of their gene neighborhood, despite the fact that 
they are more related to any of these five species with respect to taxonomy or candidate C5-
epimerases sequence identity. A clear example is seen for the candidate C5-epimerase of 
Bacillus cereus R309803. This sequence is the best hit compared to T. tengcongensis (54% 
identity, 70% similarity). The homology of the T. tengcongensis sequence to the putative C5-
epimerases from Photorhabdus (wblE) is rather low (15% identity, 31% similarity).  
Homology with V. cholera is better (23% identity, 44% similarity), but still weak compared to 
the best hit. 
Naturally, addition of more sequences would give a better understanding of the exact 
sequence distribution and a better view on the number of different clades existing. 
However, it is obvious that within this subset of sequences a clustering in different clades 
exists, which is not necessarily class-specific. An explanation of this phylogenetic distribution 
might be the existence of several C5-epimerase paralogs. Given the enormous variety in 
type-specific cell wall polysaccharides, it is expected that enzymes involved in biosynthesis 
have a substrate optimized specificity. Variations in substrate specificity of involved D-
glucuronyl C5-epimerase would certainly be feasible. 
 
Conclusions 
The C5-epimerization of D-glucuronic acid to its C5-epimer L-iduronic acid has long been 
considered typical for animal derived glycosaminoglycans. However, an increasing number 
of L-iduronic acid containing structures in microorganisms can be confidently identified in 
prokaryotes as well. Moreover, we found multiple candidate D-glucuronyl C5-epimerases in 
a wide variety of microbes by in silico analysis of available prokaryotic genome data. Gene 
neighborhood analysis of these sequences suggests a role in sugar modification, most likely 
in type-specific polysaccharides (e.g. capsule polysaccharides or O-antigens). Phylogenetic 
analysis indicates sub-clustering of the set of candidate D-glucuronyl C5-epimerases into 
several clades. This possibly correlates with the existence of different C5-epimerase paralogs 
each having a distinct substrate specificity. The exact physiological function and substrate 
specificity requires biochemical analysis. However, this subset of sequences and Blast 
analysis of metagenomes reveal the existence of multiple candidate C5-epimerase genes in 
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prokaryotes, supporting the conclusion that L-iduronic acid most likely is less rare in 
prokaryotes than expected. These putative C5-epimerases potentially may become 
important tools in controlled chemo-enzymatic synthesis of L-iduronic acid containing 
polymers like heparin and heparin-analogs. 
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Abstract 
Glycosaminoglycans are specific biologically active polysaccharides that are widespread 
among the animal kingdom. However, also some type-specific prokaryotic cell wall 
polysaccharides have been identified which show resemblance to these animal 
glycosaminoglycans. Moreover, a unique constituent of glycosaminoglycans, L-iduronic acid, 
has been shown to exist in prokaryotes as well. However, until now there is no experimental 
proof of the existence of a prokaryotic D-glucuronyl C5-epimerase, the enzyme responsible 
for the conversion of D-glucuronic acid (GlcA) into its C5-epimer L-iduronic acid (IdoA). We 
cloned a selection of putative prokaryotic D-glucuronyl C5-epimerases, to test them for D-
glucuronyl C5-epimerase activity. We confirmed C5-epimerase activity for one of these 
proteins, a hypothetical protein of the marine bacterium Bermanella marisrubri sp. RED65. 
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Introduction 
Glycosaminoglycans (GAGs) are carbohydrates that are widely spread in the animal kingdom 
in various animal tissues, involved in many biological functions. GAG were believed to occur 
exclusively in animals, however today there is increasing evidence that also GAG of 
prokaryotic origin do exist. Typically, those bacterial GAGs are less complex and 
modifications as seen for animal GAGs appear to be absent in bacterial GAGs. The C5-
epimerization of D-glucuronic acid to L-iduronic acid is such a modification. In animal GAGs 
this modification leads to increased flexibility of the GAG chain (Casu et al., 1988), facilitating 
binding properties for specific polysaccharide-protein interactions (Jia et al., 2009). 
 Previously, we performed an in silico screen on available prokaryotic genomes for 
putative D-glucuronyl C5-epimerases, which revealed multiple candidate C5-epimerases in 
both archaea and bacteria (Chapter2; Raedts et al., 2011). Here we describe the cloning and 
expression experiments of some of these candidate D-glucuronyl C5-epimerases encoding 
genes. The candidate C5-epimerase identified in the bacterium Bermanella marisrubri sp. 
RED65 (RED-C5-epimerase) has by far the highest similarity with animal C5-epimerases 
compared to the other identified candidate C5-epimerases. 
 
Material and Methods 
L-iduronic acid was purchased from Toronto Research Chemicals Inc. (North York, Canada), 
capsular polysaccharide of E. coli K5 (‘K5 substrate’) was ordered from Iduron (Manchester, 
United Kingdom). All other chemicals were bought from Sigma-Aldrich. Restriction enzymes, 
Pfu DNA polymerase and T4 DNA ligase were from Invitrogen and New England Biolabs. 
 
Gene cloning and expression 
Candidate C5-epimerase Bermanella marisrubri | A synthetic gene was designed based on 
hypothetical protein RED65_08024, as genomic DNA was not available. The codon usage 
optimized for the codon bias of Escherichia coli. The gene was cloned in vector pRSF-1b 
(Novagen) using restriction sites KpnI and BamHI, fusing the gene in frame with an amino-
terminal polyhistidine tag. The resulting vector, named pWUR537, was used to transform E. 
coli strains DH5α and Rosetta (DE3) containing pRARE (helper plasmid rare tRNAs). 
An overnight culture of E. coli Rosetta (DE3) containing pWUR537 was used to 
inoculate (1% v/v) a shake flask with 1 liter Luria Bertani medium supplemented with 50 
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μg/ml kanamycin, 50 μg chloramphenicol, and 1 mM MgSO4. At an optical density A600 ≈ 0.5, 
gene expression was induced by adding 0.05 mM isopropyl-1-thio-β-D-galactopyranoside 
(IPTG). The culture was incubated overnight at 30°C. Cells were harvested by centrifugation 
(5,000 x g for 15 minutes), and stored at -20°C until further use. 
 
Other candidate C5-epimerases | A synthetic gene was designed based on hypothetical 
protein Gae (Escherichia coli serogroup O112ab; GenBank ID: 187880578). The codon usage 
was optimized for the codon bias of Escherichia coli. The other candidate C5-epimerases 
were PCR amplified using genomic DNA as template using the following templates and 
corresponding primers (introduced restriction sites underlined): 
- Escherichia coli serotype O112ab candidate C5-epimerase (ECO-C5-epimerase): 
synthetic gene “hypothetical protein Gae”; 
BG2987 (5’-GCGGAATTCATGAAAGAAGCAACCACCTCC-3’) sense, 
BG2988 (5’-CGCCTGCAGTTACAGGCGAAACACCAC-3’) antisense. 
- Thermoanaerobacter tengcongensis MB4 candidate C5-epimerase (TTE-C5-epimerase): 
“hypothetical protein TTE0659” (GI:20671658; region 661205-662158); 
BG2497 (5’-GCGGGTACCTTACATGTTAACCAGGGAATTGGAAAAATTTACTC-3’) sense, 
BG2206 (5’-CGCGGATCCCTACTTAATTAATACAACCTCTCCGGGTTCC-3’) antisense. 
- Methanocaldococcus jannaschii DSM 2661 candidate C5-epimerase (MJA-C5-epimerase): 
 “conserved hypothetical protein MJ_1128” (GI:6626255; region 1069044-1069970); 
BG2207 (5’-GCGCCATGGCATATTTTGTTGGA GCATCTCAACCTTTATATTCTG-3’) sense, 
BG2208 (5’-CGCGGATCCCTATTCTCTCCATTTTTTGTAGTATTTTAGGTATATCTC-3’) antisense. 
- Methanothermobacter thermautotrophicus ΔH candidate C5-epimerase (MTH-C5-
epimerase): “conserved protein MTH_330” (GI:6626257; region 265312-266529); 
BG2209 (5’-GCGCCATGGATGACCCCCAGGAGGTAAACAGC-3’) sense, 
BG2210 (5’-CGCGGATCCTTATATCCTTTCGGGTTTGAGTCCCTTCC -3’) antisense. 
 
PCR amplified genes were cloned in an expression vector (Gae in pMAL, TTE0659 in pRSF, 
MJ_1128 and MTH_330 in pET24d) using the introduced restriction sites. The resulting 
plasmids were used to transform the construction host Escherichia coli DH5α. The generated 
plasmid was mini-prepped (Qiagen) and sequenced (BaseClear) to verify correct cloning. As 
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an expression host Escherichia coli BL21 (DE3) supplemented with pSJS1244 (helper plasmid, 
rare tRNAs) was used. Overnight cultures of E. coli BL21 (DE3) containing the generated 
expression vectors were used to inoculate (1% v/v) a shake flask with 1 liter Luria Bertani 
medium supplemented with 50 μg/ml kanamycin (100 μg/ml ampicillin for ECO-C5-
epimerase) and 50 μg spectinomycin. At an optical density A600 ≈ 0.5, gene expression was 
induced by adding 0.5 mM IPTG. The culture was incubated overnight at 30°C. Cells were 
harvested by centrifugation (3,000 rpm for 15 minutes). 
 
Protein purification 
Candidate C5-epimerase Bermanella marisrubri (RED-C5-epimerase) | Pelleted E. coli cells 
were resuspended in 20 mM Tris-HCl buffer (pH 7.5) containing 200 mM NaCl (buffer A). The 
resuspended cells were disrupted by sonication (intermitted cooling on ice) after which cell 
debris was removed by a centrifugation step (16,000 x g for 10 minutes). The resulting cell 
free extract (CFE) was filtered (0.45 μm) and applied on a Talon Cobalt affinity column 
(Clontech). After washing with two column volumes of buffer A and one column volume 
buffer A with 10 mM imidazole, RED-C5-epimerase was eluted with one column volume of 
bufferA containing, in a linear gradient, 10 - 250 mM imidazole. RED-C5-epimerase 
containing fractions were pooled and applied onto a HiPrep desalting to remove imidazole. 
Enzyme presence and purity was checked by SDS-PAGE analysis. A broad range protein 
marker (Biorad) was used to estimate the molecular mass. The presence of RED-C5-
epimerase was confirmed by LC-MS analysis. 
 
Candidate C5-epimerase Thermoanaerobacter tengcongensis (TTE-C5-epimerase) | The 
pelleted E. coli cells were disrupted similarly as described above. Buffer A differed in 
composition being a 25 mM Tris-HCl buffer (pH 7.5) containing 250 mM NaCl. After applying 
on the Talon cobalt affinity column and washing with two column volumes buffer A, it was 
washed with one column volume buffer with 1 mM imidazole, and eluted with one column 
volume buffer A that contained, in a linear gradient, 10 - 500 mM imidazole. Removal of 
imidazole, and enzyme presence and purity was performed identically as described above. 
 
Size exclusion chromatography 
The oligomeric state of both RED-C5-epimerase and TTE-C5-epimerase was determined by 
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size exclusion chromatography on a Superdex 200 high-resolution 10/10 column (24 ml) 
(Amersham Biosciences) equilibrated in 20 mM Tris-HCl (pH 7.5) containing 200 mM NaCl. 
Two hundred microliters of enzyme solution was loaded onto the column, using a flow rate 
of 0.5 ml per minute. Proteins used for calibration were blue dextran 2000 (>2000 kDa), 
ferritin (440 kDa), catalase (232 kDa), aldolase (158 kDa) bovine serum albumin (67 kDa), 
ovalbuvin (43 kDa), chymotrypsinogen A (25 kDa), and ribonuclease A (13.7 kDa). 
 
HPLC analysis 
Enzyme activity was determined by HPLC-PAD (pulse amperometric detection) analysis of 
the formed reaction products using a Dionex system. Either cell lysate or purified protein 
sample of a candidate C5-epimerase was mixed with N-Acetyl-de-O-sulfated heparin 
(sodium salt; Sigma-Aldrich) or any other substrate of choice. The mixture was incubated at 
30°C for the desired reaction time; typically overnight. Subsequently, protein was heat 
inactivated (100°C) and removed from the reaction mixture by a centrifugation step (16,000 
x g for 10 minutes). The reaction mixture was hydrolyzed (90°C for 4 hours) by addition of 
one volume of hydrochloric acid to an end concentration of 1 M. Hydrochloric acid was 
removed by evaporation in a speedvac, and hydrolyzed samples were redissolved in 
Millipore water. Final traces of hydrochloric acid were removed by titration with sodium 
hydroxide. Samples were analyzed for their hexuronic acid content by anion exchange 
chromatography on a Dionex system equipped with a CarboPac-100. The used effluent was 
45 mM sodium hydroxide, with an increasing gradient of sodium acetate (0-960 mM). The 
used detection method is based on PAD (electrocatalytically oxidation); to prevent loss of 
signal due to electrode poisoning, a series of pulsed potentials is applied. 
 
Tritium labeled substrate 
Either freshly prepared cell lysate or purified protein sample of a candidate C5-epimerase 
was mixed with tritium labelled N-Acetyl-de-O-sulfated heparin (sodium salt; Sigma-Aldrich) 
or K5 capsular polysaccharide. The enzyme/substrate mixture was incubated at 30°C 
overnight. Subsequently, reaction mixtures were mixed with a cocktail solution for biphasic 
separation (Li, 2010). The C5-epimerase activity could be measured by measuring tritium 
release using a biphasic liquid scintillation procedure as described before (Campbell, 1983). 
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Results 
A BLAST-search (http://blast.ncbi.nlm.nih.gov/Blast.cgi; Altschul et al., 1997) with the human 
heparan sulfate D-glucuronyl C5-epimerase protein sequence as query, indicated high 
homology with other animal heparan sulfate D-glucuronyl C5-epimerases. However, as 
described in chapter 2, also homologous sequences can be identified in genomes of both 
bacteria and archaea, although with a relatively low sequences homology (Raedts et al., 
2011). We selected some of these prokaryotic candidate C5-epimerase genes from different 
clades of the phylogenetic three, for protein expression studies. An overview of all cloned 
genes and constructed plasmids is given in Table 1. 
 
Table 1 – Overview of cloned and expressed candidate C5-epimerases 
 
Name microorganism used as template Signal peptide 
predicted 
N-terminal 
protein tag 
pWUR 
number 
Thermoanaerobacter tengcongensis MB4      yes histidine pWUR536 
Methanothermobacter thermautotrophicus ΔH      yes none pWUR611 
Methanocaldococcus jannaschii DSM 2661      yes none pWUR612 
Escherichia coli serotype O112ab      no MBP pWUR574 
Bermanella marisrubri sp. RED65      no histidine pWUR537 
 
Among this group of prokaryotic sequences, the candidate C5-epimerase sequence (RED-C5-
epimerase) of the marine bacterium Bermanella marisrubri sp. RED65 (Pinhassi et al., 2009) 
showed significantly higher homology to animal heparan sulfate D-glucuronyl C5-epimerase 
than any other prokaryotic sequence. Based on the sequence, RED-C5-epimerase is placed 
within PFAM family C5-epim_C (PF0662), representing the C-terminal domain of heparan 
sulfate D-glucuronyl C5-epimerase (http://pfam.sanger.ac.uk/family?entry=PF06662; 
Bateman et al., 2004). The gene coding for RED-C5-epimerase (RED65_08024) contains 1347 
base pairs, resulting in a protein of 448 amino acids with a theoretical molecular mass of 
51,914 Da.  
We constructed a multiple sequence alignment (T-Coffee server; 
http://www.tcoffee.org; Notredame et al, 2000), to illustrate the homology between RED-
C5-epimerase and the animal heparan sulfate D-glucuronyl C5-epimerases (Fig.1). The 
multiple sequence alignment was visualized using GeneDoc version 2.6 (Nicholas et al., 
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1997). RED-C5-epimerase has 22% identity and 36% similarity with human heparan sulfate 
D-glucuronyl C5-epimerase, mostly based on high similarity at the carboxy terminus (40% 
identity, 59% similarity). In contrast with the animal proteins, RED-C5-epimerase has no 
transmembrane helix at the amino terminus. However, the overall secondary structure is 
predicted to be rather similar to the animal heparan sulfate D-glucuronyl C5-epimerase 
(PSIPRED Server http://www.psipred.net/psiform.html; McGuffin et al., 2000). 
 
                    hhhhhhhhhhhhhhhhhhhh                                                                            sssssss        H.sap: MRCLAARVN---YKTLIIICALFTLVTVLLWNKCSSDKAIQFPRRSS-SGFRVDGFEKRAAASESNNYMNHVAKQQSEEAFPQEQQKAPPVVGGFNSNVGSKVLGLKYEEIDCLI 111 
M.mus: MRCLAARVN---YKTLIIICALFTLVTVLLWNKCSSDKAIQFPRHLS-SGFRVDGLEKRSAASESNHYANHIAKQQSEEAFPQEQQKAPPVVGGFNSNGGSKVLGLKYEEIDCLI 111 
C.ele: MKCLRWRSNRHRIYLLVACGALFLLN-----------------RHLTQEESRIDEEDEE---------LTQVDVNEDDKKIE----CEPP----------------GSIESKCIA  69 
REDC5: MKLFNKK-------------------------------------------------------------------------------------------------------IDCIE  12 
               
                                                                                                                     sssss     
 
        sssssssss    sssshhhhh    sssssss     ssssssss ss                    sss  ssssss                   hhhhhhhhhhhhhhh     
 
H.sap: NDEHTIKGRREGNEVFLPFTWVEKYFDVYGKVVQYDGYDRFEFSHSYSKVYAQRAPYHPDGVFMSFEGYNVEVRDRVKCISGVEGVPLST-QWGPQGYFYPIQIAQYGLSHYSKN 225 
M.mus: NDEHTIKGRREGNEVFLPFTWVEKYFDVYGKVVQYDGYDRFEFSHSYSKVYAQRSPYHPDGVFMSFEGYNVEVRDRVKCISGVEGVPLST-QWGPQGYFYPIQIAQYGLSHYSKN 225 
C.ele: DNGKSMKCWKDEEDVYFPVSYLKKRFDMTGKLG-KDGS-TFELYTSYAKMRSPDSTYDPLGPFGHFSTYSVETRDRVRCVSAKTDVPMST-QWDPIPYYYPIQISQYGLQHYSRM 181 
REDC5: CDG----------DIYIELKAIKEKFGLIL-----NGT-----DLTYSKTNLNVNDYFVDGDYLNFSKLSVESWEIVKLDD--CGIPKNTFRWG--EYYYPITIAHYGLELFGKY 103 
 
                     sssshhhhhhhh                 ssssssss                  sssssssssss                    hhhhhhhhhhhhhh      
 
                                             sssss      ssssss       sssss      sssssss       ssssssss    ssssssss            
 
H.sap: LTEKPPHIEVYETAEDRDKN-KPNDWTVPKGC-----FMANVADKSRFTNVKQFIAPETSEGVSLQLGNTKD-FIISFDLKFL-TNGSVSVVLETTEKNQLFTIHYVSNAQ---- 329 
M.mus: LTEKPPHIEVYETAEDRDRNIRPNEWTVPKGC-----FMASVADKSRSTNVKQFIAPETSEGVSLQLGNTKD-FIISFDLKLL-TNGSVSVVLETTEKNQLFTVHYVSNTQ---- 330 
C.ele: KLDSISNKSEASPKDDVILGVNSKEWKGAAGMHETTERLFFNDEQMGKVVNISAGAALANAGAYVYLDKSPDLHVISFDWKPYEANSSFTVLAKMKQDDLLVLINYVYSEGNGKC 296 
REDC5: INSDDIELKKYM-GPDSDINVSSNNG------------KVQICVKGTLDTGYSLILEGRASIKNLEVMPQGD-FRMYFEEDEIDTKKSYCVYNG--ESKIVNEVQYLS------- 195 
 
                                             sssssss       sss     ssssssss     sssssss       sssss         ssss               
 
                   ssss          ssssss                                       ssssss   sssss           hhhhhhhhhhhhhhhhh       
 
H.sap: ------------LIAFKER-------DIYYGIGPRTSWSTVTRDLVTDLRKGVGLSNTKAVKPTKIMPKKVVRLIAKG-KGFLDN------ITISTTAHMAAFFAASDWLVRNQD 417 
M.mus: ------------LIAFRDR-------DIYYGIGPRTSWSTVTRDLVTDLRKGVGLSNTKAVKPTKIMPKKVVRLIAKG-KGFLDN------ITISTTAHMAAFFAASDWLVRNQD 418 
C.ele: VWQEEERISDDYIVQKPKKDGQVSYSYSYIGNSPIGEWSTVTRDLLVDVARALSSGDNRKKDDNVVLHAGDLRLVSLGFRGELTVKQK---ITQRREQHSHAFYAAADWLVKNQN 408 
REDC5: --------------------------------------------LDDYLCLAES-----------------IEIKSIKLRGAVDITLPLNNIPDKPKEYWEKAVHIANWFVDEQR 249 
 
                                                                              sssssssss  ssss          hhhhhhhhhhhhhhhhh         
 
             ssssss               hhhhhhhhhhhhhhhhh   hhhhhhhhhhhhhh        sssss     ssss       sss  hhhhhhhhhhhhhh             
 
H.sap: EKGGWPIMVTRKLGEG-FKSLEPGWYSAMAQGQAISTLVRAYLLTKDHIFLNSALRATAPYKFLSEQHGVKAVFMNKHDWYEEYPTTPSSFVLNGFMYSLIGLYDLKET------ 525 
M.mus: EKGGWPIMVTRKLGEG-FKSLEPGWYSAMAQGQAISTLVRAYLLTKDYVFLSSALRATAPYKFPSEQHGVKAVFMNKHDWYEEYPTTPSSFVLNGFMYSLIGLYDLKET------ 526 
C.ele: DRGGWSVPVERSIAER-KLVLPPGWHSAMAQGHGISVLTRAFKHFNDEKYLKSAAKALKLFKINSSDGGVRGEFFG-NIWYEEYPTTPGSFVLNGFLYSLIGLYDLSQLELMIDE 521 
REDC5: EDGVWDSKFDHLFYKGRTEVMESGWASGLGQGLAISFLIRMYNESKDKAYLDACEKALSIYSVNVEDGGILRLWDTKYSFYEEYPTEPASYVLNGFIFSLLGLYDYSVI------ 358 
 
             ssssss              hhhhhhhhhhhhhhhhhh   hhhhhhhhhhhhhh         ssss     ss         sss  hhhhhhhhhhhhhh  
                
               hhhhhhhhhhhhhhhhhhh                            hhhhhhhhhhhhhhh    hhhhhhhhhhhhhhh                                 
 
H.sap: ----AGEKLGKEARSLYERGMESLKAMLPLYDTGSGTIYDLRHFMLGIAPNLARWDYHTTHINQLQLLSTIDESPVFKEFVKRWKSYLK-GSRAKHN 617 
M.mus: ----AGETLGKEARSLYERGMESLKAMLPLYDTGSGTIYDLRHFMLGIAPNLARWDYHTTHINQLQLLSTIDESPIFKEFVKRWKSYLK-GSRAKHN 618 
C.ele: NDETMRAKI-QEAQELYSAGVRSLKQLLPLYDTGSGTIYDLRHVALGTAPNLARWDYHAVHVYLLKWIAGIEKDEVLSKTADRWIGYAY-GKRAKHN 616 
REDC5: -----GSSL--KAKQLFESGLVTLKRMLPLYDLGDRSAYDLTHYTCGEFPNIARWGYHDTHLNLLMAVYRITNDEFYFKFYERWKSYVLDGFRCRHN 448 
 
               hhhhhhhhhhhhhhhhhhh                            hhhhhhhhhhhhhhh    hhhhhhhhhhhhhhh                                  
Figure 1 – Multiple sequence alignment of Bermanella marisrubri sp. Red65 RED-C5-epimerase (RED65) (Locus: 
RED_08024) compared to characterized animal heparan sulfate D-glucuronyl C5-epimerases (H.sap: Homo 
sapiens; M.mus: Mus musculus; C.ele: Caenorhabditis elegans). Secondary structure predictions are indicated 
for human and B. marisrubri (h indicates predicted α-helices, s indicates predicted β-strands). 
 
Protein production studies 
As for the animal proteins, putative signal sequences were present in many of the 
prokaryotic sequences (SignalP; Bendtsen et al., 2004). However, these have not been 
included in the PCR amplicons, resulting in truncated proteins starting at the predicted 
cleavage site. For most candidate C5-epimerases we added a protein tag to facilitate 
purification. Addition of such protein tag always was at the N-terminus, as research on the 
murine heparan sulfate D-glucuronyl C5-epimerase showed a dramatic reduction in activity 
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when the enzyme had a C-terminal tag, while an N-terminal tag had no obvious effect on 
activity (Crawford et al., 2001). 
The constructed plasmids were used to transform E. coli BL21(DE3). Every candidate 
C5-epimerase was expressed successfully resulting in significant quantities of protein. 
However, we experienced the solubility of these proteins not to be very good. Nevertheless, 
most constructs could be partly expressed as soluble protein, taking care of tightly 
controlled expression conditions with relatively low expression time, temperature and IPTG 
concentrations. Only the candidate C5-epimerase from E. coli (ECO-C5-epimerase) was 
completely insoluble. Therefore we constructed a fusion of Maltose Binding Protein (MBP) 
to the N-terminus of ECO-C5-epimerase, resulting in soluble production of the fusion 
protein. Although highly speculative, possibly the MBP compensates for the absence of the 
other members of the LPS biosynthesis pathway. Enzymes involved in the biosynthesis of cell 
surface polysaccharides, typically are associated to the inner membrane of the cell wall as 
part of in a bigger complex (review: Whitfield, 1995). Based on our findings ECO-C5-
epimerase is likely to be part of such a membrane spanning protein complex together with 
other members of the O-antigen biosynthesis pathway. This is in contrast to previous 
findings that propose ECO-C5-epimerase as a cytoplasmic enzyme (Liu et al., 2008). This 
hypothesis is based on the absence of a signal sequence in ECO-C5-epimerase. Indeed, no 
signal sequence is predicted (SignalP 3.0 Server http://www.cbs.dtu.dk/services/SignalP; 
Bendtsen et al., 2004), although a highly hydrophobic domain is predicted in the amino acid 
sequence, potentially involved in the association with other proteins. 
 
Size exclusion chromatography 
To determine the oligomeric state we performed size exclusion chromatography and applied 
purified samples of both the bacterial candidate C5-epimerases on a Superdex 200 high-
resolution 10/10 column. The oligomeric state of ECO-C5-epimerase could not be 
determined, since the fusion protein tended to form soluble aggregates of large undefined 
size. The oligomeric size of TTE-C5-epimerase could be determined as monomeric as the 
elution occurred in one major peak with a molecular mass of 28 kDa. 
The oligomeric state of RED-C5-epimerase is larger than monomeric. In freshly 
prepared protein samples RED-C5-epimerase is present in a dimeric/tetrameric form, they 
occur in about a 2:1 ratio, and appears to be a dynamic equilibrium. During storage RED-C5-
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epimerase has the tendency to form larger aggregates. Non-detergent sulfobetaines (NDSB) 
are known to efficiently prevent protein aggregation (Collins et al., 2006). We used up to 1 
M of NDSB201 and although we could not see any obvious effect in prevention of 
aggregation at 4°C, NDSB201 did prevent aggregation upon freezing. Also addition of 
reducing agents (2 mM Tris(2-carboxyethyl)phosphine) did help to prevent aggregation, and 
helped maintaining the initial oligomeric state. High levels of reducing agent (e.g. 50 mM β-
mercaptoethanol) even partly reversed aggregation. This effect possibly can be explained as 
prevention of the formation of intramolecular and intermolecular disulfide bonds between 
any of the nine cysteine residues in the amino acid sequence of RED-C5-epimerase. 
 
Neighborhood analysis 
To gain insight in the physiological role of RED-C5-epimerase we performed a gene 
neighborhood analysis. The genomic context of RED65_08024 comprises genes involved in 
biosynthesis of surface polysaccharides. In bacteria these genes generally are organized in 
gene clusters. Studies on the organization of similar clusters in Escherichia coli (Clarke et al., 
1999) or Pasteurella multocida (Chung et al., 1998), show that these clusters consist of three 
regions. Region 1 and 3 are conserved and involved in capsular polysaccharide export, while 
region 2 is involved in the biosynthesis of serotype specific polysaccharides, and therefore is 
highly variable (Whitfield, 2006). RED65_08024 and another nine ORFs, are flanked by these 
capsular polysaccharide export regions 1 and 3 (Fig.2). 
We compared the genomic context of RED-C5-epimerase with the organization of 
similar genes in other bacteria. We observed high resemblance with the capsular gene 
clusters of the aquatic bacteria Shewanella violacea DSS12 (Aono et al., 2010), Aeromonas 
hydrophila PPD134/91 (Zhang et al., 2002) and Burkholderia ambifaria IOP40-10. Not only do 
they all possess the region 1 and 3 genes involved in capsular polysaccharide transport as 
seen in Escherichia coli K10 and Pasteurella multocida X-73, they also have several genes in 
common of the type specific region 2. However, the presence of a C5-epimerase is unique to 
Bermanella marisrubri sp. RED65. Most likely this candidate C5-epimerase is involved in a 
species- or type-specific sugar modification. This would be in agreement with what would be 
expected for a bacterial D-glucuronyl C5-epimerase. As discussed in chapter 2, all 
demonstrations of L-iduronic acid being present in prokaryotes are known to be species- or 
type-specific constituents. 
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        Region 1                 Region 2         Region 3 
Bermanella
marisrubri sp. 
Red65
Burkholderia
ambifaria
IOP40-10
Aeromonas
hydrophila
PPD134/91
Capsule Export Capsule Biosynthesis Capsular Export
Escherichia 
coli K10
Pasteurella
multocida
X-73 (A:1)
Region 2 hya A to E hyaluronan capsular
Region 2 multiple genes type specific
 
Figure 2 – Genomic context of Red_08024 (in red) in comparison with other bacterial capsular polysaccharide 
biosynthesis gene clusters. Flanking genes in blue (region 1; kpsM, kpsT, kpsE and kpsD) and green (region3; 
kpsC and kpsS) are likely to be involved in polysaccharide export. The genes in between (region 2) are likely to 
be involved in serotype specific capsular polysaccharide biosynthesis. The conserved genes are predicted UDP-
N-acetyl glucosamine-2-epimerase (purple), UDP-N-acetyl-D-mannosaminuronic acid dehydrogenase (violet) 
and glycosyltransferase (magenta). The D-glucuronyl C5-epimerase (red) is unique to B. marisrubri Sp. RED65. 
 
Enzyme activity studies 
Analysis of hexuronic acids constituents in polysaccharides is easiest after hydrolysis of the 
corresponding polysaccharide. Generally enzymatic hydrolysis is preferable over chemical 
hydrolysis, since less side products are formed. Several heparinases have been characterized 
to date, each having a specific substrate specificity (Desai et al., 1993). Unfortunately none 
of them are applicable for hexuronic acid analysis since all these enzymes are lyases rather 
than hydrolases (Hovingh and Linker, 1970). As a result of the beta-elimination reaction on 
the glycosidic bond, both D-glucuronic acid and L-iduronic acid are converted to 4,5-
unsaturated hexuronic acid. 
Chemical hydrolysis with HCl does result in partial hydrolysis of heparin, liberating 
monomeric hexuronic acids. Tight control of hydrolysis time, temperature and acid 
concentration are crucial to prevent substantial formation of side products and to prevent 
differential release of D-glucuronic acid and L-iduronic acid, due to differences in acid lability 
of their glycosidic bonds (Conrad, 1980). Therefore a control sample is included in each run 
to validate the hydrolysis conditions. 
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Monomeric D-glucuronic acid can be separated from L-iduronic acid by high performance 
anion exchange chromatography (HPAE) (Whitfield et al., 1991; De Ruiter et al., 1992). We 
optimized the protocol for analysis of the hydrolyzed reaction mixture on a Dionex system, 
monitoring hexuronic acids with an electrochemical detector using pulsed amperometric 
detection (PAD) (Fig.3A). 
Using an anion exchange column (CarboPac PA-100) we were able to separate D-
glucuronic acid and L-iduronic acid. However, it is important to keep salt-levels low since the 
retention time of L-iduronic acid is lowered at increasing salt concentrations. With hardly 
any salt effect on the retention time of D-glucuronic acid, best is to keep salt concentrations 
as low as possible in the samples, to prevent dramatic decrease in separation of both 
hexuronic acids. 
 
 
A BGlcA
IdoA
 
Figure 3 – Separation of D-glucuronic acid (GlcA) and L-iduronic acid (IdoA) using an HPCL-PAD system. (A) 
Separation of standards (B) Hydrolyzed (de-O-sulfated) heparin; black = control sample, gray = sample 
incubated with RED-C5-epimerase. 
 
Using this method we tested C5-epimerase activity of the selected candidate C5-epimerases 
on various available D-glucuronyl containing GAGs and GAG precursors. Tested substrates 
included chondroitin, hyaluronan, UDP-GlcA, N-sulfated K5 and de-sulfated / re-acetylated 
heparin. Most of the samples did not give any significant changes in the hexuronic acid 
content of the hydrolysate, except for the RED-C5-epimerase. We tested the effect on de-O-
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sulfated heparin, both by addition as crude cell lysate and purified enzyme. In heparin the 
ratio between both hexuronic acids is typically 35% D-glucuronic acid and 65% L-iduronic 
acid. However, overnight incubations with RED-C5-epimerase resulted in a shift in ratio of 
both hexuronic acids where L-iduronic acid levels drop to 45% and D-glucuronic acid increase 
to 55% (Fig.3B and Fig.4). Control samples were treated identically and only differ in the cell 
lysate composition, which lacks RED-C5-epimerase. 
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Figure 4 – Hexuronic acid ratio in heparin before and after treatment with RED-C5-epimerase. Both cell lysate 
and pure protein show partial epimerization of L-iduronic acid (IdoA) into D-glucuronic acid (GlcA). 
 
We performed a time series experiment to have a better monitoring of the activity. These 
time series showed a gradually decrease in the conversion rate of the hexuronic acids until 
an equilibrium was reached with a ratio of about 55% D-glucuronic acid and 45% L-iduronic 
acid (Fig.5). 
Elongation of the reaction time did not result in more net conversion of L-iduronic 
acid, neither did addition of higher amounts of enzyme. The reverse reaction was tested by 
mixing RED-C5-epimerase with heparonan (K5 polysaccharide). We could detect some trace 
levels of L-iduronic acid although the amounts were rather low, and therefore were 
considered not conclusive. 
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Figure 5 – Analysis of the hexuronic acid content of heparin as a result of RED-C5-activity. 
 
To confirm this D-glucuronyl C5-epimerase activity we performed an additional screen based 
on the tritium release method using 3H-labeled polysaccharide substrate (Campbell et al., 
1983; Kusche et al., 1991). We tested RED-C5-epimerase activity on two different tritium 
labeled substrates, K5 polysaccharide (De-acetylated/N-sulfated) and heparin and all 
measurements were performed in duplo (Table 2).  
 
Table 2 – Activity measurement of D-glucuronyl C5-epimerase mediated tritium release. When no significant 
activity could be determined N.A. is stated.  
Substrate Enzyme Buffer 3H release (cpm) 
Heparin RED-C5-epimerase HEPES N.A. 
Heparin RED-C5-epimerase TRIS-HCl 64 ±29 
Heparin Control (D-glucuronyl C5-epimerase) HEPES 274 ±55 
K5 polysaccharide RED-C5-epimerase HEPES N.A. 
K5 polysaccharide RED-C5-epimerase TRIS-HCl 35 ±23 
K5 polysaccharide Control (D-glucuronyl C5-epimerase) HEPES 27 ±20 
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For both substrates we detected significant D-glucuronyl C5-epimerase activity using RED-
C5-epimerase, although this activity was only observed using a TRIS-HCl buffer prepared 
with TCEP and NDSB-201. A HEPES buffer lacking TCEP and NDSB-201 did not give any 
significant activity. Activity was low compared to the murine heparan sulfate D-glucuronyl 
C5-epimerase which was used as a control. The fact that we were unable to detect activity of 
C5-epimerase in absence of TCEP and NDSB-201 is most likely due to oxygen related 
inactivation upon storage. 
 
Discussion 
L-iduronic is a common and essential sugar in several animal glycosaminoglycans. Previous in 
silico analyses (Chapter 2) demonstrate that L-iduronic acid not only is typical for eukaryotic 
GAGs, but occasionally also can be found as a constituent in type specific prokaryotic cell 
wall polysaccharides. From glycosaminoglycan biosynthesis we know that L-iduronic acid is 
synthesized via a C5-epimerization of D-glucuronic acid (review: Li, 2010), a rather common 
sugar that is found in most life forms. L-iduronic acid in prokaryotes is likely to be 
synthesized in a similar way, which implies the involvement of a D-glucuronyl C5-epimerase.  
We selected five putative D-glucuronyl C5-epimerases based on a previously analysis 
(Raedts et al., 2011). The selected genes were cloned and expressed in E. coli and tested for 
D-glucuronyl C5-epimerase activity. For all but one of the produced candidate C5-
epimerases, we have not been able to show conversion of D-glucuronic acid / L-iduronic 
acid. Point of discussion could be whether this is due to alternative substrate requirements 
or inadequate reaction conditions. With MBP-ECO-C5-epimerase as an exception, we have 
no knowledge on the capsular / lipopolysaccharide composition and as such nothing is 
known about the substrate specificity of the different candidate C5-epimerases. 
Identification of these cell wall polysaccharides could be a first step in providing insight in 
both the physiological role and substrate acceptance of these candidate C5-epimerases. 
The candidate C5-epimerase from the marine bacterium Bermanella marisrubri sp. 
RED65 is an exception on this, as we were able to measure conversion of hexuronic acid 
levels in the glycosaminoglycan heparin. For hydrolyzed (de-O-sulfated) heparin / RED-C5-
epimease reaction mixtures we detected a conversion of L-iduronic acid into D-glucuronic 
acid (Fig.4 and Fig.5). This makes us speculate that RED-C5-epimerase has similar catalytic 
properties and results in similar conversion ratios as the animal heparan sulfate D-glucuronyl 
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C5-epimerase. An epimerization reaction typically ends up in an equilibrium between the 
two specific epimers. For animal D-glucuronyl C5-epimerases it has been postulated that the 
epimerization equilibrium is slightly towards D-glucuronic acid over L-iduronic acid (Hagner-
McWhirter et al., 2000). 
In case of the animal GAGs, the subsequent O-sulfation results in irreversibility of the 
epimerization reaction in vivo, and thus in accumulation of L-iduronic acid to levels up to 
90% of the total hexuronic acid amount (Hagner-McWhirter et al., 2004). The de-O-sulfated 
heparin that we used as substrate does not have such a “pull” of the equilibrium and 
therefore is likely to result in a state of equilibrium upon addition of a D-glucuronyl C5-
epimerase. This equilibrial state is clearly shown in figure 5. The observed conversion must 
be an effect of the RED-C5-epimerase, as control-samples do not show the shift in hexuronic 
acid ratio. No further conversion was observed after prolongated incubation or after 
addition of more enzyme. 
We were unable to proof significant L-iduronic acid levels for the RED-C5-epimerase / 
K5 substrate incubations using HPLC-PAD analysis. However, tritium labeled substrate assays 
resulted in low but significant levels of tritium release, indicating reversible D-glucuronyl C5-
epimerase activity. Likely the K5 polysaccharide is a poor substrate for the enzyme; likewise 
for the murine heparan sulfate D-glucuronyl C5-epimerase it is known that activity on the K5 
polysaccharide also is less than on heparin (Li, personal communication). 
As far as we know this is the first example showing D-glucuronyl C5-epimirase activity 
in prokaryotes. Most likely, the existence of more prokaryotic D-glucuronyl C5-epimerases is 
anticipated, as several L-iduronic acid containing cell wall polysaccharides have been 
described (Raedts et al., 2011). Unfortunately the responsible D-glucuronyl C5-epimerases 
have not been identified yet, as genomic data is generally not available for the 
corresponding organisms. This study reveals that prokaryotic candidate C5-epimerases such 
as RED-C5-epimerase potentially are applicable as a biotechnological tool in the controlled 
chemo-enzymatic synthesis of L-iduronic acid containing glycosaminoglycans as heparin. 
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Abstract 
The epimerization of D-glucuronic acid into L-iduronic acid is an essential step in the 
biosynthesis of heparin. The gene coding for the responsible C5-epimerase from mouse has 
been identified and cloned previously (Li et al, 1997). Although the corresponding enzyme 
has in vitro epimerization activity, still many restrictions exist in order to use this D-
glucuronyl C5-epimerase in an industrial process. Protein production levels, number of 
accepted substrates and in vitro activity are all rather low. Therefore we aimed to set up C5-
epimerase production in a microbial expression system. A synthetic Mus musculus D-
glucuronyl C5-epimerase gene was used to transform two different expression hosts. Protein 
expression levels were tested in both the yeast Pichia pastoris and the bacterium Escherichia 
coli BL21(DE3). No detectable levels of C5-epimerase expression were observed in P. 
pastoris. Successful bacterial expression was achieved. Initial solubility problems of the C5-
epimerase could be overcome by fusion of the C5-epimerase to maltose bind protein (MBP). 
D-glucuronyl C5-epimerase activity was confirmed indicating an active fusion protein. 
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Introduction 
Glycosaminoglycans (GAGs) are a specific class of biological active carbohydrates that are 
present throughout the animal kingdom. A well-known example is heparin. This GAG has a 
major pharmaceutical application as an anti-coagulation drug. It is a polymer that is highly 
negatively charged due to the presence of sulfate- and carboxyl residues. The sulfatation 
step can occur at multiple positions, while the carboxyl group is part of a hexuronic acid. 
Typically two types of hexuronic acids can be found in GAGs; D-glucuronic acid and its C5-
epimer L-iduronic acid. Variation in the relative amounts of these two significantly influences 
the physiological properties of the carbohydrate chain. This makes the C5-epimerization an 
essential modification in glycosaminoglycans like heparin. 
The conversion of D-glucuronic acid to L-iduronic acid is catalyzed by a single enzyme. 
The responsible enzyme, a D-glucuronyl C5-epimerase, is conserved throughout the animal 
kingdom (Fig.1). This enzyme is localized in the Golgi apparatus (Crawford et al., 2001) where 
it probably acts in a larger complex with other enzymes involved in heparin biosynthesis 
(Sasisekharan and Venkataraman, 2000). Previous studies have led to the (biochemical) 
characterization of the D-glucuronyl C5-epimerase. Early research was mainly on protein 
isolates from bovine tissue (Campbell et al., 1994). Later research shifted to recombinant 
Mus musculus (mouse) D-glucuronyl C5-epimerase produced in insect cells co-transfected 
with baculovirus (Li et al., 2001) or Chinese hamster ovary cells (Crawford et al., 2001). 
For long time production of the recombinant M. musculus D-glucuronyl C5-epimerase 
has been limited to animal or insect cell expression systems (Jalkanen et al., 2008). 
Functional expression of the enzyme in microbial expression systems has been problematic 
for long time, although recently progress has been made on yeast expression systems (Li, 
2010) and bacterial expression systems (Li et al., 2010). Establishment of D-glucuronyl C5-
epimerase production in a bacterial expression system would enhance rapid, large scale and 
less expensive production of this mammalian C5-epimerase. An additional advantage would 
be the possibility for enzyme engineering. Protein improvement using laboratory evolution 
generally needs large and easily culturable libraries, which makes Escherichia coli very 
attractive as a production host. Protein expression experiments of D-glucuronyl C5-
epimerase in E. coli have been attempted before, resulting in production of large quantities 
of D-glucuronyl C5-epimerase. However, major solubility problems do exist for this protein 
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being expressed in this bacterial host, resulting in neither soluble nor functional protein. 
Functional expression of a D-glucuronyl C5-epimerase is crucial when aiming for 
controlled synthesis of heparin. Most heparin modifications can be done in a chemical way, 
the only exception being the epimerization of D-glucuronic acid towards L-iduronic acid. To 
reach successful chemo-enzymatic synthesis of heparin a more robust and better expressed 
D-glucuronyl C5-epimerase is crucial. In this study for production of elevated quantities of a 
functional D-glucuronyl C5-epimerase in a microbial host. Two distinct expression systems 
are tested, each applicable in large scale production processes. This study describes the 
attempts to obtain improved solubilization and stabilization of C5-epimerase expression in E. 
coli by fusion to maltose binding protein (MBP). The MBP protein is highly soluble in E. coli, 
and is known to be a potential solubilizing factor for E. coli based protein production (Kapust 
and Waugh, 1999). Fusion of MBP to the amino terminus of D-glucuronyl C5-epimerase 
(MBP-MmC5) possibly increases the overall solubility/stability. In addition expression studies 
have been performed in the yeast Pichia pastoris. Based on bioinformatical predictions there 
are three putative N-glycosylation sites in the murine protein (Fig.1). These sites are 
potential bottlenecks for bacterial-based expression, since bacterial systems are generally 
unable to modify proteins post-translationally. The yeast P. pastoris is widely used as 
microbial expression host because of its ability for N-glycosylation similar to mammalian 
systems, and therefore possibly can improve protein expression. 
 
Materials and methods 
Chemicals were purchased from Sigma-Aldrich. L-iduronic acid was purchased from Toronto 
Research Chemicals. Restriction enzymes, Pfu DNA polymerase and T4 DNA ligase were from 
Invitrogen and New England Biolabs. All plasmids were constructed in E. coli DH5α. The used 
bacterial expression host was E. coli BL21 (DE3) (Novagen), containing the tRNA helper 
plasmid pSJS1244. The used bacterial expression vectors were pET24d (Novagen) and pMAL-
C2 (New England Biolabs). For yeast expression we used strain P. pastoris GS115 and the 
expression vector pPIC9 (invitrogen). 
 
Bioinformatics 
Sequences coding for heparosan D-glucuronyl C5-epimerases were identified by performing 
BLAST searches (http://blast.ncbi.nlm.nih.gov/Blast.cgi; Altschul et al., 1997) using protein 
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sequences of the characterized C5-epimerases from mouse, human and C. elegans. 
Retrieved sequences were aligned in a multiple sequence alignment using the T-Coffee 
server (http://www.tcoffee.org; Notredame et al, 2000). The alignment was manually 
checked and adjusted when considered appropriate. The multiple sequence alignment was 
visualized using GeneDoc version 2.6 (Nicholas et al., 1997). A bootstrapped phylogenetic 
tree corrected for multiple substitutions, was generated with ClustalX version 1.83 
(Thompson et al., 1997). The tree was displayed using the neighbor-joining method with 
TreeView version 1.6.5. (Page et al., 1996). 
These sequences were scanned for conserved motifs against multiple databases by 
using InterProScan (http://www.ebi.ac.uk/Tools/InterProScan; Zdobnov and Apweiler, 2001). 
The amino terminus was screened for putative signal sequences using the SignalP 3.0 Server 
(http://www.cbs.dtu.dk/services/SignalP; Bendtsen et al., 2004). Putative N-glycosylation 
sites were identified using NetNGlyc 1.0 (Gupta et al., 2004). The protein secondary 
structure was predicted using the PSIPRED Server (http://www.psipred.net/psiform.html; 
McGuffin et al., 2000). Conserved protein folds were recognized by using the PHYRE Protein 
Fold Recognition Server (http://www.sbg.bio.ic.ac.uk/phyre/; Kelley and Sternberg, 2009). 
 
Gene optimization and cloning 
A synthetic gene was designed based on M. musculus (mouse) D-glucuronyl C5-epimerase 
(MmC5) mRNA (GI: 133892759; base pair 7-1863). The gene was optimized towards the 
codon bias of P. pastoris and generated by BaseClear (Leiden, the Netherlands). Restriction 
sites XhoI / EcoRI, introduced flanking the gene, were used to clone the synthetic gene in 
expression vector pPIC9. E. coli DH5α was transformed with the ligation mix to amplify the 
resulting plasmid named pWUR543. The truncated genes used for E. coli based expression 
were created by PCR using the previously mentioned synthetic MmC5 gene as template. 
Three different sense primers used were for the amplification; BG2853 (truncation1; 
5’-CCCGAATTCAGCGACAAAGCAATCCAATTTCCTCG-3’), BG3143 (truncation2; 5’-
CGCGAATTCGTAGAAGTCCGTGACAGAGTCAAATGTATAAG-3’) and BG3144 (truncation3; 5’-
CGCGAATTCACTGCCCACATGGCTGCTTTCTTTGC-3’). The antisense primer was BG2854 (5’-
CCCCTGCAGTTAGTTATGCTTTGCCCTACTTCCTTT-3’). The introduced flanking restriction sites 
EcoRI / PstI (underlined) were used to clone the gene in the bacterial expression vector 
pMal-C2 (New England Biolabs). All plasmids were transformed into E. coli DH5α. 
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MmC5 production in Pichia pastoris 
P. pastoris was transformed with pWUR543 according to the supplier ‘s protocol. Successful 
integration of the murine MmC5 gene in the P. pastoris genome was confirmed by PCR 
analysis. A starter culture was grown overnight at 30°C in a 100 ml baffled Erlenmeyer flask 
with 10 ml BMGY medium (Buffered Minimal Glycerol Yeast extract). Biomass was collected 
via a centrifuge step, and used to inoculate 50 ml of fresh BMMY medium (Buffered Minimal 
Methanol Yeast extract). To achieve sufficient aeration a 500 ml baffled flask was used, that 
was shaken briskly. The MmC5 gene is under control of the AOX1 promoter, therefore 
expression was induced by addition of 0.5% v/v methanol after which cultivation was 
continued for 24 hours at 30°C. After the induction phase the medium was separated from 
the biomass by a centrifugation step. Excreted proteins in the medium were enriched using a 
centrifugal protein concentrator with a cut-off of 30 kDa. A 10 mM HEPES buffer (pH7) 
containing 50 mM NaCl was used to wash the protein fraction. Both the enriched secreted 
protein fraction as a total cell pellet fraction were checked on protein content by SDS-PAGE 
analyses. As a control identical fractions of wild type P. pastoris were used. Five protein 
bands that size-wise could be the C5-epimerase were isolated from the gel, and analyzed by 
mass spectrometry for protein identification. 
 
MmC5 production in Escherichia coli 
Expression vectors pWUR544 (no tag), pWUR575 (truncation1), pWUR576 (truncation 2) and 
pWUR577 (truncation 3) were used to transform E. coli BL21(DE3) harboring pSJS1244. For 
each construct a single colony was used to prepare a starter culture by inoculating Luria-
Bertani medium (LB) containing 100 μl/ml ampicillin and 50 μl/ml spectinomycin. The starter 
culture was grown overnight at 37°C while shaking. A larger culture was started by 
inoculation of 100 ml LB (similar antibiotic content) with 1% starter culture. The culture was 
grown at 37°C, while shaking, until OD600 = 0.6 was reached. Protein expression was induced 
by addition of isopropyl β-D-1-thiogalactopyranoside (IPTG) to a final concentration of 0.25 
mM, and growth was continued for another 3 hours while shaking at a temperature of 30°C. 
Cells were harvested by centrifugation, and resuspended in 10 ml of 10 mM HEPES buffer 
(pH7) with 50 mM NaCl. The cells were disrupted by sonication with intermitted cooling 
steps on ice. The crude cell lysate was centrifuged (16,000 x g) to remove cell debris. The 
supernatant was applied on a gravity flow column of amylose resin, and purified according 
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the manufacturer’s protocol. All elution fractions that contained MBP-MmC5 were pooled, 
and checked by SDS-PAGE analysis. Purified MBP-MmC5 fusion proteins were used for 
inductively coupled plasma atomic emission spectroscopy (ICP-AES) and for activity 
measurements. Activity measurements were based on HPLC-PAD analysis and tritium 
release from labeled substrate as described in Chapter 3. 
 
Results 
Bioinformatics 
To get a better understanding of the occurrence and conserved residues of heparosan D-
glucuronyl C5-epimerases, we performed BLAST searches with protein sequence human C5-
epimerase. These reveal candidate genes in almost all available animal genomes. In analogy 
to heparin, the presence of candidate C5-epimerase is not restricted to vertebrates that 
have a vascular blood system, but also can be found in many invertebrates (e.g. insects, 
nematodes, protozoa). An example where no homologous gene was found is the genome of 
the sponge Amphimedon queenslandica. While being virtually ubiquitous in animals, the C5-
epimerase seems absent in plants and fungi, where no single candidate could be identified. 
A number of sequences of evolutionary diverse animals have been selected to 
compose a multiple sequence alignment (Fig.1). Sequence homology is not uniform 
throughout the amino acid sequence. Least homology is seen at the amino-termini of the 
candidate C5-epimerases. SignalP analysis reveals an N-terminal signal peptide for most 
sequences. Therefore the first 32 amino acids where not included in the constructed 
recombinant proteins (see below). For the central part of the sequence three glycosylation 
sites are predicted; for the murine sequence these sites are Asp-225, Asp-304, and Asp-394 
(Fig.1). Possibly this N-glycosylation is needed structurally. 
In contrary to the more variable N-terminus, the carboxy-terminus of the C5-
epimerases are highly conserved. All members have such a conserved C-terminal domain 
and are included in the family PFAM06662 (Bateman, et al., 2004). Secondary structures 
predictions indicate seven putative α-helixes in this domain. Based on predictions with 
PHYRE these helixes possibly are arranged in an alpha/alpha toroid fold. The alpha/alpha 
toroid fold comprises up to seven alpha-hairpins are arranged in closed circular array. 
Members that are proven to have such a fold include glycosidases and lyases. It is likely that 
the D-glucuronyl C5-epimerase protein shares structural homology with such a protein.
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Mmus: -------------------------------------MRCLAARVNYKTLIIIC-ALFTLVTVLLWNKCSSDKA-IQF-----------------------------------PRH  42 
Hsap: -------------------------------------MRCLAARVNYKTLIIIC-ALFTLVTVLLWNKCSSDKA-IQF-----------------------------------PRR  42 
Btau: -------------------------------------MRCLAARVNYKTLIIIC-ALFTLVTVLLWNKCSSDKA-IQV-----------------------------------PRH  42 
Ggal: -------------------------------------MRCLAARVNYKTLIIIC-ALFTLVTVLLWNRCSSDGS-GPF-----------------------------------PRS  42 
Xlae: -------------------------------------MRCLAARVNYKTLIFIC-SLFTLVTVLLWNKCSSNDHTSNL-----------------------------------SWD  43 
DreA: -------------------------------------MRCLVARINHKTLIVIC-AVFALITILLWNKCSSDKD-LPS-----------------------------------PVR  42 
DreB: -------------------------------------MRCLAAGVHYKTLIVIC-ALLSLLTVLLWNKCTSEKA-LRF----------------------------------LPQH  43 
Tnig: -------------------------------------MRCLAARVNYKTLIIIC-ALFTLITVLLWNRCSSNTS-LRF----------------------------------LPRA  43 
Gacu: -------------------------------------MRCLAARVNYKTLIVIC-ALFTLITVLLWNRCSSDSS-LRF----------------------------------LPRD  43 
BflA: -------------------------------------M------------------------------------------------------------------------------   1 
BflB: -------------------------------------M------------------------------------------------------------------------------   1 
Dmel: MSKYLSSQRDALSAPALPVSRENREPPKFQGVKQREPLVFFIMRLNLKAVLLVLTVAVVVITLGVYMRCAAFSFSPD-----------------------------------FVRP  81 
Tcas: -------------MSSLPKPIGSGASQKFFHVTKDPPLFFIMMRLNVKVALLFLTTIGFFTVLILWSVCGKEPNNLQD----------------------------------W-R-  67 
Agam: ------------------------------------------MRLNLKFLLISLCVTVALITFALWANCGVGHGFV--------------------------------------PK  36 
Apis: ------------------------------------------MRLNIRTLFLVLSSLIIVCTLSLWSNCSNQTF-DT-----------------------------------F---  35 
Isca: --------------------------------------------------------------------C-----------------------------------------------   1 
Spur: -------------------------------------MRLMSRRSCFRTLLLLL-ATSSFITFTFLLRCHGGSRPEDDVKAELLIAARGNVGDVGNTIIDINSLDSRPEDISSRRH  78 
Skow: -------------------------------------MRVFSYRANFKHLSVAS-LLFALVILVLYSKCNNERP-QSM----------------------------------D-SF  42 
Nvec: -----------------------------------------------------------------Y--------------------------------------------------   1 
Cele: -------------------------------------MKCLRWRSNRHRIYL-LVACGALF--LL-NRHLTQEES-RI--------------------------------------  36 
Cbre: -------------------------------------MKCWRWRSNRHRIYL-FTACAVLF--LL-SKYISSEKE-RV--------------------------------------  36 
Bmal: -------------------------------------MIRFKL----RHIITILLTVFALS--ILWIVQSSRKTV-SS--------------------------------------  34 
Hmag: -------------------------------------MSSISPLFFYQD------------------QVSSN-SK-SF--------------------------------------  21 
Tadh: -------------------------------------------------------MLFLLVYIIKWLS---DTPI-F-----------------------------------KENH  22 
                                                                                                                               
                                                                                                                               
                                                                                                                               
Mmus: L-----SSGFRVDGLEKRSAASESNHYANHI-AKQQSEEAFPQEQQKAPPVV-GGFNS-------------NGGSKVLGLKYEEIDCLIN-DEHTIKGRRE--GNEVFLPFT-WVE 134 
Hsap: S-----SSGFRVDGFEKRAAASESNNYMNHV-AKQQSEEAFPQEQQKAPPVV-GGFNS-------------NVGSKVLGLKYEEIDCLIN-DEHTIKGRRE--GNEVFLPFT-WVE 134 
Btau: L-----SSGFRVDALEKKAAASESNNYVNHM-AK-QSEEAFPQEQQKAPPVV-GGFNN-------------NGGGRVLGLKYEEIDCLIN-DEHTIKGRRE--GNEVFLPFT-WVE 133 
Ggal: P-----AG------PERRAA-AASNGPARDV-GK-QSEEASPQEQQKAPPVV-GGFN------------------KAPGLKYEEIDCLIN-DEHTIKGRRE--GSEVFLPFS-WVE 121 
Xlae: P-----QGGLRVDSLDKRAAASESNA-ANS--PP-RSEEASPQEQQKAPPLV-G--------------------SKGTGQKYEEIDCMVN-EEQSVRCRKE--GTEVYMPFS-WVE 125 
DreA: P-----LEF------------------AAPT-P-EKEEENEGQ-APEAPP-----------------------GS--REVAYEQIDCLIN-EGVLIKGRRE--GGEVYLPFS-WVE 103 
DreB: P-----QPP--------------PSPK-------IDSHPQQPQ-PPEPPPVV-G------------------------GVRYEEIDCLIN-DDATIKGRRE--GSEVYMPFS-WME 103 
Tnig: A-----LVA--------------PSPRVGDS-S-ISSQQQPPQ-PPEPPPVV-G------------------------GSKFEEIDCLIN-DEVNIKCRRA--GGEIYMPFG-WME 108 
Gacu: T------SA--------------PSPKVGDA-S-ISSQQHPPQ-PPEPPPVV-GA---------------------ASGIKYEDIDCLVN-DESTIKGRRE--GAEVYLPFS-WVE 110 
BflA: -------------------------------------------------------------------------------------ECLIN-EEYSIECRRE--NDEVYLPFS-FLE  28 
BflB: -------------------------------------------------------------------------------------GAMRQ--------------------------   6 
Dmel: L-----DRSAR-------------------------QS-SS--------------------------------G--GEATALHDIECSIN-QEYTVHCKRDENANEVYVPFS-FLR 130 
Tcas: R-----TGKF-------------------------SLD-RL-----------------------------------AELQSAEEIDCDIN-GEYVIGCRKE--GDEVYLPFS-FLH 113 
Agam: W-----PQHH------------------------GDSGKLL--------------------------------P--TPFEQTEEIDCIIN-QEYAIGCRKE--GDEVYLPFS-FLQ  85 
Apis: ------STNIK-----------------------PN-YE-------------------------------------SLVQNIKSIDCLINGNNVHVDCLIK--NNTVYIPFS-FLK  81 
Isca: -------------------------------------------------------------------------------TTPQDIPCIIN-DEYSVSCRRE--ASEVYVPFS-FLR  34 
Spur: IAEHRQDAQFQQQPQQKQQQPQQKQQQPQSQQKQQQQSLLPQQKQQQPPQSLQQFQEQPPQEQRRQETYIKYNEPQLPLHQYKEIDCVVN-SDYTVQARLE--NGEVYLPFS-FIH 190 
Skow: P-----LISHDH----------------DPG-G-RRLEDSGGGHE------L-SLNNQ-------------N-G--GSILRYQPIECVIN-SDYTIEGRRE--GAEVFLPFS-FIE 108 
Nvec: ----------------------------------------------------------------------------------EILEVNVNGGEKKLQGRLDSSSGEPYVPFS-FVK  34 
Cele: ---------------------DEEDEELTQV-DV-NED-D--KKIE------------------------------CEPPGSIESKCIAD-NGKSMKCWKD--EEDVYFPVS-YLK  92 
Cbre: ---------------------DEEDEELNPV-AL-QEEEK--QKIE------------------------------CEPPGSIESKCTAD-NGKPMRCWKD--EEDVYFPVS-YLK  93 
Bmal: -------------------------DTLQPC-CT-AAN----EEIE------------------------------SRSSTLKEISCTVD-NEKTYQCYEEEFTNEVYFPFNAFLK  88 
Hmag: ---------------------------LA---------------------------DS-------------NGNEKIALPSFSTVHVNVN-FIQKFNGLSI--NNELYVPFE-FLK  66 
Tadh: Q-----QQQAQ---------HSKSS---------IQVQQR--QDQNGANSIQ-KEYNA----------------N-QCVNHHQSIKINYF-NRQTFQGKNF--NGKVFIPAE-FLS  91 
                                                                                                                              
                                                                                                                               
                                                                                                                               
Mmus: KYFDVYGKVVQY-DGYDRFE-FSHSYSKVYAQR----SPYHPDGVFMSFEGYNVEVRDRVKCISGVEGVPLSTQWGPQGYFYPIQIAQYGLSHYSK-------NLTEKPP--HIEV 235 
Hsap: KYFDVYGKVVQY-DGYDRFE-FSHSYSKVYAQR----APYHPDGVFMSFEGYNVEVRDRVKCISGVEGVPLSTQWGPQGYFYPIQIAQYGLSHYSK-------NLTEKPP--HIEV 235 
Btau: KYFDVYGKVVQY-DGYDRFE-FSHSYSKVYAQR----APYHPDGVFMSFEGYNVEVRDRVKCISGVEGVPLSTQWGPQGYFYPIQIAQYGLSHYSK-------NLTEKPP--HIEV 234 
Ggal: KYFEVYGKIAQY-DGYDRFE-FSHSYSKVYTQR----APYHPDGVFMSFEGYNVEVRDRVKCISGVEGVPLSTQWGPQGYFYPIQIAQYGLSHYSK-------NLTEKPP--HIEV 222 
Xlae: KYFEVYGKIAQY-DGFERFE-FSHSYSKVYAQR----GPYHPDGVFMSFEGYNVEVRDRVKCISGVEGVPLSTQWGPQGYFYPIQIAQYGLSHYSK-------NLTEKPP--HVEV 226 
DreA: KYFDVYGRLVQY-DGMERFE-FSHSYSRVYAQR----EPYHPDGVFMSFEGYNVEVRDRVKCISGVEGVPIPTQWGPQGYFYPIQIAQYGLSHYSK-------NLTEKPP--DIKI 204 
DreB: KYFEVYGKVVQY-DGYDRFE-FSHSYSKVYAQR----EQYHPNGVFMSFEGYNVEVRDRVKCISGVEGVPLSTQWGPQGYFYAIQIAQYGLSHYSK-------NLTERPP--HVEV 204 
Tnig: KYFEVYGKVAQY-DGYDRFE-FQHSYSKVYTQR----EPYHPDGVFMSFEGYNVEVRDRVKCISGVEGVPLSTQWGPQGYFYAIQIAQYGLSHYSK-------NLTERPP--HVES 209 
Gacu: KYFDVYGKVVQY-DGYDRFE-FQHSYSKVYAQR----EPYHPDGVFMSFEGYNVEVRDRVKCISGVEGVPLSTQWGPQGYFYAIQIAQYGLSHYSK-------NLTERAP--HVEV 211 
BflA: KYFEVSGHIAEY-DGYDRFE-WQHSYSRIYQPR----GPYTPAGIFMSFENYNVEIRDRVKAISGVEGVPVSTQWGPDPYFYPIQIAQFGLSHYSK-------NLTEKEP--RVTV 129 
BflB: -------------------------------------------------RGEMGAM-----RRRGEMGVPVSTQWGPDPYFYPIQIAQFGLSHYSK-------NLTEKEP--RVTV  59 
Dmel: NYFDVSGAVSTNSNEVAKFN-WVHSTAKVNLPR----GKYDARGVYMYFENYNVEVRDRVKCISAAEGVPVSTQWEKRGYFYPTQIAQFALSHYSK-------NLTEPAP--RVRV 232 
Tcas: KYFEVYGKLATY-DGLERFE-WSHSYSRVYHPK----GKYDPRGVFMYFENYNVEVRDRVKCVSAVEGVPISTQWESQGYYYPTQIAQFGLSHYSK-------NLTEPEP--RRKI 214 
Agam: KYFDVYGSLNVV-DGSRRFD-WTHSYGKVNYPK----GAYDPRGIFMYFENYNVEMRDRVKCISAIDGVPISTQWESQGYFYATQIAQFGLSHYSK-------NLTEPEP--RRKT 186 
Apis: NYFEVYGKIIETDENKKKFH-WSHSYSKIYHQN----GKYDSRGVFTNFQNYKVEERDRVKCVSASEGVPVSTQWNPHGYYYPTQIAQFGLSHYSK-------NLTLPSP--KVRV 183 
Isca: KYFEVYGKLAYR-EGKEVLD-WQHSYSKVMVPQ----ARYQHTGPFLWFENYNVAVRDRVKCISGLEGVPISTQWDPRGHLYPVQIAQFGLSHFSK-------NLSEPRP--LVIV 135 
Spur: KYFEVQGQVVQY-NGAERFE-WQHSNARIYVQ-----DPYKVDGIFMSFHHYNVESRDRVKYFSGVEGVPLSTQWGQQGYFYPIQVAQFGLSHYSK-------NLTERPP--RVTM 290 
Skow: KYFEVYGKIAEY-DGYERFE-WQHSYSKIYYPK----EQYKPDGIFMSFDHYNVELRDRVKCISGIEGVPISTQWGPQGYFYPIQIAQFGLSHYSK-------NLTEQEP--RVIV 209 
Nvec: EYFEIYGEVQKQ-KEKKVLE-WRHSYSEIHESK----FEYDPKGTFLWFQGYHVEGRLRVKCICGKEEVPVSSQWNPNGHYYPIQIAQYGLSHYSSYIAERDDT-------GKVKL 137 
Cele: KRFDMTGKLGK--DG-STFE-LYTSYAKMRSPD----STYDPLGPFGHFSTYSVETRDRVRCVSAKTDVPMSTQWDPIPYYYPIQISQYGLQHYSRMKLDSISNKSEASPKDDVIL 200 
Cbre: KRFDMTGRVGK--DG-STFE-LFTSYAKMRTPD----ANYDPLGVFGHFSTYSVETRDRVRCISAKTNVPMSTQWDPVPYYYPIQIAQYGLQHYSRMKLESL-NKTD----SEVIL 196 
Bmal: KHFDVSGMIFKD-SVARHFE-WSTSHARVRFPDF---NNYDYHGVFGHFASYSVETRDRVRCISAQYGVPLSTQWSAVPYFYPIQIAQYALQHYSRFKTAPS----------SI-V 188 
Hmag: HYYEIYGTFEKVEPGDPLQFTWLNADPNVLNPNQLTFLSYSFQRNYLNFHESDVANRGRVKCICGKYEVPISTQWDKKGYYYPTQIAQYGLSHLSKHYIENQIKMDRTVGHQRYQL 182 
Tadh: SQFGWVGESQNL-NGEKVWS-ISKRKARVVDPI----GRYNYKGPFTWFNFYKVEKRERVKYIDSVTGVPISTQWSQKGYFYPTQICQFALSHFTRLLL----NGTKI----NQRI 193 
                                                                                                                               
                                                                                                                               
                                                                                                                               
Mmus: YETAEDRDRNIRPNEWTVP-----------KGCFMASV--ADKSRS--TNVKQFIAP--------------ETSEGVSLQLGNTKD----FIISFDLKLL-TNGSVSVVLETT--- 314 
Hsap: YETAEDRDKN-KPNDWTVP-----------KGCFMANV--ADKSRF--TNVKQFIAP--------------ETSEGVSLQLGNTKD----FIISFDLKFL-TNGSVSVVLETT--- 313 
Btau: YETAEDRDKNSKPNDWTVP-----------KGCFMASV--ADKSRF--TNVKQFIAP--------------ETSEGVSLQLGNTKD----FIISFDLKFL-TNGSVSVVLETT--- 313 
Ggal: YETAEEKDRGSRAAEWTVP-----------KGCSLSTV--PDKAKF--TSVKHFVAP--------------ENTEGVSLQLGNARD----FIISFDLKLV-TNGSISVVLETT--- 301 
Xlae: YERADEKSG--VTGVWNIP-----------KGASVTTV--FDNTKN--SHVKHFVVP--------------EKSDGASLELGNTKD----FILSLDVKFV-SNGSISVVMETT--- 303 
DreA: YGMLEEKEG--GSSQWDVP-----------KGCTLSKI--QDQGHS--GFVHHFVTA--------------ENSEGVSLVLDNAKD----FVLTFDVKFI-SNGSVSVVLETT--- 281 
DreB: YDTAEERDS--RSSAWTVP-----------KGCSLTRV--YDKTRA--TSVREFSAP--------------ENSEGVSLPLGNTKD----FIISFDLKFT-SNGSVSVILETT--- 281 
Tnig: YDTAEERDGRAAAAPWSVP-----------KGCSLSRV--HDKSRA--TSVRQFSAQ-----------------------------------VWTSSSP--HNGSVSVVLETT--- 270 
Gacu: YDTAEDRDGRAGAAPWTAS-----------KGCVLSRV--HDKSRA--TSVRQFNA---------------ELSEGVSLQLGNSKD----FILSLDVKFV-SNGSVSVTLETT--- 289 
BflA: YERGDGR----VGTRWEVPGKLSPGKLSPGKPVQLESV--TDKDCG--CRVLQFSTDTL------------PPGSGPTLMLGASSDQILSFHIKFSPSAVLSNVSVVVDTS----- 220 
BflB: YERGDGR----VGTRWEVPGKLSPGKLSPGKPVQLESV--TDKDCG--CRVLQFNTDTL------------PPGSGPTLMLGASSDQILSFHIKFWPSPVLSNVSVVVDTS----- 150 
Dmel: LEDGDG-----NQMEWSTP-----------KTSNMTRI--WHHKFN--TSVVQFETAP-------------GYEGVISIALNQTLD----LLLSVDLLLV-TNSSSLMITVQNR-- 308 
Tcas: IEDGER-----ELAKWGVP-----------HPGTIERV--YDKTAG--SKVLKFKTGEL-------------YLDAIKLKMEHVLD----FIMSLNIVLS-GNSSFSIVLQNR--- 289 
Agam: VEDGER-----ETATWIVP-----------KGSSMNRT--IDRARAGAGAVLSFSTGK-------------SFDTAVVLPMDHVLD----LVLSVDVLLK-PNSTLCVTLQNR--- 263 
Apis: LENGQ------LNPLWNVP-----------KTSKIQIA--FNAQVN--SNVIDFIS---------------------------TED----FFISFDVALSLSTSSSIVISIKEI-- 245 
Isca: LDDGIRA----QYGSW-VASSK--------GKAGYTRF--VDDTAQ--SHVVEFTTS--------------AEDQGVAFALRKELYN---LTLSVDLRVI-FNGSLSVVLTAGGGG 216 
Spur: YEDVEGH----DLSSWSNP----------SPNGEIKI-------------VTSDTSP--------------SSSSVWSHSLDTKSD----FVIAFDLKLL-GNASITIVAESE--- 357 
Skow: YENGENT----AMPGWLLGN----------TKSHVENV--LDEEKG--SRVIEFITD--------------TGSPSVTLNLKNSED----FELSFDFKCF-DNCTILVILDTS--- 285 
Nvec: FEDAESV----FDSNWVVSEPNKVENIVDEERGSRVIK--FWTQGFVGEGVSLHLDS-------------STKEYVLSFHLKQTGD-----VIITVSIETKHN-TQHL-------- 220 
Cele: -----GV----NSKEWKGA------AGMHETTERLFFNDEQ------MGKVVNISAGAAL------------ANAGAYVYLDKSPDL---HVISFDWKPYEANSSFTVLAKMK--- 277 
Cbre: -----GV----KSNEWKGA------AGMHETTERLFFNDEE------KGKVVNISAGDSL------------ANAGAYVYLDKSTDL---HVVSFDWKPYDGNASFTVLAKVQMK- 275 
Bmal: FTK--GT----IAEEWNDN-------TLGGNGFKLGFDKEANSTRVEINSVDHGV------------------------SLVLDGDPA--FSVLSFFWLADVDGSFTISLKLA--- 262 
Hmag: YDQGLEMFI--VKLKFIKL-----LSSFELRIVATDSNEYIMQYILLTSPVLNCDQKHLFEHCKGNGSGEMQGGTVGHQRYQLYDQGLEMFIVKLKFIKLL--SSFELRIVAT--- 286 
Tadh: LFDCKSM---DIVSTWKVH-----------QTTSIQCIDAIVDGPN--KRVMKFAQSH----------------SSKAMSLNMQSSFKR-FIARFEVQFKGSGSISFLV--TT--- 271 
 
****
****
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Mmus: EKNQLFTVHYVSNT-----------------QLIAFRDR------DIYYGIGPR--TSWSTVTRDLVTDLRKGVGLS-NTKAVKPTKIMP----KKVVRLIAKGKGFL-DNITIST 399 
Hsap: EKNQLFTIHYVSNA-----------------QLIAFKER------DIYYGIGPR--TSWSTVTRDLVTDLRKGVGLS-NTKAVKPTKIMP----KKVVRLIAKGKGFL-DNITIST 398 
Btau: EKNQLFTVHYVSNT-----------------QLIAFKER------DIYYGIGPR--TSWSTVTRDLVTDLRKGVGLS-NTKAVKPTRIMP----KKVVRLIAKGKGFL-DNITIST 398 
Ggal: EKNQLFTVHYVSNT-----------------QLIAFRER------DIYYGIGAR--TSWSTITRDLVTDLRKGVGLS-NTKAVKQTRIMP----KKVVRLIAKGRGFL-DNVTISA 386 
Xlae: EKNQIFTVHYITNT-----------------QLIAFRDH------DVFYGVGSR--TAWSTLTRDLVTDLKKGVGLS-NTKAVKQTKIMP----KKVVQIVVKGSGFL-DNITIST 388 
DreA: EKGPPYIIHYITSP-----------------LLLSFKDK------EVIYGIGPR--ATWSTVSRDLMTDLRKGVGLS-NTKVVKATKIMP----RRVVQLVLKGSGFI-SNITVSS 366 
DreB: EKGPPFVIHYVTTT-----------------QLILLKDR------DITYGIGPR--TTWTTVTRDLLTDLRKGIGLS-NTKAVKATKTMP----RRVVKLVVHGTGTI-DNITIST 366 
Tnig: EKGPPFVIHYVTST-----------------QLIAFKDR------DVTYGIGPR--TGWSTLTRDLLTDLRKGVGLS-NTKAVKATKIMP----RRVVRLVLHGRGFV-DNVTIST 355 
Gacu: EKGPPFTIHYVTNA-----------------QLIAFKDH------EITYGIGAR--GAWSTLTRDLLTDLRKGVGLS-NTKAVKATKIMP----RRVVRLVLHGRGFV-DNVTIST 374 
BflA: YKKQ-YILHYTSGQ-----------------QLISARGT------SIYYGLGPR--TDWSLVTRDLLCDLRKGVGLS-NSKSVKKTKITI----KRVSKVVLQGKGRI-SNITMAT 304 
BflB: YKKQ-YILHYTSGQ-----------------QLISARGT------SIYYGLGPR--TDWSLVTRDLLCDLRKGVGLS-NSKSVKKTKITI----KRVSKVVLQGKGRI-SNITMAT 234 
Dmel: DTRHNYSLHYIPAD-----------------LLLSVQDT------NIYYGLGGSALNKWRHITRDLHIDLQKGIMG--DKRSPLKIRRSD----LEVISIGFLGLGFF-DNITLST 394 
Tcas: ETREIYNLHYITSD-----------------VLITVQDN------NVYHGLGMN--QEWKKLTRDLIVDLQKGLNYLDKDKSKRKIPKSK----LKIITILLRGYGAI-DNLTLSS 375 
Agam: ETQKLYHVYYILAD-----------------LLIGVQDE------NIYYGIGLNCTGGWKHLTRDLFVDLQKGLPQYASTDKRRKMRRTE----LKVVEISLLGNGSI-DNLTLST 351 
Apis: KDQEVWNLHYICSR-----------------TFIFAKGH------NIYHGMHCGREFGWKKLTRNVLVDLQKGLHVL--KKTTAKMFRSK----YKLCDFKLYGVGFL-DNLTLSS 331 
Isca: GKPSLYGVHYIMTD-----------------THLAVDDR------DIYYGIGTS--RSWMHLTRDLGVDLVKGLSFG-QHRTAARP--RN----LRVHSIVLRGHGLL-DNLTLSS 299 
Spur: EQGRIISLVYTTDD-----------------DGFVIGNR------KVTYGLGPV--TQWRKITRALQIDYRKAMASLSTLKYKLTRKFIL----QRLLRIELRGHGFI-DNIEIGT 443 
Skow: DKDKYFHIHYTTSR-----------------EAISRRGT------HIYYGLGSC--RSWRTFTRDLLNDLRKGVGQT-NGKSVKKAKVSL----RSIVKLSVQGFGRI-DNVKLST 370 
Nvec: -------IHYTSDE-----------------EMISVKQN------EIFMGIGTW--KGWRKITRNLDTDLRKGLRLS-EKSPNKKPKNTPKFSVTEIQTITLKGSGCI-DNITLSR 302 
Cele: QDDLLVLINYVYSEGNGKCVWQEEERISDD-YIVQKPKKDGQVSY-SYSYIGNSPIGEWSTVTRDLLVDVARALSSG-DNRKKDDNVVLHAG-DLRLVSLGFRGELTVKQKITQRR 389 
Cbre: QDDLLVLINYVFSEGNGKCVWQEEEKSFDDEFIVQKPKKDGQVSY-SYSYIGSKPFGEWSTVTRDILVDVARALSSG-ENRKKDDNVVLHPG-DVRLVSLGFRGQLAVKQQIFQRE 388 
Bmal: YSQKTILLHYVHN---------------DDEQCVSHNKKTSKVEYNYSLGAEPN-PNEWRWICRDLLVDTGDVI----------------------LDSITFRGHSVI-RSFEQRS 339 
Hmag: DSNE-YIMQYILDD-----------------VMIEKRNLN-----QIVHGLGRN--VFRSEITRDLNVDLVKGL-LS--GKHSGDTFGI---KIQKILSLDIDNVQYV-KAVQFVY 370 
Tadh: KRQQQFTIRYSTAK-----------------VGVSFSERSK----TVIYGIGTR--NVLSRITRDLEIDLCKALLLERRRKGSRKGALSKKAALISVDAVTLQGSGLL-GKLSLVD 363 
                                                                                                                               
                                                                                                                               
                                                                                                                               
Mmus: TAHMAAFFAASDWLVRNQDE-KGGWPIMVTRKLGEGFKSLEPGWYSAMAQGQAISTLVRAYLLTK-DYVFLSSALRATAPYKFPSEQHGVKAVFMNKHDWYEEYPTTPSSFVLNGF 513 
Hsap: TAHMAAFFAASDWLVRNQDE-KGGWPIMVTRKLGEGFKSLEPGWYSAMAQGQAISTLVRAYLLTK-DHIFLNSALRATAPYKFLSEQHGVKAVFMNKHDWYEEYPTTPSSFVLNGF 512 
Btau: TAHMAAFFAASDWLVRNQDE-KGGWPIMVTRKLGEGFKSLEPGWYSAMAQGQAISTLVRAYLLTK-DHIFLNSALRATAPYKFLSEQHGVKAVFMNKHDWYEEYPTTPSSFVLNGF 512 
Ggal: TAHMAAFFAASNWLVRNQDE-RGGWPIMVTRKLGEGFRSLDPGWYSAMAQGQAISTLVRAYLLTK-EHAFLSSALRATAPYKLPSEQHGVKAVFMNRHDWYEEYPTSPSSFVLNGF 500 
Xlae: TAHTAAFFAASDWLVRNQDA-KGGWPIMVTRKLGEGFKALEPGWYSAMAQGQAISTLVRAYLLTK-EQYYLDSALRATAPFKLPSEKHGVKAVFMNKYDWYEEYPTTPSSFVLNGF 502 
DreA: TAHMAAFFAASDWLLHNQDE-HGGWPIKVTRKLGEGFKSLEPGWYSAMAQGQAMSTLVRAYLVTH-NPSYLGAAIRATSPFKRTPEQHGVKATFMNKFDWYEEYPTTPSSFVLNGF 480 
DreB: TSHMAAFYAASDWLVRNQDE-RGGWPIMVTRKLGEGFRALEPGWYSAMAQGQAMSTLVRAYLMTK-DDRYLKAALRATGPFKLPSEQHGVKAVFMNKYDWYEEYPTIPSSFVLNGF 480 
Tnig: TAHMAAFFAASDWLLRNQDE-RGGWPIMVTRKLGEGFRA--PG----ARLGQAMSTLVRAYLFTK-DQAYLNAALKAVGPYKVPSAQHGVKAVFMNKYDWYEEYPTTPSSFVLNGF 463 
Gacu: TAHMAAFFAASDWLMRNQDE-RGGWPIMVTRKLGEGFRPLEPGWYSAMAQGQAMSTLVRAYLLTR-EPAYLNAALKAVGPFKVPSAQHGVKAVFMNKYDWYEEYPTTPSSFVLNGF 488 
BflA: SSHIPQFFDAADWFVRNQDD-RGGWPINVIRKLVDGMQELPPGWYSAMAQGQAMSTLTRAFLRTR-DRRYLDAALRGTKPFRVPSESGGVLAVFMNKHRWYEEYPTTPSSFVLNGF 418 
BflB: SSHIPQFFDAADWFVRNQDD-RGGWPINVIRKLVDGMQELPPGWYSAMAQGQAMSTLTRAFLRTR-DRRYLDAALRGTKPFRVPSESGGVLAVFMNKHRWYEEYPTTPSSFVLNGF 348 
Dmel: SDHLAHFYDAAEWFVHNQDPKTGGWTNPVRRSL-NGFAELRPGWISAMGQGHAISVLARAYWHSGGDERYLRAAAAGLQPYRVYSRDGGVLAQFMDKFYWYEEYPTTPPSYVLNGF 509 
Tcas: SEHIQQFYDAAEWFVRHQDTETGGWPIPVKRKLASGFHDLQSGWYSAMGQGHAISVLSRAYHHSGGDVRYLQAALAGLKPFQVPSTKGGVLATFLNKYHWYEEYPTKPASFVLNGF 491 
Agam: SEHISHFYDAAEWLIRHQDPSTGGWPIPVRRKLGSGFGELARGWYSAMAQGHAISLLARAYYHSKGDKRYLRAALDGLKLFRIPSYQGGVLATFLGKYAWYEEYPTTPHSFVLNGF 467 
Apis: SDHISQFYAAAHWFNKHQDKESGGWINPVTRKISPVIKPLKPGWLSAMGQGQAISLLSRAFFHSGGNEMYLKTAHTALKPFKIPTKNGGVLSEFMNLHPWYDEYPTVPPIFILNGF 447 
Isca: SAHEAHFFDAADWFVRRQDD-AGGWPIKVTRRLSNGMLELEPGWYSAMAQGQAMSVLTRAFAATG-KRDYLDAALRAVGPFRIRSESRGVMTTFLGKFVWYEEYPTVPSSFVLNGF 413 
Spur: SLHMYHFYDAADWLVHHQDE-RGGWPIMVERILDDK-MSLSPGWYSSMAQGQAMSVLTRAYIKSR-RKKYIKAALHAARLFQIPSAQGGVLARFMDKYTWYEEYPTSPGSFVLNGF 556 
Skow: TAHMAHFYDAANWLLNNQDK-KGGWPIWITRILIDEMGELPPGWYSAMAQGHAMSVLVRAYRKSG-KPEYLKAALKATYPFNKLSSQGGVKAVFLDKYPWYEEYPTNPSSFVLNGF 484 
Nvec: SARLDFFMAAANWFVRNQDK-NGGWPITVKRKIMEGV-EMAPGWYSAMAQGQAMSLLTRAYYHTN-NSVYLEAALKATSLFGVPANKGGVRAMFMDKYPWYEEYPTTPSLYVLNGF 415 
Cele: EQHSHAFYAAADWLVKNQND-RGGWSVPVERSIAERKLVLPPGWHSAMAQGHGISVLTRAFKHFN-DEKYLKSAAKALKLFKINSSDGGVRGEFFG-NIWYEEYPTTPGSFVLNGF 502 
Cbre: EQHLHAFKSAADWLAENQDV-KGGWAVPVERSIADRKLVLPPGWHSAMAQGHGISVLTRAFKHFD-DEKYLNSALKALELFKTNASDGGVRAEFFG-NVWYEEYPTTPGSFVLNGF 501 
Bmal: SAHLEHFLVAADWLTNNQDE-HGGWSVPVERSIADKRLILPAGWYSAMAQGHALSVLTRAYVVTN-DMKYFQGAKRALQLFKIKASKGGVLNELFG-HPWFEEYPTTPGTFVLNGF 452 
Hmag: EDHIAKFMAAADWLLYYQDD-QGGWKTNVSRIVIPEIR-TDAGWYSAMGQGQAISLLCRVYFYTK-DTKYLNSALRATHLFRIPSAKNGILAMLFDKYPWYEEYPTVPPLYVLNGF 483 
Tadh: SADKDFFIDAANWLVANQDR-SGGWPVSVSHKINKLTLTLKPGWYSAMAQGQAMSTLTRAFHLTK-EYKYLRTALLATKPFHIPASEGGVLATVFGTYKFYEEYPTKIPLLVLNGF 477 
                                                                                                                               
                                                                                                                               
                                                                                                                               
Mmus: MYSLIGLYDLKETA--GE-------TLGKEARSLYERGMESLKAMLPLYDTGSGTIYDLRHFML-GIAPNLARWDYHTTHINQLQLLSTIDESPIFKEFVKRWKSYLKGSRAKHN  618 
Hsap: MYSLIGLYDLKETA--GE-------KLGKEARSLYERGMESLKAMLPLYDTGSGTIYDLRHFML-GIAPNLARWDYHTTHINQLQLLSTIDESPVFKEFVKRWKSYLKGSRAKHN  617 
Btau: MYSLIGLYDLKETA--GE-------KLGKEARSLYERGMESLKAMLPLYDTGSGTIYDLRHFML-GIAPNLARWDYHTTHINQLQLLSTIDESPIFKEFVKRWKSYLKGSRAKHN  617 
Ggal: MYSLIGLYDLKETA--GE-------KLGKEARLLYERGMESLKAMLPLYDTGSGTIYDLRHFML-GTAPNLARWDYHTTHINQLQLLSTIDEAPIFKEFVRRWKSYLRGGRAKHN  605 
Xlae: IYALLGLHDLKETA--GE-------RQGKEARLLYERGIESLRAMLPLYDTGSGSIYDLRHFML-GTAPNLARWDYHTTHINQLQLLASVDGSPIFRDFIRRWKSYLRGGRAKHN  607 
DreA: IYSLIGLYDVAETA--GN-------KLGREAGILFSQGLESLKAMLPLFDTGSGTVYDLRHFTL-GVALNLARWDYHTTHINQLQLLASIDGAPIFRDHVKRWKTYLKGGRAKHN  585 
DreB: IYSLIGLFDLAQTA--GE-------KLGRDAGQLYSKGMESLKVMLPLYDTGSGTIYDLRHFIL-GTAPNLARWDYHTTHINQLQLLGTIDNSPIFRDSVKRWKSYLKGGRAKHN  585 
Tnig: IYSLLGLFDLTETA--GE-------KLGREARQLFSHGMESLKAMLPLFDTGSGSIYDLRHFML-GTAPNLARWDYHTTHINQLQLLASIDSSPIFRDVVKRWKNYLKGIRAKHN  568 
Gacu: IYSLLGLHDVSDTA--GE-------KLGREAGLLFARGMESLKAMLPLFDTGSGSIYDLRHFML-ATAPNLARWDYHTTHINQLQLLASIDNAPVFRDVVKRWKNYLKGIRAKHN  593 
BflA: IYSLIGLYDLKETA--PA-------QEGREAAELFEEGMRSLKAMMPLYDTGAGTVYDLRHFML-GIAPNIARWDYHTTHVNLLQLLVSIDPDPALAATLRRWVGYTKGRRAKHN  523 
BflB: IYSLIGLYDLKETA--PA-------QEGREAAELFEEGMRSLKAMMPLYDTGAGTVYDLRHFML-GIAPNIARWDYHTTHVNLLQLLVSIDPDPALAATLRRWVGYTKGRRAKHN  453 
Dmel: IYSLLGLYDLNSTA--PG-------KIAREAGKLFAQGMHSLKKMLLLFDTGSGTSYDLRHLSL-GVAPNLARWDYHATHVNQLLLLATIDSDPLIAQTAERWKGYMFGRRAKHN  614 
Tcas: IYSLLGLYDLMTIA--PP-------GQADEAEFLFREGMISLKGMLLFYDMGSVTSYDLRHVTL-GVAPNLARWDYHATHINQLLLLSTIENEPLFAQTAERWIGYMAGKRAAHN  596 
Agam: IYSLLGLYDLNSTA--PA-------NQSNEAAVLFEQGMASLKKMLLLYDTGSGTSYDLRHFTL-GIAPNLARWDYHATHVNQLLLLATIDPDPLISQTAERWKNYMVGKRAPHN  572 
Apis: MYSLIGLYDLFSLAPNGS-------EVSQEAHSLWKQGMTSLKNLLPLFDMGSRSAYDLRHVTL-DIAPNIARWDYHATHINQLLLLATLDNATVIQTTAKRWIGYMNGARASHN  554 
Isca: IYSLFGLYDLKSTC--GE---GSSEELCRDAGKLFADGMVSLKRMLPLFDTGSGTVYDLRHFSL-GVAPNLARWDYHTTHINQLLYLGTIDDDPVFGATAERWVQYMKGKRAPHN  522 
Spur: IYSMIGLYDVLSVA--DV-------EESRESRRLYDEGMVSLKAMLLLFDMGTGTLYDLRHLAL-GKAPNVARWDYHATHISQLQLLASIDPDPIFKETVARWIGYTKGKRARHN  661 
Skow: IYSLIGLYDLMMTA--SD-------EDRVEAERLYREGLTSLKALLPLYDTGSGTVYDLRHITT-GVAPKLARWDYHTTHISQLQLLSSIEKNSLFQNTLERWIEYMKGKRAKHN  589 
Nvec: IYSLVGLHDLTLAA---------P-KK-TEAKAFFDDGMKSLKALLLMFDAGSGTFYDLRHVSM-RAPPNLARWDYHTLHVSLLHFISGIDSDRVVKDTAVRWTGYTKGKRAKHN  518 
Cele: LYSLIGLYDLSQLELMIDENDETMRAKIQEAQELYSAGVRSLKQLLPLYDTGSGTIYDLRHVAL-GTAPNLARWDYHAVHVYLLKWIAGIEKDEVLSKTADRWIGYAYGKRAKHN  616 
Cbre: LYSLIGLYDLSKLESLN----SEHNSKIQEAKELYSTGIQSLKQLLPLYDTGSGTIYDLRHVAL-GSAPNLARWDYHAVHVYLLKWIANLEKDDFLSKTADRWIGYAYGKRAKHN  611 
Bmal: LYSLIGLYDFAQIS--------NSHDSDNDSAALFSAGLESLRIFLPLFDTGSGTFYDLRHLGL-KTAPNLARWDYHSVHIYLLKWLYIITKDEFFNVTANRWVSYATGHRAKHN  558 
Hmag: IYSLFGLYDLLNIA--SS-------KDAAEAQYLFYQGMNSLETVLPLFDNGHGSFYDLRHISIPGSMPNRARWQYHRVHIEQLHAIVELTKNSVVNRTLQRWIGYGWGILAKHN  589 
Tadh: IYSLFGLYDLKSAV--ED---VNAHNITSDAAELYRDGIRTLKNLLPLYDAGSDTFYDLRHVVI-KAEPIIARSTYHALHISQLLHIDTIEEDPLFARIAKRWMEYMNGGRANHN  586 
****
▼
 
Figure 1 – Multiple sequence alignment of animal D-glucuronyl C5-epimerases. Putative N-glycosylation sites 
are indicated with asterisks (below sequence). The start positions of all made truncations are indicated as 
triangles. Secondary structure predictions are indicated as cylinders (α-helixes) and arrows (β-strands). 
Abbreviations: Mmus: Mus musculus (mouse); Hsap: Homo sapiens (human); Btau: Bos taurus (cow); Ggal: 
Gallus gallus (chicken); Xlae Xenopus laevis (frog); DreA: Danio rerio isoform A (zebrafish); DreB: Danio rerio 
isoform B (zebrafish); Tnig: Tetraodon nigroviridis (pufferfish); Gacu: Gasterosteus aculeatus (three spined 
stickleback); BflA: Branchiostoma floridae isoform A (lancelet fish); BflB: Branchiostoma floridae isoform B 
(lancelet fish); Dmel: Drosophila melanogaster (fruit fly); Tcas: Tribolium castaneum (red flour beetle); Agam: 
Anopheles gambiae (malaria mousquito); Apis: Acyrthosiphon pisum (pea aphid); Isca: Ixodes scapularis (black-
legged tick); Spur: Strongylocentrotus purpuratus (purple sea urchin); Skow: Saccoglossus kowalevskii (Acorn 
worm); Nvec: Nematostella vectensis (starlet sea anemone); Cele: Caenorhabditis elegans (nematode); Cbre: 
Caenorhabditis brenneri (nematode); Bmal: Brugia malayi (filarial roundworm); Hmag: Hydra magnipapillata 
(freshwater polyp hydra); Tadh: Trichoplax adhaerens (Placozoa).  
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Studies based on polymannuronan- and chondroitin C5-epimerases indeed indicate 
structural homology of these epimerases with specific lyases (Pacheco et al., 2008). 
Unfortunately, no known structure in the Protein Data Bank (PDB) has sufficient homology 
with heparosan D-glucuronyl C5-epimerases to generate a reliable 3D model. 
Throughout the sequence there are multiple highly conserved tyrosine and histidine 
residues, of which most are located in the C-terminal domain. Some of these residues may 
be functional analogs of the catalytic residues in the polymannuronan- and chondroitin C5-
epimerase. For chondroitin D-glucuronyl C5-epimerase 1, evidence has been provided that 
one tyrosine (Tyr-261) and two histidine residues (His-205 and His-450) are involved in 
catalysis (Pacheco et al., 2008). A model has been proposed in which His-450 is the C5-
proton abstractor, Tyr-261 mediates a β-elimination reaction, and His-205 eventually re-
protonates the C5 from the opposite site. The proposed catalytic mechanism of alginate C5-
epimerase AlgE4 also involves a conserved histidine and tyrosine. The tyrosine (Tyr-149) 
probably acts as proton abstractor and a histidine (His-154) as proton donor (Rozeboom et 
al., 2008). 
 
MmC5 production in P. pastoris 
To achieve optimal codon usage we constructed a synthetic gene optimized towards the 
codon bias of P. pastoris. This resulted in a 3.5% decrease of the GC content to 42.4%, which 
is an ideal level for P. pastoris. We could successfully integrate this synthetic murine MmC5 
gene in the P. pastoris genome by homologous recombination. Successful integration of the 
gene was confirmed by PCR analysis. 
Growth conditions could be optimized for batch-culture growth in baffled Erlenmeyer 
flasks. It is known that sufficient aeration is crucial for good expression; this could be 
achieved by heavy shaking and using relative little medium per flask providing ample 
headspace. We did grow multiple batches of the recombinant P. pastoris strain with 
variations in medium composition and expression time. 
Generally, multiple proteins are being secreted by P. pastoris to the medium. Protein 
analysis of the medium by SDS-PAGE confirmed the presence of secreted protein (Fig.2). 
Levels of expressed protein in the medium fractions were generally low, and were only 
detectable after silver staining. In comparison with a control strain, protein excretion levels 
were higher for the epimerase strain. To isolate sufficient protein the medium fraction was 
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concentrated and washed with buffer, after which fractions were separated by gel filtration. 
Of the secreted proteins that had the highest expression levels, several candidate protein 
fractions (numbered 1-5) were isolated from the SDS-PAGE gel. 
 
 
Figure 2 – Protein production of MmC5 in P. pastoris, both excreted (Medium) and total cells (Pellet). Indicated 
protein bands (1-5) have been isolated and analyzed by mass spectrometry. MmC5 is expected to be ≥65kDa. 
None of the analyzed bands was MmC5. Strain of P. pastoris GS115 was used as a background control (Ctrl). 
 
These fractions were Trypsin digested and analyzed by mass spectrometry to reveal the 
protein identity. No murine C5-epimerase sequence was identified in the analyzed fractions. 
Hence, we were not able to proof C5-epimerase expression in P. pastoris. 
We tried variations in medium composition and expression time, however these 
never resulted in detectable C5-epimerase expression. Possibly, the enzyme is not secreted 
successfully. For the non-secreted protein fraction we noticed no obvious difference 
between the control P. pastoris and the MmC5 strain and therefore we did not select any 
non-secreted protein fraction for mass-spectrometry analysis. However, gel analysis cannot 
exclude low expression levels of non-secreted protein. A solubilizing factor potentially can be 
a solution to solve these possible in vivo solubility problems, for example maltose binding 
protein (MBP). Recent research showed the potential of MBP as a solubilizing factor in P. 
pastoris based recombinant enzyme production (Dälken et al., 2010). 
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MmC5 production in E. coli 
In parallel with C5-epimerase expression in P. pastoris we tested C5-epimerase production in 
the bacterium Escherichia coli. We cloned the synthetic mouse MmC5 gene successfully in 
several different bacterial expression vectors, generating several different constructs (Fig.3). 
 
wild type
non-tagged
truncation 1
truncation 2
truncation 3
SS Nt Ct
Nt Ct
MBP Nt Ct
MBP Nt’ Ct
MBP Ct
 
Figure 3 – Schematic representation of constructed C5-epimerases for truncation studies. Used abbreviations: 
SS - signal sequence, Nt - amino terminus, Ct - carboxyl terminus, MBP - maltose binding protein. 
 
Protein expression levels were examined for each construct. The D-glucuronyl C5-epimerase 
showed major solubility problems when expressed in E. coli (Fig.4A). We could not detect 
any soluble protein expression, while large quantities of insoluble protein were observed as 
inclusion bodies. Numerous variations in expression conditions were tried but none had any 
positive effect. To tackle this solubility problem we created several fusion proteins in which 
the E. coli Maltose Binding Protein (MBP) is fused to the N-terminus of the murine D-
glucuronyl C5-epimerase (Fig.3). In total three different fusion constructs were tested in 
which fragments of the poorly conserved amino terminus of D-glucuronyl C5-epimerase are 
removed. Positions where truncations start are based on secondary structure predictions 
(Fig.1), to prevent disruption of secondary structures. The truncation studies showed 
increased solubility upon removal of the N-terminus of the C5-epimerase (Fig.4B). 
Another important parameter for protein solubility is the culture induction time. 
Maximum protein solubility appears to be reached after 3 hours of protein expression. After 
24 hours of expression the amount of soluble protein decreases to levels hardly detectable. 
The amount of insoluble protein produced after 24 hours is massive. Protein solubility is 
severely affected in time; long expression time leads to formation of inclusion bodies (not 
shown). 
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Figure 4 – Murine D-glucuronyl C5-epimerase production in E. coli. (A) Non-tagged C5-epimerase is produced 
massively (size 67kDa). (B) N-terminal fusion with Maltose Binding Protein (MBP; 43 kDa) results in soluble 
protein in the cell free extract (CFE). The three N-terminal truncation are 110 kDa (truncation1), 95 kDa 
(truncation2) and 70 kDa (truncation3) in size. 
 
All three truncated fusion proteins do bind to the amylose-resin. The MBP-fusion constructs 
could be enriched from cell lysate. However the enriched protein was not pure, even after 
extensive washing. Many E. coli proteins apparently associate with the truncated fusion 
proteins, most likely via non-specific, hydrophobic interactions. Size exclusion 
chromatography analysis (using a Superdex 200) of the ‘purified’ soluble MBP-MmC5 fusion 
protein did not result in one single defined oligomeric state but rather in soluble aggregates 
of high molecular weight. More examples are known of MBP fusion constructs that result in 
large soluble aggregates (Zanier et al., 2007). The native fold of such a fusion protein is not 
necessarily affected. However, generally one can expect major problems in crystallization 
trials (Smyth et al., 2003) and therefore we did not proceed with structure elucidation to 
confirm the predicted alpha/alpha toroid fold. 
In contrast to other C5-epimerases, the D-glucuronyl C5-epimerase seems to be Ca2+ 
independent (Valla et al., 2001). To confirm the absence of calcium and other divalent ions 
we performed divalent metal analysis using inductively coupled plasma atomic emission 
spectroscopy (ICP-AES). No significant amounts of potential cofactors were observed in 
MBP-MmC5 samples, except for detection of Zn2+ in some enzyme samples. Affinity to zinc 
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has never been reported for the murine D-glucuronyl C5-epimerase. We tested the addition 
of Zn2+ to the medium or reaction buffer but we did not see any effect on protein production 
levels or activity (see below) when added. Apart from zinc, no other metal was found to be 
associated with MBP-MmC5. 
 
To screen the generated fusion proteins for D-glucuronyl C5-epimerase activity, we 
incubated both purified enzyme and cell lysate with K5 capsular polysaccharide. After 
hydrolysis of the polysaccharide, the samples of monosaccharides were analyzed for their 
hexuronic acid content using a HPLC-PAD system. Significant amounts of monomeric 
glucosamine and D-glucuronic acid were observed, indicating proper hydrolysis. However 
formation of L-iduronic acid for any of the constructs was not too obvious. We could detect 
some trace levels of L-iduronic acid although the amounts were rather low, and therefore 
not conclusive. 
To confirm this D-glucuronyl C5-epimerase activity we performed an additional 
screen based on the tritium release method using 3H-labeled polysaccharide substrate 
(Campbell et al., 1983; Kusche et al., 1991). We tested MBP-MmC5 activity both as freshly 
prepared cell lysate and as purified protein. Two substrates were tested, K5 polysaccharide 
(De-acetylated/N-sulfated) and heparin, and all measurements we done in duplo (Table 1).  
 
Table 1 – Activity measurements using MBP-MmC5 mediated tritium release. The abbreviation N.A. means     
no significant activity observed. 
Substrate Enzyme Quantity 3H release (cpm) 
Heparin MBP-MmC5 50 1487 ±199 
Heparin MBP-MmC5 5 634 ±206 
Heparin MBP-MmC5 truncation 2 50 N.A. 
Heparin MBP-MmC5 truncation 3 50 N.A. 
Heparin Control 2 172 ±47 
K5 polysaccharide MBP-MmC5 50 167 ±25 
K5 polysaccharide MBP-MmC5 5 114 ±19 
K5 polysaccharide MBP-MmC5 (overnight) 5 26 N.D. 
K5 polysaccharide MBP-MmC5 truncation 2 50 N.A. 
K5 polysaccharide MBP-MmC5 truncation 3 50 N.A. 
K5 polysaccharide Control 2 13 ±7 
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For both substrates we detected significant C5-epimerase activity using the freshly prepared 
cell lysate, although a significant reduction of activity was observed upon overnight storage. 
We were unable to detect activity of the purified protein, most likely due to inactivation 
upon storage. We also tested both truncated variants of MBP-MmC5 for activity; no activity 
could be determined for these two truncated C5-epimerases. 
In parallel with our studies, similar truncation studies have been performed by Liu 
and colleagues (University of North Carolina). They claimed functional protein expression of 
an MBP fusion protein with the human D-glucuronyl C5-epimerase (Muñoz et al., 2006). 
They showed partial epimerization of the D-glucuronic acid residues in N-sulfo-heparosan 
upon mixing with their fusion protein and an MBP fusion protein of 2-O-sulfotransferase 
(MBP-2-OST). The addition of MBP-2-OST appears to enhance epimerase activity as shown 
previously for 2-OST (Pinhal et al., 2001). Just recently they confirmed their finding in 
another report (Li et al., 2010). They prepared six N-terminal truncated (human D-glucuronyl 
C5-epimerase) constructs each as a fusion protein with MBP. Also all their constructs could 
be expressed. They claim activity for their longer constructs, while C5-epimerase 
functionality is lost after truncation of the region N92-W203. This leads them to the 
conclusion that the catalytic site is partly located in this region of the protein. 
 
Discussion 
We did not succeed in obtaining C5-epimerase expression in Pichia pastoris, as no significant 
amounts of C5-epimerase were detected. It is unclear whether expression levels are below 
threshold or completely zero. Possibly there are problems in the α-Factor secretion signal 
preventing popper C5-epimerase secretion. The addition of an affinity-tag can help in 
selective protein enrichment and in detecting possible low levels of C5-epimerase. When 
antibodies are available, western blot could provide a more sensitive, and selective method 
to prove expression. Alternatively one could check transcription levels of the D-glucuronyl 
C5-epimerase gene. A highly sensitive activity assay could give ultimate prove of possible low 
levels of C5-epimerase activity, unfortunately no such assay is available yet. 
Apart from the discussion whether or not there is expression, it has become clear 
that D-glucuronyl C5-epimerase expression in P. pastoris does not work in small scale batch 
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approach. An alternative setup for expression could possibly result in more successful 
protein expression. Previous findings by others using a fed-batch expression systems did 
show production of functional C5-epimerase (Weegar et al., 2003), when P. pastoris is grown 
in a laboratory scale fermentor. However, this activity was limited to a narrow time span. 
Their system completely lost C5-epimerase activity in time, possibly due to proteolytic 
degradation of the epimerase. Oxygen deficiency is one possible reason leading to enhanced 
proteolysis. As variations in medium pH can have a positive effect in protease deactivation, 
we tried buffered media of different pH values. However, we never observed a detectable 
effect on protein expression. 
Alternatively, and based on our findings, the loss of epimerase activity could also be a 
result of lack of protein stabilization. Medium enrichment with a higher amino acid content 
did not have an effect. Possibly, and in parallel with the observed E. coli based expression, D-
glucuronyl C5-epimerase needs the stabilizing effect of other protein residues. This supports 
the hypothesis that this specific enzyme acts in a larger protein complex and needs other 
members of the heparin biosynthesis pathway for stabilization and activity. 
 
The synthetic gene designed for P. pastoris could successfully be expressed in E. coli. 
However, here again the native C5-epimerase showed severe solubility problems. Fusion of 
the C5-epimerase to a MBP-tag greatly improved the solubility. Also removal of the animo-
terminus of the D-glucuronyl C5-epimerase resulted in increased solubility. Larger 
truncations result in more soluble MBP-MmC5 in the CFE, and less insoluble MBP-MmC5. 
Protein purification by means of amylase resin results in enrichment for all different MBP-
MmC5 truncations, however some E. coli proteins stably associate to truncation 1-3. The 
hypothesis that the animal D-glucuronyl C5-epimerase acts in a larger protein complex 
would be in agreement with this observation. The enzyme needs the stabilizing effect of 
maltose binding protein to reach soluble protein expression, allowing the production of large 
quantities of soluble MBP-MmC5. 
We could observe trace levels of L-iduronic acid formation using HPLC-PAD analysis. 
However, since these levels were low these results alone were not conclusive. To confirm 
C5-epimerase activity we used the 3H release assay, using tritium labeled substrate. The 
constructed full length fusion protein not only has an increased solubility but also still is 
active. The two truncated C5-epimerases were also tested for activity, but turned out to be 
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completely inactive. It is tempting to speculate that the truncated N-terminus is essential for 
activity, as both truncated C5-epimerases are completely inactive. However, it cannot be 
excluded that the MBP possibly blocks activity of the two truncated fusion-proteins. 
In parallel with our findings, similar results have been reported for parallel 
experiments done with the human C5-epimerase upon fusion with MBP. In contrast to our 
analyses, these studies did include the 2-O sulfotransferase, which is proven to enhance the 
C5-epimerase activity substantially (Li et al., 2010). They used a novel activity assay based on 
an engineered 2-OST, only able to act on L-iduronic acid. Via a coupled enzyme assay they 
can indirectly measure C5-epimerase activity. Using this method they could demonstrate 
activity of the MBP-hsC5-epimerase. They have confirmed their method by using 
disaccharide RPIP-HPLC analysis. Both their and our findings indicate that soluble and 
function D-glucuronyl C5-epimerase expression in E. coli is feasible. This facilitates 
alternative production methods of D-glucuronyl C5-epimerases as well it enables the 
construction of large mutant libraries allowing enzyme optimization studies. 
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Abstract 
Maltose Binding Protein (MBP) has been developed as a general tool to enhance the 
production of heterologous proteins as MBP fusion in Escherichia coli. The target protein of 
the present study is the hyaluronan synthase from Pasteurella multocida (PmHAS). We 
created a MBP-PmHAS fusion protein, and compared expression levels in E. coli with a 
control PmHAS (PmHAS-His). The fusion with MBP resulted in a three-fold increase in PmHAS 
protein solubility. Although MBP is a rather large protein-tag, it does not block HAS activity 
of the MBP-PmHAS fusion protein. Compared with the control protein there is no difference 
in specific activity of the MBP-PmHAS fusion protein.
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Introduction 
Glycosaminoglycans are biological active polysaccharides widely spread among the animal 
kingdom. Hyaluronan, also referred to as hyaluronic acid, is a widely used and well-studied 
glycosaminoglycan. It is a linear, negatively charged polysaccharide that, compared to other 
glycosaminoglycans, is rather large with as much as 2,000-25,000 disaccharides of D-
glucuronic acid (GlcA) and N-acetyl-D-glucosamine (GlcNAc) (Kogan et al., 2007). These 
disaccharides are joined alternately by β(1-3) and β(1-4) glycosidic bonds, forming a 
uniformly repetitive structure (Fig.1). Unlike other glycosaminoglycans, hyaluronan 
biosynthesis does not require post-polymerization modifications like epimerization or 
sulfation. 
n
OO
CH2OHCOO -
HNAc
OH
OHD-GlcA
O O
OH
D-GlcNAc
 
Figure 1 – Repetitive disaccharide of hyaluronan comprising D-glucuronic acid and N-acetylglucosamine 
 
Hyaluronan is involved in numerous biological processes, one of them reflected by its name. 
Hyaluronan is derived from ‘hyaloid’, Greek for the vitreous of the eye. Moreover, 
hyaluronan is also present in the synovial fluid of articular joints and the intercellular space 
of the epidermis. This wide variety of biological functions results in a large number of 
applications that exist for hyaluronan in the field of medicine and cosmetics, with a 
worldwide market for hyaluronan estimated close to $1 billion (Chong et al., 2005). 
Hyaluronic acid is isolated from animal tissue, a good source is rooster comb that has 
hyaluronan concentrations up to 0.75% v/v (Laurent et al., 2002). Another frequently used 
source of hyaluronan are the capsules of certain (pathogenic) bacteria where they play a role 
as a virulence factor (Wessels et al., 1991). Although both are good sources of hyaluronan, 
major drawbacks exist in (1) possible co-purification of immunogenic contaminants and (2) 
the undefined molecular sizes of the isolated hyaluronan fractions. Both these features are 
highly undesirable when aiming at pharmaceutical and cosmetic applications. A way to 
prevent either problem would be the controlled enzymatic synthesis of size-defined 
hyaluronan. 
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The biosynthesis of hyaluronan involves specific glycosyltransferases, pertinently called 
hyaluronan synthases (HASs; EC 2.4.1.212). Unlike other glycosyltransferases these HASs are 
able to transfer two different UDP-sugars, UDP-GlcA and UDP-GlcNAc, to the growing 
polymer. Multiple HASs have been identified the past two decades (DeAngelis, 1999; Weigel 
and DeAngelis, 2007). Apart from vertebrates HASs, also a viral and multiple bacterial HASs 
have been identified (Weigel, 2002). 
Comparison of all these different HASs has led to the division of these enzymes into 
two different classes (DeAngelis, 1999). Almost all HASs are so-called Class I HASs. These are 
integral membrane proteins containing multiple membrane domains present throughout the 
protein sequence. One glycosyltransferase domain is responsible for the transfer of both 
UDP-sugars. The hyaluronan synthase from the gram negative bacterium Pasteurella 
multocida (PmHAS) is the only example of a Class II HAS (DeAngelis, 1996). PmHAS is a 
peripheral membrane protein that is membrane associated via its carboxyl-terminus. 
Differently than Class I HASs, PmHAS has two glycosyltransferase domains, each responsible 
of the transfer of one of the UDP-sugars (DeAngelis and Padgett-McCue, 2000; Jing and 
DeAngelis, 2003; Kooy, 2010). These UDP-sugars are added at the non-reducing end of the 
growing hyaluronic acid chain (Fig.2). 
 
-UDP
-UDPGlcNAc
GlcA
PmHAS
-UDP
-UDP
“HA4 acceptor molecule”
Chain growth at the Non-reducing end
GlcA GlcNAc GlcA GlcNAc
GTase
GTase
 
Figure 2 – Schematic representation PmHAS mediated hyaluronan biosynthesis. Two active sites (GTase) are 
present each responsible for the transfer of one UDP-sugar to the non-reducing end of an acceptor molecule. 
UDP is released upon chain elongation. 
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The initiation step is very slow, addition of an acceptor molecule (typically a tetramer; HA4) 
increases chain elongation speed. Addition of HA4 also reduces the polydispersity, the 
resulting polymers vary less in size (Jing and DeAngelis, 2004). 
The PmHAS gene has been cloned and heterologically expressed in Eschericia coli 
previously (DeAngelis, 1998). The C-terminal membrane association domain could be 
removed, resulting in a cytoplasmatic protein, without losing HAS activity (Jing and 
DeAngelis, 2003). Although the current levels of PmHAS production may be is sufficient for 
biotechnological purposes, increased production levels as well as improved protein solubility 
are desirable. We aim for this by fusing PmHAS to maltose binding protein (MBP), resulting 
in a MBP-PmHAS fusion protein (Fig.3). In this study we describe the stabilizing effect of MBP 
on PmHAS, in comparison with a PmHAS lacking such stabilizing tag. 
 
Wild type PmHAS GlcNAC GlcA membrane domain
GlcNAC GlcA H PmHAS-His
MBP GlcNAC GlcA MBP-PmHAS
 
Figure 3 – Schematic representation of wild type PmHAS (top), and constructed fusion proteins. Abbreviations 
used are GlcNAC / GlcA = glycosyltransferase domains, MBP = maltose binding protein, H = polyhistide-tag. 
 
Materials and methods 
Chemicals, UDP-sugars and the pyruvate kinase and lactate dehydrogenase were purchased 
from Sigma-Aldrich. HA4 was a kind gift of Floor Kooy (A&F Wageningen UR). Used restriction 
enzymes, Pfu DNA polymerase and T4 DNA ligase were from Invitrogen Amylose Resin was 
purchased from New England Biolabs, the Talon metal Affinity Resin was purchased from BD 
Biosciences. 
The used bacterial expression vectors were pET101/D-TOPO (Invitrogen) and pMAL-
C2 (New England Biolabs). The His-tagged construct (pET101) was a kind gift from Jan 
Springer (A&F Wageningen UR), the MBP-tagged construct (pMAL-C2) was constructed in E. 
coli DH5α. The used bacterial expression host was E. coli BL21 (DE3) (Novagen), containing 
the tRNA helper plasmid pSJS1244. 
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Gene cloning 
The MBP-tagged fusion protein was created by PCR using the His-tagged construct as 
template. The sense primer used was BG2650 (5’- 
CCCGAATTCAATACATTATCACAAGCAATAAAAGCATATAACAGC-3’), the antisense primer was 
BG2651 (5’-CCCCTGCAGTTAAATATCTTTTAAGATATCAATCTCTTCTTGATATTCAGC-3’). The 
introduced flanking restriction sites EcoRI / PstI (underlined) were used to clone the gene in 
the bacterial expression vector pMal-C2. E. coli DH5α was transformed with the ligation mix 
to amplify the resulting plasmid named pWUR539. 
 
Protein expression 
Expression vector pWUR539 (MBP-tag) was used to transform E. coli BL21(DE3) harboring 
pSJS1244. For each construct one single colony was used to prepare a starter culture by 
inoculating Luria-Bertani medium (LB) containing 100 μl/ml ampicillin (and 50 μl/ml 
spectinomycin for pSJS1244). The starter culture was grown overnight at 37°C while shaking. 
A larger culture was started by inoculation of 100 ml LB (similar antibiotic content) with 1% 
starter culture. The culture was grown at 37°C, while shaking, until OD600 = 0.6 was reached. 
Protein expression was induced by addition of isopropyl β-D-1-thiogalactopyranoside (IPTG) 
to a final concentration of 0.5 mM, and growth was continued for another 3 hours while 
shaking at a temperature of 37°C. Cells were harvested by centrifugation, and resuspended 
in 5 ml of 20 mM TRIS-HCl buffer (pH7.5) with 50 mM KCl. The cells were disrupted by 
sonication with intermitted cooling steps on ice. The crude cell lysate was centrifuged 
(16,000 x g) to remove cell debris. Protein expression levels were checked by SDS-PAGE 
analysis, quantities were measured after staining with Coomassie Brilliant Blue (Bradford 
analysis and analysis with Quantity ONE® Bio-Rad). For protein purification the supernatant 
was applied on a gravity flow column (Bio-Rad) of amylose resin (MBP-PmHAS) or Talon resin 
(PmHAS-His), and purified according the manufacturers’ protocol. 
 
PmHAS activity measurements 
Protein samples always were freshly prepared and kept on ice until used. Hyaluronan 
production could be confirmed by gel electrophoresis (Ikegami-Kawai and Takahashi, 2002). 
The reaction mixture contained 10 μg PmHAS, 10 mM of each UDP-sugar and 0.1 mM HA4 in 
a TRIS-HCl buffer (50 mM pH 7.1, 5 mM MnCl2, 1.1 M ethylene glycol). The reaction was 
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performed overnight at 30°C analyzed on a 6% TBE polyacrylamide gel (invitrogen) and 
stained with Stains-All as described previously (Kooy et al., 2009). 
The glycosyltransferase activity of PmHAS was measured using a coupled enzyme assay 
(Krupa et al., 2007). This assay is based on the UDP release upon hyaluronan elongation 
reaction, which is directly linked to decrease in NADH, which could be 
spectrophotometrically measured at 340 nm (Equation 1-3). 
 
(1) n UDP-GlcA + n UDP-GlcNAc + HA4   –[PmHAS]→   (GlcA-GlcNAc)n-HA4 + 2n UDP 
(2) UDP + phosphoenolpyruvate   –[pyruvate kinase]→   UTP + pyruvate 
(3) pyruvate + NADH   –[L-lactate dehydrogenase]→   L-lactate + NAD+ 
 
The standard reaction condition buffer was composed of 20 mM TRIS-HCl (pH 7.5), 1 M of 
ethylene glycol, 50 mM KCl, 13 mM MnCl2, 1.4 mM phosphoenolpyruvate (PEP), 28 μM UDP-
GlcA, 1.32 mM UDP-GlcNAc and 48 μM HA4. The two coupled enzymes were present in 
excess, knowing 30 U/ml pyruvate kinase and 37 U/ml lactate dehydrogenase. In total 0.15 
mM NADH was used to have the measurements in the linear range (ε340 = 6.3 mM-1cm-1). 
The typical volume of added PmHAS was 40 μl. All assays were performed using a Hitachi 
U2001 spectrophotometer with a temperature controlled cuvette holder set at 30°C. 
 
Results and Discussion 
Two tagged PmHASs were tested for their expression levels and protein solubility. Aiming for 
a better soluble PmHAS, we created a MBP-PmHAS fusion protein (Fig.3). Maltose binding 
protein (MBP) is well known for its stabilizing effect in Escherichia coli (Kapust and Waugh, 
1999). As a reference we used a previously constructed His-tagged PmHAS, as a polyhistidine 
tag does facilitate easy protein purification but it generally does not result in any stabilizing 
effect. Both PmHAS fusion proteins are truncated (lacking C-terminal docking sequence) in 
order to gain maximal solubility. 
Both PmHAS fusion proteins could be successfully expressed in E. coli BL21(DE3). We 
noticed that protein solubility is severely affected by elongated expression time, resulting in 
large quantities of insoluble protein. This could be partially prevented by having an 
expression time of 3 hours, although this did not completely prevent PmHAS ending up in 
Chapter 5 
 
98 
inclusion bodies. Comparison of protein expression of both fusion proteins clearly shows 
differences in protein solubility levels (Fig.4). 
 
 
 
Using identical expression conditions, obvious differences in protein solubility levels can be 
observed. The PmHAS-His and MBP-PmHAS cultures were grown in parallel experiments to 
ensure identical expression conditions. Multiple independent expression experiments show 
an increase of solubility levels from 20% for PmHAS-His to almost 60% for MBP-PmHAS 
(Fig.5). Also the total amount of MBP-PmHAS produced generally is larger than PmHAS-His, 
although absolute quantities vary too much per batch to be conclusive. 
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Figure 4 
Comparison recombinant PmHAS 
fusion protein expression levels 
in E. coli BL21(DE3). The arrows 
indicate the size of PmHAS-His 
(lane 1-4; 81 kDa) and MBP-
PmHAS (lane 5-8; 126kDa). Odd 
numbers represent soluble 
protein, even numbers insoluble 
protein. Marker (M) sizes are 
indicated on the left in KDa. 
 
Figure 5  
Comparison recombinant 
PmHAS fusion protein 
expression levels in E. 
coli BL21(DE3). Indicated 
is the relative amount of 
soluble enzyme (light 
grey bars) compared to 
insoluble enzyme (dark 
grey bars). Total amount 
of each PmHAS fusion 
product is set at 100%. 
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Obviously PmHAS solubility is greatly improved by fusion to MBP. However, since maltose 
binding protein is a rather large protein, it might be well possible that such large body blocks 
the active site. Hence MBP-PmHAS was tested for its hyaluronan synthesizing capacity, using 
both MBP-PmHAS in cell free extract and purified enzyme. One batch freshly prepared and 
one batch of three weeks old MBP-PmHAS were analyzed to test protein stability. The 
reactions were incubated overnight to ensure complete conversion, ethylene glycol was 
added to stabilize the enzyme. The produced hyaluronan was checked on a TBE gel (Fig.6). 
 
 
 
Overnight incubations of MBP-PmHAS with both-UDP sugars and HA4, resulted in the 
production of high molecular weight hyaluronan for both MBP-PmHAS in cell lysate and for 
purified enzyme. The old batch of MBP-PmHAS lost activity. This corresponds with untagged 
PmHAS, which has similar stability problems when stored at 4°C (unpublished data). 
No inhibitory effect was observed of the MBP molecule on HAS activity. However, to 
exclude any effect of the MBP-tag on the activity, we did some more in-depth comparison 
between MBP-PmHAS and PmHAS-His. Therefore we compared the specific activity of both 
fusion proteins. We measured multiple batches of freshly prepared and purified MBP-
PmHAS and PmHAS-His using a coupled enzyme assay (equation 1-3) on a temperature 
controlled spectrophotometer. Since MBP is a rather large tag, the molecular mass of MBP-
PmHAS increases significantly. Therefore, to correct for the change in protein-size we not 
only expressed activity in per mg (Fig.7A), but also in the activity per mole (Fig.7B). 
We could not observe an obvious difference in specific activity of both fusion 
proteins after corrected for the increased mass of MBP-PmHAS. The measured activities are  
Figure 6 – TBE-gel based analysis of 
hyaluronan synthesis by using MBP-
PmHAS. Lane M give an indication of 
the molecular mass. Lane 1 represent 
hyaluronan production using cell 
lysate containing MBP-PmHAS, lane 2 
represent hyaluronan production by 
using purified MBP-PmHAS.. 
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in good agreement with values found in literature (Kooy, 2010). Although protein solubility is 
greatly improved, a better protein stability is still desirable. We noticed loss of activity over 
time for both fusion proteins. Stability of MBP-PmHAS seems increased compared to 
PmHAS-His, but more detailed research is needed to be conclusive. 
 
Conclusions 
The constructed fusion protein potentially is a great tool for enzymatic hyaluronan synthesis, 
as large quantities of protein easily can be produced. Even though MBP is a fairly large 
domain, no negative effect is observed on HAS activity. This suggests that PmHAS can be N-
terminally coupled to a carrier material without losing activity. Such a carrier coupled 
PmHAS could greatly improve controlled hyaluronan synthesis. PmHAS mutants that have 
lost affinity of one the UDP-sugars have been created by others (Jing and DeAngelis, 2003). 
Step wise addition and subsequent easy removal of such a coupled PmHAS mutant from the 
reaction mixture potentially is a tool to synthesize hyaluronan oligosaccharides of a 
controlled chain length, greatly reducing hyaluronan polydispersity. 
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Figure 7 – (A) Comparison 
of the specific activity of 
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Specific activity expressed 
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Abstract 
The use of enzymes as catalysts in industrial processes is steadily increasing. Enzymes are, 
however, optimized to function optimally in their natural environment, which often differs 
from the conditions used in industrial settings. To enable a more rational approach in 
engineering such enzymes, various bioinformatics tools are being developed for ‘smart 
library design’. Here we used multiple sequence alignments and a correlated mutation 
analysis tool (CMA) to identify targets for mutagenesis. CMA analysis of the RmlC-like cupin 
super-family revealed a set of correlated amino acids. Using the phosphoglucose isomerase 
from Pyrococcus furiosus (PfPGI) as model enzyme, we subsequently varied correlated 
residues Pro27 and Tyr28 by saturation mutagenesis. Although this amino acid pair is located 
in a conserved loop distant from the active site, their predicted relevance could be 
confirmed by activity measurements of the generated PfPGI mutants. The generated library 
showed a positive relationship between the prevalence of a certain amino acid pair in the 
superfamily and the activity of the corresponding PfPGI mutant. We hypothesize that the 
observed differences in PfPGI activity are caused by subtle structural changes in metal 
coordination. Obtained crystal structures of four selected PfPGI variants are currently under 
investigation.
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Introduction 
Enzymes have been recognized and implemented as useful catalysts for numerous industrial 
purposes. An enormous variety of enzymes can be found in nature, providing a rich source of 
potential biocatalysts. However, in evolution these enzymes are optimized to function 
optimally in in vivo environments, which may differ from in vitro industrial conditions. 
Therefore there is often a need for further protein optimization for applicability in industrial 
settings. Generally this is achieved by the generation of large libraries of variants, from 
which a few mutants with improved features are selected. As the screening of large libraries 
typically is costly and time inefficient, reductions in library-size by “smart library design” 
would be an appreciated step forward (Chica et al., 2005; Lutz, 2010). 
Selection of specific amino acid residues for mutagenesis, requires identification of 
key residues. Such amino acids either can be identified through experimental analyses, or via 
functional predictions using bioinformatics. Comulator, an extension of the 3DM software 
suite, is a recently developed bioinformatics tool that uses a correlated mutation analyses 
(CMA) algorithm to identify coevolved residues in (large) multiple sequence alignments 
alignments (MSAs) (Kuipers et al., 2009; Jochens and Bornscheuer, 2010). 
Subject of study is the RmlC-like cupin super-family; a large group of structurally 
related proteins present in all three domains of life (Dunwell et al., 2000) which includes 
isomerases, dioxygenases, oxidoreductases and storage proteins. Although members of this 
family cover a broad spectrum of different functions, all members of the family share the 
same β-barrel structure composed of β-strands. The name cupin reflects this structure and 
has been derived from the latin word “cupa” (small barrel). Much structural data has been 
collected for different members of the cupin superfamily (Dunwell et al., 2004). 
One of the best characterized members of the cupin superfamily is the cupin type 
phosphoglucose isomerase of the hyperthermophilic archaeon Pyrococcus furiosus (PfPGI; 
E.C.5.3.1.9). PfPGI is a glycolytic enzyme, that catalyses the reversible isomerization of 
glucose-6-phosphate to fructose-6-phosphate (Verhees et al., 2001; Hansen et al., 2001). 
Multiple crystal structures of this homodimer (monomeric subunit is 21.5 kDa) have been 
solved, and ample insight in the catalytic activity of the enzyme has been gained (Berrisford 
et al., 2003; Berrisford et al., 2004; Berrisford et al., 2006). The enzyme can be well 
expressed in E. coli, is very stable in vitro and activity can be monitored easily. All this makes 
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PfPGI an ideal candidate for our studies. 
In this study we want to obtain a proof of principle that correlated mutation analyses 
can help in identification of structural / functional important sites, and can be used as a tool 
to identify potential “hot spots” for mutagenesis. We generated a library of substitutions at 
such a hot spot, by varying two correlated amino acids identified by CMA (Fig.1). The 
predicted relevance of the correlated residues could be validated by activity measurements. 
By use of smart library design a small set of promising candidates might be equally effective 
to improve enzyme activity, as a complete (random) library is. 
 
 
Figure 1 – Residue pair frequency table of amino acid couple 27 and 28. For wild type PfPGI these residues are 
Pro132 and Tyr133. Occurrences are relative to the number of unique sequences in the super family alignment. 
 
Experimental procedures 
Yeast glucose-6-phosphate dehydrogenase was purchased from MP biomedicals. Chemicals 
were purchased from Sigma-Aldrich and Roche. The PfPGI mutant library was created by 
BaseClear (The Netherlands), the genes were cloned in expression vector pET24d (Novagen). 
 
PfPGI mutant library 
The cloning of the gene pgiA has been described previously (Verhees et al., 2001). A site 
saturation library was designed and created based on CMA using the Comulator software. 
The constructed library consisted of pgiA variants that had alterations in two strongly 
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correlated amino acids; proline 132 and tyrosine 133. The corresponding numbering in the 
3DM alignment was Pro27 and Tyr28 (Fig.1). The created pgiA mutants were cloned in 
expression vector pET24d and used to transform Escherichia coli. 
 
PfPGI expression and purification 
Starter cultures of the pgiA mutants were inoculated from a glycerol stock and grown 
overnight in Luria Bertani medium supplemented with 50 μg/ml kanamycin (LB/Km) in a 
37°C shaker. The overnight culture was used to inoculate (0.2% v/v) sterile glass tubes of 10 
milliliter LB/Km medium. When the optical density of the culture reached A600 = 0.5, gene 
expression was induced by addition of 0.1 mM isopropyl-1-thio-β-D-galactopyranoside 
(IPTG). Growth was continued overnight at 37°C, after which the cells were harvested by 
centrifugation (4,600 x g for 15 minutes). Pelleted E. coli cells were resuspended in 20 mM 
Tris-HCl buffer (pH 8.0) and disrupted by sonication. DNAse was added to degrade the DNA 
in the cell lysate to reduce viscosity. Cell debris was removed by centrifugation (16,000 x g 
for 15 minutes). E. coli proteins were denatured by heating the cell free extract at 70°C for 
30 minutes, and removed by centrifugation (16,000 x g for 15 minutes). The result was a 
heat treated cell free extract containing mainly PfPGI. Its purity was checked by SDS-PAGE. 
Protein concentrations were determined by Coomassie Brilliant Blue G250 (Bradford, 1976), 
with bovine serum albumin as reference and analysis on SDS-PAGE (Quantity One®, Bio-Rad). 
PfPGI was purified to homogeneity using FPLC as described before (Kuipers et al., 
2009). Heat treated cell free extract was diluted to lower the salt concentration, filtered 
through a 0.45 μm filter and loaded on a Q-sepharose fast flow column (Amersham 
Pharmacia Biotech). The column was equilibrated with 20 mM Tris-HCl (pH 8.0). PGI activity 
eluted at 180 mM of NaCl during a linear gradient of 0 to 1 M NaCl. The fraction with the 
highest activity was loaded on a pre-equilibrated Superdex 200 GL column, and eluted in 20 
mM Tris-HCl (pH 7.0) containing 100 mM NaCl, protein concentrations and purity were 
determined. The purified enzyme fraction was used for activity assays. Metal analysis was 
performed on samples of the same fraction by using ICP-AES. 
 
PfPGI activity assay 
Divalent metals was stripped from purified PfPGI using 50 mM ETDA incubated at 50°C for 20 
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min just prior to the activity measurement. PfPGI activities were determined by measuring 
NADPH formation in a coupled enzyme assay with yeast glucose-6-phosphate 
dehydrogenase. This enzyme was present in excess to ensure that the detection of NADPH 
absorbance at 340 nm (ε = 6.3 mM-1cm-1) corresponded to PfPGI activity. The assay mixture 
contained 0.5 mM NADP, 5 mM D-fructose-6-phosphate and 0.35 units of D-glucose-6-
phosphate dehydrogenase, all in 20 mM Tris-HCl buffer (pH 7.0). All assays were performed 
using a Hitachi U2001 spectrophotometer with a temperature controlled cuvette holder set 
at 50°C. The optimal activity was measured after titration with MnCl2, while an excess of this 
salt resulted in enzyme inhibition. 
 
Results and Discussion 
By using the Comulator CMA algorithm, as described previously (Kuipers et al., 2009), 
predictions were made to generate a PfPGI library. We used a refined multiple sequence 
alignment of the cupin super-family, containing a total of 1824 sequences. The amino acids 
with the highest pair-wise correlated mutation score, were those at residue position 27 and 
28 (3DM-numbers) (Fig.1). This amino acid pair is located in a structurally conserved surface 
loop (Kuipers et al., 2009) that can be found in most members of the cupin super-family 
including PfPGI (Fig.2). 
 
 
Figure 2 – Cartoon 
representation of the 
PfPGI 3D-structure 
(PDB number: 1x82).             
The correlated amino 
acid pair P27 / Y28 is 
indicated in red. In 
yellow those residues 
that are involved in 
metal ion binding. 
Inhibitor 5-phospho-
D-arabinonate (5PA) 
is shown as a stick 
model. 
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Previous experiments have shown that a PfPGI double mutant, exhibited elevated PGI 
activity-levels while both single mutants were less active than wild type PfPGI (Kuipers et al., 
2009). This result is not obvious since this surface loop is not in close proximity to the 
catalytic residues. 
To examine the effect on the PGI activity of the correlated residues Pro27 and Tyr28 
in more detail, we selected fifteen mutants (out of the 400 possible) that correspond to 
amino acid pairs that are either highly abundant or (almost) absent within the refined cupin 
superfamily alignment (Fig. 1 and Table 1).  
 
Table 1 – Selected amino acid pairs, their natural occurrence and metal ion dependency according literature. 
Amino acid 
pair 
Occurrence in 
alignment (%) 
Molecular function                             
involved proteins 
Metal ion 
bound 
G27 / D28 
N27 / R28 
R27 / G28 
A27 / G28 
E27 / G28 
K27 / G28 
P27 / G28 
V27 / G28 
G27 /G28 
S27 / G28 
P27 / Y28 
A27 / D28 
G27 / Y28 
V27 / Y28 
P27 / R28 
A27 / Y28 
23.54 
11.28 
10.79 
10.68 
8.50 
4.63 
4.41 
1.80 
0.98 
0.71 
0.71 
0.16 
0.05 
0.0 
0.0 
0.0 
oxidoreductase 
dioxygenase, oxidoreductase 
dioxygenase, oxidoreductase, isomerase 
dioxygenase, storage protein, isomerase 
isomerase, storage protein 
isomerase 
storage protein, isomerase, dioxygenase 
isomerase 
dioxygenase, isomerase 
storage protein 
isomerase (including PfPGI) 
dioxygenase, oxidoreductase 
oxidoreductase 
- 
- 
- 
Fe 
Fe 
Fe, Mn 
Fe, Ni, Mg, Mn 
Mn 
Mn 
Mn, Ni 
Mn 
Cu 
unknown 
Fe 
Fe 
Fe 
- 
- 
- 
 
Cultures of these mutants could be grown as described previously and PfPGI expression 
could be induced successfully. As a control we included a mutant harboring an empty 
pET24d, to have a correction for background protein concentrations and to exclude possible 
background activity. Most E. coli proteins could be removed from the cell lysate by a heat 
treatment step and subsequent centrifugation. The heat stable cell free extract was used for 
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PfPGI activity measurements, to compare activity of the selected mutants with wild type 
(WT) PfPGI (Fig.3). In parallel to previous experiments PfPGI was stripped with EDTA to 
remove any bound divalent cations and subsequently titrated with Mn2+ as cofactor, as this 
cation results in highest in vitro activity (Berrisford et al., 2003). 
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Figure 3 – Graphical representation of the relative PfPGI mutant activity (Y-axis) compared to residue pair 
occurrence according Comulator predictions (X-axis). All activities are relative to the wild type PfPGI (“PY”). 
 
PfPGI activity was detected in lysates of all fifteen mutants, while activity in the lysate of the 
negative control strain was completely absent. Despite the fact that the selected residues 
are localized in a surface loop rather than in the catalytic site, significant differences were 
detected in PGI activity of the different mutants; none of the PfPGI mutants completely lost 
activity. Interestingly, we observed elevated activities for those amino acid combinations 
that are abundant in the protein family alignment (pair frequencies; Figs. 1 and 3). Those 
correlations that are less abundant or absent in the CMA, typically have activity levels that 
are comparable or lower than wild type PfPGI (amino acid pair “PY”). These findings suggests 
a positive correlation between the natural prevalence of an amino acid pair, and the activity 
of the corresponding mutant. 
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To validate these values we selected some of these mutants for further purification to 
homogeneity, to enable a more precise analysis of the PfPGI specific activity. Therefore a 
total of five large batch cultures were grown; WT PfPGI and PfPGI mutants P27A/Y28G, 
P27R/Y28G, P27A/Y28D and P27V. The first two mutants have a high occurrence compared 
to wild type, while the other two mutants represent an amino acid combination that is not 
found in the CMA. Heat stable cell lysate of these five PfPGI mutants was produced and 
further purified to homogeneity by two additional FPLC steps as described previously. The 
pure PfPGI samples were used to determine the specific activity of each of these PfPGI 
mutants (Fig.4). 
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Figure 4 – Specific activity of wild type PfPGI compared to selected single and double mutants. 
 
The specific activities measured for these purified PfPGIs are in good agreement with the 
previously obtained values as described in Figure 3, although the relative activity presented 
there was slightly overrated, probably due to difficulties in obtaining accurate protein 
concentrations in cell lysate. Again we observed an increased activity for both P27R/Y28G 
and P27A/Y28D in comparison with the wild type protein, while both P27V and P27A/Y28D 
have respectively a similar or decreased specific activity compared to WT PfPGI. 
 
An important matter to be addressed is the molecular basis of the observed differences in 
activity. As mentioned, the correlated amino acid pair is located in a surface loop. Despite 
the fact that this loop is conserved within the cupin family, it is also located rather far from 
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the catalytic site. It is tempting to speculate that conformational changes in the PfPGI 
structure could lead to the observed differences in activity. 
In contrast to conventional non-cupin PGIs, catalysis of a cupin-type PGI is metal 
dependent. Removal of divalent metals results in complete loss of activity, which can be 
restored by the addition of divalent metals. Most divalent cations can function as cofactor, 
although affinities are different for each specific cupin type PGI (Hansen et al., 2005). 
Analysis of the 3DM data reveal the possibility that these differences at position 27 and 28 
are the result of a difference in cofactor binding, either with respect to specificity or affinity. 
Although there is no absolute correlation, typically those amino acid pairs that have a higher 
activity than the wild type, bind manganese (Table 1). This mainly is true for those that have 
an isomerase function according to literature.  
Iron is identified to be associated with PfPGI when isolated both as recombinant 
protein from E. coli, and as native protein from Pyrococcus furiosus (Berrisford et al., 2003). 
However, also metals other than Fe2+ have been found associated with PfPGI. In vitro 
experiments of PfPGI show highest activity with Mn2+ as cofactor (Berrisford et al., 2003), 
which is therefore used as the cation of choice for our experiments. Possibly this is an in 
vitro artefact, as the wild type PfPGI obviously is optimized to function in vivo. As long as 
PfPGI is not rate limiting in the glycolysis of P. furiosis, there will not be any selection 
pressure for protein optimization. 
To identify possible differences in metal binding of wild type PfPGI and the developed 
mutant PfPGIs, we performed metal analysis (ICP-AES) on PGI samples that were not treated 
with EDTA. Previous studies on wild type PfPGI already indicated that under physiological 
conditions the occupation of the metal binding sites is likely to be a mixture of divalent 
metals (Hansen et al., 2005). Comparison of wild type PfPGI with double mutant P27A/Y28G 
revealed a clear difference in the associated divalent metal. ICP-AES results suggests 
predominantly manganese for the double mutant, while the wild type manganese levels are 
eight-fold lower and predominantly Mg2+ is bound. 
The results suggest that the metal coordination of the different mutants is affected, 
resulting in different activities. To prove this hypothesis we have initiated crystallization 
trials of both wild type PfPGI and the four PfPGI mutants. The crystallizations are set up with 
manganese as incorporated cofactor. Multiple well diffracting crystals (1.5 - 2.1 Å) have been 
obtained (Table 2). Structure comparison of PfPGI wild type and mutants is ongoing. 
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Table 2 – PfPGI mutants for which well-diffracting crystals were obtained 
PfPGI crystal Cofactor / substrate present Resolution 
P27R / Y28G 
P27R / Y28G 
P27A / Y28G 
P27A / Y28G 
P27A / Y28D 
P27A / Y28D 
P27V 
manganese 
manganese and fructose-6-phosphate 
manganese 
manganese and fructose-6-phosphate 
manganese 
manganese and fructose-6-phosphate 
manganese 
   2.0 Å 
1.75 Å 
   1.5 Å 
   1.4 Å 
   1.6 Å 
   2.2 Å 
   1.9 Å 
 
Conclusions 
Enzymatic conversions have great potential as green alternative for the chemical catalysis in 
biotechnological applications. However, natural enzymes are not optimized for industrial 
biocatalysis. Multiple examples exist of successful enzyme engineering. Mostly these 
optimizations have been achieved in an evolutionary approach, by random introduction of 
mutations and subsequent selection for the desired optimized features. Successful 
application of laboratory evolution urges high-throughput selection methods; however, lack 
of an appropriate screen restricts the chance on success dramatically. 
Rational mutagenesis approaches are an alternative way of protein engineering, 
where only one or a few site specific mutations are introduced at carefully selected amino 
acid positions. Correct prediction of a specific substitution at a certain position is very 
difficult and often has been proven a less successful approach. In the present study, we used 
correlated mutation analysis (CMA) as a tool to identify correlated amino acids residues, 
which likely have a high chance of affecting the specific activity of an enzyme. The observed 
correlations represent hot spots that are targets for variation in ‘smart library’ design 
(Jochens and Bornscheuer, 2010). The residues identified by CMA are limited in their 
combinatory freedom. Alterations of these amino acid residues have been shown to result in 
improved features. The work we describe here supports this principle, as we observed a 
positive link in the prevalence of an amino acid combination in the super family multiple 
sequence alignment and the activity level of a mutant. 
We hypothesize that the observed change in activity originates from a change in 
metal affinity or specificity. We observed a change in associated divalent metal in double 
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mutant P27A/Y28G in comparison with wild type PfPGI. We hope to get refined crystal 
structures of the created mutants in the near future revealing potential changes in cofactor 
binding, contributing in better understanding of PfPGI and general knowledge in CMA based 
protein optimization. 
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Introduction 
Glycosaminoglycans like heparin and heparan sulfate have a long history as useful 
pharmaceuticals. Traditionally these glycosaminoglycans are isolated from livestock derived 
(waste) tissue. Although this is a rich source of material, several disadvantages related to 
these materials exist as well, as outlined in Chapter 1. Hence, the need for chemo-enzymatic 
glycosaminoglycan synthesis is obvious. Although much research has been performed on 
glycosaminoglycan-acting enzymes like PmHAS and the murine heparan sulfate D-glucuronyl 
C5-epimerase, it has become clear that there are still several hurdles to get over to before 
industrially applicable enzymes can be developed. To reach successful optimization of the D-
glucuronyl C5-epimerase we identified three bottlenecks and made attempts to overcome 
these. In this concluding chapter, our major achievements are summarized and discussed, 
and approaches to solve the remaining problems are proposed. Also the achievements in the 
optimization of PmHAS are described. 
 
Bottleneck one – Stability of glycosaminoglycan modifying enzymes 
In this thesis we describe the attempts to improve enzyme production-levels and enzyme 
stability for two GAG modifying enzymes: the heparan sulfate murine D-glucuronyl C5-
epimerase (MmC5) in Chapter 4 and the Pasteurella multocida hyaluronan synthase 
(PmHAS) in Chapter 5. Attempts of heterologous expression of both genes in an industrially 
suitable host like Escherichia coli gave rise to serious limitations in protein production levels 
and protein stability. As discussed for both constructs, most likely, this is a result of the 
protein topology in vitro. 
The heparan sulfate D-glucuronyl C5-epimerase is known to be associated in vivo 
with the 2-O-sulfotransferase (Pinhal et al., 2001). It is hypothesized that also other enzymes 
involved in heparosan chain modification associate with these two enzymes (Sasisekharan 
and Venkataraman, 2000). Regardless of the exact composition of the in vivo complex, it has 
become clear that heterologous expression of the heparan sulfate D-glucuronyl C5-
epimerase is not feasible in Escherichia coli. In order to overcome stability issues of 
individual sub-complex members like the heparan sulfate D-glucuronyl C5-epimerase, we 
constructed an MBP-MmC5 fusion protein. MBP (maltose binding protein) is known to have 
a positive effect on the soluble production of heterologous proteins in E. coli (Kapust and 
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Waugh, 1999). Expression experiments show massive production of the non-tagged control 
MmC5 in E. coli, however all protein ends up in inclusion bodies (Chapter 4). We made many 
variations in expression conditions and buffer compositions, however none did result in any 
solubilization of MmC5. On the other hand our constructed MBP-MmC5 fusion protein was 
successful as substantial amounts of MBP-MmC5 could be produced in a soluble form. 
Activity measurements confirm D-glucuronyl C5-epimerase activity in the soluble fraction, 
providing an alternative way of production of this enzyme (Chapter 4). 
The second glycosaminoglycan modifying enzyme that we worked on was PmHAS. 
This enzyme is membrane-associated via a membrane docking sequence. Removal of this 
domain results in ‘solubilization’ of PmHAS (Jing and DeAngelis, 2003). However, still most of 
the produced PmHAS is present in inclusion bodies. Similarly to MmC5, we could increase 
protein production-levels of soluble PmHAS by fusing the enzyme to the solubilizing MBP-tag 
(Chapter 5). Protein solubility levels could be increased almost threefold, while hyaluronan 
synthase activity is still present and no deleterious effect on the protein activity was 
observed. 
 
Protein engineering 
Although protein production levels have been increased successfully for both enzymes, 
further protein optimization may be desirable. Characteristics like enzyme stability and 
substrate specificity are examples of potential engineering steps. Basically, there are two 
different approaches for protein mutagenesis; “rational design” and “directed evolution”. 
 
Rational design | Rational design (often computational design) is based on site-specific 
changes of carefully selected amino acid residues, having a predicted relation with particular 
enzyme characteristics. Changes often are limited to relatively easily identifiable amino acid 
residues like the active site or other substrate interacting residues (for an example see 
Machielsen et al., 2009). Ideally a 3D-model exists of the structure, resulting in more reliable 
predictions. However, alternative in silico methods to identify important residues gradually 
arise, of which Chapter 6 gives a good example of comulator based mutagenesis of PfPGI . 
 As structural data of the D-glucuronyl C5-epimerase is lacking, no solid predictions for 
site-specific changes can be made; however, some speculation of possible key residues are 
provided below. In order to allow for future structural analyses, we made two truncated 
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variants of the MBP fused MmC5, providing indications on the relevance of the N-terminal 
domain (Chapter 4). 
 
Directed evolution | When a 3D-model of the enzyme of interest is lacking, or for 
improvement of poorly understood residues, protein improvement is still possible by a 
strategy, known as laboratory evolution or directed evolution. This method is based on the 
generation of a large set (library) of variants of a gene of interest. There are various ways to 
achieve this, including randomly introduction of a limited number of point mutations by for 
example error prone PCR (Cadwell and Joyce, 1992), or recombination of DNA fragments by 
gene shuffling of natural variants (Stemmer, 1994). 
A crucial aspect of the ‘laboratory evolution’ approach, is a suitable screening and 
selection method (review: Boersma et al., 2009). A commonly used phrase regarding 
directed evolution is “you get what you screen for”. To screen for an improved parameter of 
choice, the required method needs to be both selective and high-throughput. Depending on 
the screening/selection method used, libraries easily can be expanded from thousands to 
millions of mutants. 
 Knowing these described techniques, we aimed to improve the enzyme stability of 
PmHAS and MmC5. The idea was, in analogy to the MBP-tag, to use a colored protein tag like 
mCherry or GFP (green fluorescent protein) instead, facilitating easy monitoring of soluble 
protein (Waldo, 2003). By challenging the mutant library with conditions that denature the 
wild type, mutants with improved stability should remain soluble. Unfortunately, both the 
mCherry and GFP experiments failed due to lack of solubility of both tags in E. coli when 
fused to PmHAS/MmC5 (unpublished results). However, this method could still be a useful 
tool for enzyme optimization, since we demonstrated that the addition of an N-terminal 
protein tag had no negative effect on either protein. Crucial is sufficient solubility of the 
protein of interest / colored protein-tag fusion product in E. coli. Alternatively, the fusion 
protein of choice can provide a selection advantage, for example a fusion protein with an 
antibiotic resistance marker, providing antibiotic resistance as long as the protein of choice is 
produced in a soluble form. 
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Bottleneck two – Screen for D-glucuronyl C5-epimerase activity 
Absolutely essential for the improvement of an enzyme is a reliable and reproducible 
method to assay the enzyme activity. Preferably the assay is fast, cheap and easy. For the D-
glucuronyl C5-epimerase no such assay exists to date. We tested a variety of possible 
methods. Some have been described in earlier chapters, here we give a complete overview 
of considered and tested assays. 
 
Hexuronic acid coloring assay 
Many high-throughput enzyme assays are based on the development or change in color 
upon the enzymatic reaction. The resulting changes quickly and easily are observed visually 
or using spectrophotometry. Examples of such assays are described in Chapter 5 and 
Chapter 6 of this thesis, using a spectrophotometric method to monitor the decrease in 
NADH levels. 
Also coloring reactions specifically for hexuronic acids do exist. They have been 
developed and described already 65 years back (Dische, 1946) and are based on the reaction 
of hexuronic acids with carbazole and sulfuric acid, resulting in a pink color development. 
The method has been used to identify hexuronic acids in glycosaminoglycans (Hoffman et 
al., 1956). Differences in color development are claimed; D-glucuronic acid (GlcA) gives three 
times more intense coloring than L-iduronic acid (IdoA). Over time the assay conditions have 
been further optimized (Radhakrishnamurthy and Berenson, 1963). The addition of borate 
to the concentrated sulfuric acid results in better coloring (Bitter and Muir, 1962). 
Substitution of carbazole by meta-hydroxydiphenyl (mHDP) (Blumenkrantz and Asboe-
Hansen, 1973) and addition of sulfamate (Filisetti-Cozzi and Carpita, 1991), results in 
reduced interference from neutral sugars, and thus in better specificity for hexuronic acids. 
We tested hexuronic acid detection in 96-well plates, based on earlier reports (van 
den Hoogen et al., 1998; Cesaretti et al., 2003). Using different sugars (1 mg/ml each) we 
tested for mHDP based color formation (Fig.1). Indeed the coloring is rather specific for 
hexuronic acids. Unfortunately, we could not observe differences in color formation 
between heparin (mainly IdoA) and GlcA. Therefore this assay can be considered adequate 
to screen for formation of hexuronic acids, but insufficient for detection of hexuronic acid 
epimerization. 
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Figure 1 – Meta-hydroxydiphenyl (mHDP) based color formation of different sugars (1mg/ml) 
 
Tritium labeled substrate 
A widely used method to assay D-glucuronyl C5-epimerase activity is based on the exchange 
of the C5-proton with water upon the epimerization reaction. This method makes use of a 
tritium labeled substrate and enzyme activity results in exchange of tritium with water 
resulting in 3H2O formation. Upon biophasic separation of the 3H2O from the labeled 
substrate, the substrates remain in the water phase, while 3H2O is extracted to an organic 
phase. Any accumulation of radioactivity in this organic phase is the result of D-glucuronyl 
C5-epimerase activity (Campbell et al., 1983; Kusche et al., 1991). This accumulation of 
tritium in the organic phase can be measured using a scintillation counter. 
This method has been used in Chapter 3 and Chapter 4 to measure RED-C5-
epimerase and MBP-MmC5 D-glucuronyl C5-epimerase activity, respectively. Although this 
method is not exactly high-throughput, measurement of multiple samples is certainly 
feasible. Another advantages include the methods’ sensitivity and the long history of using 
this method, which allows comparison with earlier results. An absolute disadvantage, and 
therefore the biggest bottleneck of this method, is the availability of labeled substrate. Every 
single substrate that should be tested needs to be tritium labeled, which is a laborious and 
expensive task. This makes this method not very suitable for testing a wide variety of 
different substrates or D-glucuronyl C5-epimerase orthologs with alternative substrate 
specificities.
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HPLC-PAD 
A method independent of the used substrate, has been described in Chapter 3. Here we 
show a method to separate D-glucuronic acid from L-iduronic acid by high performance 
anion exchange chromatography (HPAEC). We have optimized a protocol for analysis of a 
glycosaminoglycan hydrolysis mix on a Dionex system (Fig.2A/B), by which we monitored 
hexuronic acids with an electrochemical detector using pulsed amperometric detection 
(PAD). This sensitive detection method is based on electrocatalytical oxidation of 
carbohydrates at a gold electrode by application of a positive potential and a alkalic 
environment. Proportional to the carbohydrate concentration a current is generated, that is 
used to detect and quantify carbohydrates. To prevent loss of signal due to electrode 
poisoning, a series of pulsed potentials is applied. 
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Figure 2 – Chromatogram HPLC-PAD separation of glucosamine (GlcN), D-glucuronic acid (GlcA) and L-iduronic 
acid (IdoA). (A) Addition of salt disturbs retention-time of mainly IdoA. (B) Hydrolysis profile of de-O-sulfated 
(N-sulfated) heparin. Standards are shown in grey, samples are shown in black. 
 
Although this method is highly sensitive and virtually any substrate can be used, it also 
requires tightly controlled depolymerization conditions of the used substrates and requires 
proper control samples. Since the depolymerization involves high concentrations of 
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hydrochloric acid at high temperatures, unwanted degradation products are readily formed. 
Parameters as hydrolysis time, temperature and pH need to be tightly controlled, as well as 
the buffer and salt concentration. This method is also rather laborious. Glycosaminoglycans 
are typically hard to hydrolyze, resulting in long hydrolysis times at elevated temperatures. 
Upon hydrolysis, the hydrochloric acid needs to be completely removed by an evaporator. 
Both steps take several hours, implying that this method is not useful for screening large 
libraries of C5-epimerase variants. 
 
Nitrous acid based depolymerization 
Depolymerization of heparin / heparan sulfate is not an easy task since these 
glycosaminoglycans are known to be remarkably resistant to acid hydrolysis. However, it has 
been known for over half a century that glycosidic bonds of amino sugars with an 
unsubstituted amino group (e.g. glucosamine) can be easily cleaved by nitrous acid (Conrad, 
1993). Addition of nitrous acid (pH 1.5 at 100°C) removes all N-sulfate groups instantly, while 
2-3 h incubation is sufficient to remove all N-acetyl groups (Shively and Conrad, 1976). 
Subsequent nitrosation of the unsubstituted amino group leads to loss of N2, accompanied 
with the conversion of glucosamine to 2,5-anhydro-D-mannose (Fig.3A). As a result the 
glycosidic bond with the neighboring hexuronic acid is disrupted, leading to 
depolymerization. 
We have tried to implement this way of depolymerization in the previously described 
HPLC-PAD method. However, two problems were encountered. Firstly there is a need of 
both 2,5-anhydro-D-mannose / hexuronic acid disaccharide standards. Secondly, the use of 
nitrous acid results in an accumulation of salt in the samples which is known to disturb the 
separation of D-glucuronic acid and L-iduronic acid (Fig.2A). Although both problems can be 
overcome, the benefits versus hydrochloric acid based hydrolysis were considered 
insufficient to continue with this method. 
 
Heparin Lyases 
Several lyases have been described that are able to depolymerize heparin. The bacterium 
Flavobacterium heparinum has three different heparin lyases (or heparinases), each with a 
typical substrate specificity (Desai et al., 1993). Heparinase II has the broadest substrate 
specificity and can cleave substrates which contain D-glucuronic acid as well as L-iduronic 
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acid. Heparinase I (EC 4.2.2.7) and Heparinase III (EC 4.2.2.8) only specifically cleave the 
linkage GlcN-IdoA and GlcN-GlcA, respectively. 
 The substrate specificity of Heparinase I could make this lyase a potential tool to 
assay C5-epimerization activity. Cleavage mediated by lyases proceeds via a β-elimination 
reaction on the glycosidic bond. As a result both GlcA and IdoA are converted to a Δ4,5-
unsaturated hexuronic acid (Fig.3B). The double bond between C4 and C5 of the reaction 
product can be detected easily by UV spectroscopy at 232 nm. It has been reported that 
Heparinase I is less active on heparin with reduced amounts of (especially 2-O) sulfation 
(Desai et al., 1993). 
Since heparosan is completely O-unsulfated after the epimerization step (only the 
glucosamine is deacetylated / resulfated), it is questionable whether Heparinase I is able to 
accept this product as a substrate. We performed a pilot experiment to test activity of 
Heparinase I (Sigma-Aldrich) on epimerized N-sulfated heparosan (K5NSepi; Iduron). We 
could not detect any cleavage, and therefore did not proceed. However, potentially this 
method is useful in a combined assay with 2-O-sulfotransferase, giving rise to a rather fast 
and easy assay. 
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Figure 3 – Two methods leading to heparin depolymerization. (A) Nitrous acid efficiently removes the sulfate 
group from the glucosamine, which subsequently is converted to 2,5-anhydro-D-mannose (anh. Man), resulting 
in cleavage of the glycosydic bond. (B) Heparinases catalyze a β-elimination reaction on the glycosidic bond also 
resulting in cleavage. Both GlcA and IdoA are converted to the same Δ4,5-unsaturated hexuronic acid (ΔUA).
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Antibodies 
Antibodies are known for their ability to recognize epitopes in a highly specific way, making 
them very useful for specific detection. Although heparin / heparan sulfate are non-alien 
molecules in mammals and thus typically raising little immunogenic reaction, antibodies 
successfully have been generated using phage display (Dennissen et al., 2002). An antibody 
has been described that recognizes N-sulfated-D-glucosamine linked to L-iduronic acid, while 
D-glucuronic acid and O-sulfation are no epitopes (Kurup, 2007). We tested specificity 
binding properties of this antibody (HS4E4) for heparan sulfate (HS) and K5 polysaccharide, 
N-sulfated K5 (K5NS) and K5NS that is C5-epimerized (K5NSepi). 
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Figure 4 – Recognition and sensitivity of antibody HS4E4 on different heparin-like structures 
 
Figure 4 shows good discrimination between non-epimerized substrates (K5 and K5NS) 
versus epimerized K5NS. Antibody HS4E4 therefore potentially can be used as a tool to 
identify D-glucuronyl C5-epimerase activity in future experiments. The sensitivity on partially 
epimerized substrate still is subject for further testing. However, the potential as a high-
throughput screening method of such an antibody is evident. 
 
Biosensors 
All above mentioned assays are based on in vitro activity measurements of the enzyme. An 
alternative approach would be the detection of D-glucuronyl C5-epimerase activity in vivo. A 
possible solution we have considered, is based on the development of a so-called biosensor. 
The basics of such a tool are based on an binding module that specifically senses L-iduronic 
acid, while D-glucuronic acid is not recognized. Additionally this sensing capacity must be 
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coupled to some kind of reporter module. The binding of L-iduronic acid to the binding 
module should result in a conformational change, which activates the reported module. A 
schematic representation of such system can be seen in figure 5. 
An example of such ligand-binding biosensor has been demonstrated by Guntas and 
co-workers (Guntas et al., 2005). They successfully fused MBP to the β-lactamase (BLA) gene. 
Their resulting (periplasmatic) biosensor facilitates growth of those cells that bind sucrose, 
while those that cannot bind this sugar are restricted in growth by the presence of 
ampicillin. The strength of such tool results from its base of high-throughput selection rather 
than screening, facilitating the use of very large libraries. 
The construction of such tool however is very laborious and risky. Not only should the 
binding module be very and exclusively selective for binding the formed product, also an 
adequate conformational change is needed to activate the reporter module. An additional 
problem for glycosaminoglycans might be the substrate uptake. All described D-glucuronyl 
C5-epimerases act on the polymer heparosan. E. coli will not be able to transport the needed 
oligomeric sugars across the cell membrane. As a result either selection needs to be for a D-
glucuronyl C5-epimerase acting on monomeric D-glucuronic acid, or metabolic engineering 
steps are required such that the needed substrate can be produced by the cell itself. An 
approach would be the introduction of the heparosan biosynthesis operon of the pathogen 
E. coli K5, containing all genes required for the production of heparosan (Petit et al., 1995; 
Sieberth et al., 1995; Hodson et al., 2000; Sugiura et al., 2010). 
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Figure 5 
Schematic representation 
of proposed biosensor. 
The product formed 
(IdoA) can be specifically 
bound by a binding 
module. The resulting 
conformational change 
results in the activation of 
the reporter module, 
introducing a selection 
advantage for the cells 
harboring D-glucuronyl 
C5-epimerase activity. 
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Bottleneck three – Knowledge on glycosaminoglycan modifying enzymes 
Since the identification of heparan sulfate D-glucuronyl C5-epimerase as the biocatalyst 
responsible for L-iduronic acid production in heparin / heparan sulfate, much research has 
been done, expanding our general understanding of this specific enzyme. Although much 
knowledge has been gained on the biochemistry, structural knowledge on this enzyme is still 
lacking.  
 
Key residues of heparan sulfate D-glucuronyl C5-epimerase 
Understanding the catalytic mechanism of any enzyme, requires knowledge on the amino 
acid residues that are involved in catalysis. Close examination of natural variations in D-
glucuronyl C5-epimerase homologs may help to identify key residues of the enzyme. 
Ultimate proof of a key role of residues is typically obtained by site directed mutagenesis of 
candidate amino acids. These residues generally are selected since they are conserved 
and/or based on structural data. Site directed mutagenesis of such catalytic residues to 
dissimilar amino acids, will result in loss of catalytic activity. 
Many animal heparan sulfate D-glucuronyl C5-epimerase sequences are available. 
Almost all have a similar domain distribution and can be well aligned, as seen in Chapter 4. 
An exception is the heparan sulfate D-glucuronyl C5-epimerase gene sequence (accession: 
XP_002189772) from Taeniopygia guttata (zebra finch), which shows a remarkable 
recombination, with the very C-terminus positioned at the N-terminal part of the protein. 
However, based on the large number of undetermined nucleotides in the gene sequence 
data, it cannot be ruled out that this is an artefact due to misassembly of the genome data. 
Based on the multiple sequence alignment of the other animal heparan sulfate D-glucuronyl 
C5-epimerase sequences, this paragraph deals with some speculation on possible key 
residues. 
 
Heparin binding site | Many reports have appeared discussing residues involved in heparin 
and glycosaminoglycan binding. Based on numerous heparin binding proteins, several 
heparin-binding consensus sequences have been proposed (Table 1). Essential in 
glycosaminoglycan binding are basic amino acids (Capila and Linhardt, 2002). Mostly these 
basic amino acids are lysine (K) or arginine (R), although occasionally it also might be a 
histidine (H). Arginine is known to bind tighter to GAGs than lysine, while histidine binds 
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significantly less tightly than the other two. Also glutamine (Q) and tyrosine (Y) residues are 
enriched in known heparin / heparan sulfate binding sites, they are believed to play a role in 
inaction via hydrogen bonding. For example for the antithrombin III binding site it has been 
suggested that the phenolic hydroxyl group of tyrosine might interact with the N-acetyl 
group (Bae et al., 1998). 
 
Table 1 – Consensus glycosaminoglycan binding-sites. Abbreviations: B = basic amino acid; X = hydropathic 
amino acid; T = turn. Apo = apolipoprotein; AT = antithrombin; FGF = fibroblast growth factor. 
GAG binding consensus Examples binding protein Reference 
XBBXBX Vitronectin, Fibronectin Cardin and Weintraub, 1989 
XBBBXXBX Apo E, Apo B, ATIII Cardin and Weintraub, 1989 
XBBBXXBBBXXBBX von Willebrand Factor Sobel et al., 1992 
TXXBXXTBXXXTBB FGF-1, FGF-2, FGF β-1 Hileman et al., 1998 
 
Moreover, molecular modeling studies have shown that these basic residues are distributed 
in such way, that their corresponding secondary structural conformation typically leads to 
orientation at one side of the α-helix (XBBBXXBX) or β-strand (XBBXBX). These basic residues 
(B) will be faced towards the glycosaminoglycan chain, while the hydropathic 
(neutral/hydrophobic) residues (X) are facing the protein core. 
Examination of the murine heparan sulfate D-glucuronyl C5-epimerase amino acid 
sequence reveals several basic amino acids, also conserved in heparan sulfate D-glucuronyl 
C5-epimerase homologs in other animals. Of the mentioned GAG binding sequences (Table 
1), the motif XBBXBX is also present in the murine protein (residue 603-607). However, 
multiple sequence alignment analysis indicates that this motif is only conserved in 
vertebrates. Additionally conflicting are the secondary structure predictions that indicate an 
α-helix at this position, while the XBBXBX motif is seen for β-strands. Therefore it is likely 
that other residues are involved in binding instead, in an alternative binding motif. Highly 
conserved lysine and arginine residues, possibly involved in heparin binding, of known D-
glucuronyl C5-epimerases are indicated in Figure 6. Helical wheel diagrams of some of the α-
helices are included as Supplementary Figure 1, showing orientation of these conserved 
residues at one side of the helix. 
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****
▼
Mmus: 135 KYFDVYGKVVQY-DGYDRFE-FSHSYSKVYAQR----SPYHPDGVFMSFEGYNVEVRDRVKCISGVEGVPLSTQWGPQGYFYPIQIAQYGLSHYSK-------NLTEKPP-- 235 
Hsap: 135 KYFDVYGKVVQY-DGYDRFE-FSHSYSKVYAQR----APYHPDGVFMSFEGYNVEVRDRVKCISGVEGVPLSTQWGPQGYFYPIQIAQYGLSHYSK-------NLTEKPP-- 235 
Btau: 134 KYFDVYGKVVQY-DGYDRFE-FSHSYSKVYAQR----APYHPDGVFMSFEGYNVEVRDRVKCISGVEGVPLSTQWGPQGYFYPIQIAQYGLSHYSK-------NLTEKPP-- 234 
Ggal: 122 KYFEVYGKIAQY-DGYDRFE-FSHSYSKVYTQR----APYHPDGVFMSFEGYNVEVRDRVKCISGVEGVPLSTQWGPQGYFYPIQIAQYGLSHYSK-------NLTEKPP-- 222 
Xlae: 126 KYFEVYGKIAQY-DGFERFE-FSHSYSKVYAQR----GPYHPDGVFMSFEGYNVEVRDRVKCISGVEGVPLSTQWGPQGYFYPIQIAQYGLSHYSK-------NLTEKPP-- 226 
DreA: 104 KYFDVYGRLVQY-DGMERFE-FSHSYSRVYAQR----EPYHPDGVFMSFEGYNVEVRDRVKCISGVEGVPIPTQWGPQGYFYPIQIAQYGLSHYSK-------NLTEKPP-- 204 
DreB: 104 KYFEVYGKVVQY-DGYDRFE-FSHSYSKVYAQR----EQYHPNGVFMSFEGYNVEVRDRVKCISGVEGVPLSTQWGPQGYFYAIQIAQYGLSHYSK-------NLTERPP-- 204 
Tnig: 109 KYFEVYGKVAQY-DGYDRFE-FQHSYSKVYTQR----EPYHPDGVFMSFEGYNVEVRDRVKCISGVEGVPLSTQWGPQGYFYAIQIAQYGLSHYSK-------NLTERPP-- 209 
Gacu: 111 KYFDVYGKVVQY-DGYDRFE-FQHSYSKVYAQR----EPYHPDGVFMSFEGYNVEVRDRVKCISGVEGVPLSTQWGPQGYFYAIQIAQYGLSHYSK-------NLTERAP-- 211 
BflA:  29 KYFEVSGHIAEY-DGYDRFE-WQHSYSRIYQPR----GPYTPAGIFMSFENYNVEIRDRVKAISGVEGVPVSTQWGPDPYFYPIQIAQFGLSHYSK-------NLTEKEP-- 129 
BflB:   6 -------------------------------------------------RGEMGAM-----RRRGEMGVPVSTQWGPDPYFYPIQIAQFGLSHYSK-------NLTEKEP--  59 
Dmel: 131 NYFDVSGAVSTNSNEVAKFN-WVHSTAKVNLPR----GKYDARGVYMYFENYNVEVRDRVKCISAAEGVPVSTQWEKRGYFYPTQIAQFALSHYSK-------NLTEPAP-- 232 
Amel:  62 KYFEIYGKLATY-DGLERFE-WLHSYSKIVNPK----GKYDPRGVFMTFENYNVEVRERVKCISGNDGVPISTQWESQGYYYPTQIAQFGLSHYSK-------NLTEPEP-- 162 
Tcas: 114 KYFEVYGKLATY-DGLERFE-WSHSYSRVYHPK----GKYDPRGVFMYFENYNVEVRDRVKCVSAVEGVPISTQWESQGYYYPTQIAQFGLSHYSK-------NLTEPEP-- 214 
Agam:  86 KYFDVYGSLNVV-DGSRRFD-WTHSYGKVNYPK----GAYDPRGIFMYFENYNVEMRDRVKCISAIDGVPISTQWESQGYFYATQIAQFGLSHYSK-------NLTEPEP-- 186 
Apis:  82 NYFEVYGKIIETDENKKKFH-WSHSYSKIYHQN----GKYDSRGVFTNFQNYKVEERDRVKCVSASEGVPVSTQWNPHGYYYPTQIAQFGLSHYSK-------NLTLPSP-- 183 
Isca:  35 KYFEVYGKLAYR-EGKEVLD-WQHSYSKVMVPQ----ARYQHTGPFLWFENYNVAVRDRVKCISGLEGVPISTQWDPRGHLYPVQIAQFGLSHFSK-------NLSEPRP-- 135 
Spur: 191 KYFEVQGQVVQY-NGAERFE-WQHSNARIYVQ-----DPYKVDGIFMSFHHYNVESRDRVKYFSGVEGVPLSTQWGQQGYFYPIQVAQFGLSHYSK-------NLTERPP-- 290 
Skow: 109 KYFEVYGKIAEY-DGYERFE-WQHSYSKIYYPK----EQYKPDGIFMSFDHYNVELRDRVKCISGIEGVPISTQWGPQGYFYPIQIAQFGLSHYSK-------NLTEQEP-- 209 
Nvec:  35 EYFEIYGEVQKQ-KEKKVLE-WRHSYSEIHESK----FEYDPKGTFLWFQGYHVEGRLRVKCICGKEEVPVSSQWNPNGHYYPIQIAQYGLSHYSSYIAERDDT-------G 137 
Cele:  93 KRFDMTGKLGK--DG-STFE-LYTSYAKMRSPD----STYDPLGPFGHFSTYSVETRDRVRCVSAKTDVPMSTQWDPIPYYYPIQISQYGLQHYSRMKLDSISNKSEASPKD 200 
Cbre:  94 KRFDMTGRVGK--DG-STFE-LFTSYAKMRTPD----ANYDPLGVFGHFSTYSVETRDRVRCISAKTNVPMSTQWDPVPYYYPIQIAQYGLQHYSRMKLESL-NKTD----S 196 
Bmal:  89 KHFDVSGMIFKD-SVARHFE-WSTSHARVRFPDF---NNYDYHGVFGHFASYSVETRDRVRCISAQYGVPLSTQWSAVPYFYPIQIAQYALQHYSRFKTAPS---------- 188 
Hmag:  67 HYYEIYGTFEKVEPGDPLQFTWLNADPNVLNPNQLTFLSYSFQRNYLNFHESDVANRGRVKCICGKYEVPISTQWDKKGYYYPTQIAQYGLSHLSKHYIENQIKMDRTVGHQ 182 
Tadh:  92 SQFGWVGESQNL-NGEKVWS-ISKRKARVVDPI----GRYNYKGPFTWFNFYKVEKRERVKYIDSVTGVPISTQWSQKGYFYPTQICQFALSHFTRLLL----NGTKI---- 193 
                                                                                                                               
                                                                                                                               
                                                                                                                               
Mmus: 315 LFTVHYVSNT-----------------QLIAFRDR------DIYYGIGPR--TSWSTVTRDLVTDLRKGVGLS-NTKAVKPTKIMP----KKVVRLIAKGKGFL-DNITIST 399 
Hsap: 314 LFTIHYVSNA-----------------QLIAFKER------DIYYGIGPR--TSWSTVTRDLVTDLRKGVGLS-NTKAVKPTKIMP----KKVVRLIAKGKGFL-DNITIST 398 
Btau: 314 LFTVHYVSNT-----------------QLIAFKER------DIYYGIGPR--TSWSTVTRDLVTDLRKGVGLS-NTKAVKPTRIMP----KKVVRLIAKGKGFL-DNITIST 398 
Ggal: 302 LFTVHYVSNT-----------------QLIAFRER------DIYYGIGAR--TSWSTITRDLVTDLRKGVGLS-NTKAVKQTRIMP----KKVVRLIAKGRGFL-DNVTISA 386 
Xlae: 304 IFTVHYITNT-----------------QLIAFRDH------DVFYGVGSR--TAWSTLTRDLVTDLKKGVGLS-NTKAVKQTKIMP----KKVVQIVVKGSGFL-DNITIST 388 
DreA: 282 PYIIHYITSP-----------------LLLSFKDK------EVIYGIGPR--ATWSTVSRDLMTDLRKGVGLS-NTKVVKATKIMP----RRVVQLVLKGSGFI-SNITVSS 366 
DreB: 282 PFVIHYVTTT-----------------QLILLKDR------DITYGIGPR--TTWTTVTRDLLTDLRKGIGLS-NTKAVKATKTMP----RRVVKLVVHGTGTI-DNITIST 366 
Tnig: 271 PFVIHYVTST-----------------QLIAFKDR------DVTYGIGPR--TGWSTLTRDLLTDLRKGVGLS-NTKAVKATKIMP----RRVVRLVLHGRGFV-DNVTIST 355 
Gacu: 290 PFTIHYVTNA-----------------QLIAFKDH------EITYGIGAR--GAWSTLTRDLLTDLRKGVGLS-NTKAVKATKIMP----RRVVRLVLHGRGFV-DNVTIST 374 
BflA: 221 -YILHYTSGQ-----------------QLISARGT------SIYYGLGPR--TDWSLVTRDLLCDLRKGVGLS-NSKSVKKTKITI----KRVSKVVLQGKGRI-SNITMAT 304 
BflB: 151 -YILHYTSGQ-----------------QLISARGT------SIYYGLGPR--TDWSLVTRDLLCDLRKGVGLS-NSKSVKKTKITI----KRVSKVVLQGKGRI-SNITMAT 234 
Dmel: 309 NYSLHYIPAD-----------------LLLSVQDT------NIYYGLGGSALNKWRHITRDLHIDLQKGIMG--DKRSPLKIRRSD----LEVISIGFLGLGFF-DNITLST 394 
Amel: 238 IYYLHYITSN-----------------IVLHTYNN------HVYYGIGQI-NHQWRRFTRDLVIDLQKGLYL--NDKNKKKMSRSK----LKIVKITLYGSGMI-DNVTLST 322 
Tcas: 290 IYNLHYITSD-----------------VLITVQDN------NVYHGLGMN--QEWKKLTRDLIVDLQKGLNYLDKDKSKRKIPKSK----LKIITILLRGYGAI-DNLTLSS 375 
Agam: 264 LYHVYYILAD-----------------LLIGVQDE------NIYYGIGLNCTGGWKHLTRDLFVDLQKGLPQYASTDKRRKMRRTE----LKVVEISLLGNGSI-DNLTLST 351 
Apis: 246 VWNLHYICSR-----------------TFIFAKGH------NIYHGMHCGREFGWKKLTRNVLVDLQKGLHVL--KKTTAKMFRSK----YKLCDFKLYGVGFL-DNLTLSS 331 
Isca: 217 LYGVHYIMTD-----------------THLAVDDR------DIYYGIGTS--RSWMHLTRDLGVDLVKGLSFG-QHRTAARP--RN----LRVHSIVLRGHGLL-DNLTLSS 299 
Spur: 358 IISLVYTTDD-----------------DGFVIGNR------KVTYGLGPV--TQWRKITRALQIDYRKAMASLSTLKYKLTRKFIL----QRLLRIELRGHGFI-DNIEIGT 443 
Skow: 286 YFHIHYTTSR-----------------EAISRRGT------HIYYGLGSC--RSWRTFTRDLLNDLRKGVGQT-NGKSVKKAKVSL----RSIVKLSVQGFGRI-DNVKLST 370 
Nvec: 221 ---IHYTSDE-----------------EMISVKQN------EIFMGIGTW--KGWRKITRNLDTDLRKGLRLS-EKSPNKKPKNTPKFSVTEIQTITLKGSGCI-DNITLSR 302 
Cele: 278 LVLINYVYSEGNGKCVWQEEERISDD-YIVQKPKKDGQVSY-SYSYIGNSPIGEWSTVTRDLLVDVARALSSG-DNRKKDDNVVLHAG-DLRLVSLGFRGELTVKQKITQRR 389 
Cbre: 276 LVLINYVFSEGNGKCVWQEEEKSFDDEFIVQKPKKDGQVSY-SYSYIGSKPFGEWSTVTRDILVDVARALSSG-ENRKKDDNVVLHPG-DVRLVSLGFRGQLAVKQQIFQRE 388 
Bmal: 263 TILLHYVHN---------------DDEQCVSHNKKTSKVEYNYSLGAEPN-PNEWRWICRDLLVDTGDVI----------------------LDSITFRGHSVI-RSFEQRS 339 
Hmag: 287 -YIMQYILDD-----------------VMIEKRNLN-----QIVHGLGRN--VFRSEITRDLNVDLVKGL-LS--GKHSGDTFGI---KIQKILSLDIDNVQYV-KAVQFVY 370 
Tadh: 272 QFTIRYSTAK-----------------VGVSFSERSK----TVIYGIGTR--NVLSRITRDLEIDLCKALLLERRRKGSRKGALSKKAALISVDAVTLQGSGLL-GKLSLVD 363 
                                                                                                                               
                                                                                                                               
                                                                                                                               
Mmus: TAHMAAFFAASDWLVRNQDE-KGGWPIMVTRKLGEGFKSLEPGWYSAMAQGQAISTLVRAYLLTK-DYVFLSSALRATAPYKFPSEQHGVKAVFMNKHDWYEEYPTTPSSFVLNGF 513 
Hsap: TAHMAAFFAASDWLVRNQDE-KGGWPIMVTRKLGEGFKSLEPGWYSAMAQGQAISTLVRAYLLTK-DHIFLNSALRATAPYKFLSEQHGVKAVFMNKHDWYEEYPTTPSSFVLNGF 512 
Btau: TAHMAAFFAASDWLVRNQDE-KGGWPIMVTRKLGEGFKSLEPGWYSAMAQGQAISTLVRAYLLTK-DHIFLNSALRATAPYKFLSEQHGVKAVFMNKHDWYEEYPTTPSSFVLNGF 512 
Ggal: TAHMAAFFAASNWLVRNQDE-RGGWPIMVTRKLGEGFRSLDPGWYSAMAQGQAISTLVRAYLLTK-EHAFLSSALRATAPYKLPSEQHGVKAVFMNRHDWYEEYPTSPSSFVLNGF 500 
Xlae: TAHTAAFFAASDWLVRNQDA-KGGWPIMVTRKLGEGFKALEPGWYSAMAQGQAISTLVRAYLLTK-EQYYLDSALRATAPFKLPSEKHGVKAVFMNKYDWYEEYPTTPSSFVLNGF 502 
DreA: TAHMAAFFAASDWLLHNQDE-HGGWPIKVTRKLGEGFKSLEPGWYSAMAQGQAMSTLVRAYLVTH-NPSYLGAAIRATSPFKRTPEQHGVKATFMNKFDWYEEYPTTPSSFVLNGF 480 
DreB: TSHMAAFYAASDWLVRNQDE-RGGWPIMVTRKLGEGFRALEPGWYSAMAQGQAMSTLVRAYLMTK-DDRYLKAALRATGPFKLPSEQHGVKAVFMNKYDWYEEYPTIPSSFVLNGF 480 
Tnig: TAHMAAFFAASDWLLRNQDE-RGGWPIMVTRKLGEGFRA--PG----ARLGQAMSTLVRAYLFTK-DQAYLNAALKAVGPYKVPSAQHGVKAVFMNKYDWYEEYPTTPSSFVLNGF 463 
Gacu: TAHMAAFFAASDWLMRNQDE-RGGWPIMVTRKLGEGFRPLEPGWYSAMAQGQAMSTLVRAYLLTR-EPAYLNAALKAVGPFKVPSAQHGVKAVFMNKYDWYEEYPTTPSSFVLNGF 488 
BflA: SSHIPQFFDAADWFVRNQDD-RGGWPINVIRKLVDGMQELPPGWYSAMAQGQAMSTLTRAFLRTR-DRRYLDAALRGTKPFRVPSESGGVLAVFMNKHRWYEEYPTTPSSFVLNGF 418 
BflB: SSHIPQFFDAADWFVRNQDD-RGGWPINVIRKLVDGMQELPPGWYSAMAQGQAMSTLTRAFLRTR-DRRYLDAALRGTKPFRVPSESGGVLAVFMNKHRWYEEYPTTPSSFVLNGF 348 
Dmel: SDHLAHFYDAAEWFVHNQDPKTGGWTNPVRRSL-NGFAELRPGWISAMGQGHAISVLARAYWHSGGDERYLRAAAAGLQPYRVYSRDGGVLAQFMDKFYWYEEYPTTPPSYVLNGF 509 
Amel: SEHMEQFYDAARWFVSNQNITSGGWANPVRRKVATGMATLEPGWYSSMGQGHAISVLARAYYHSG-EEKYLQAAVRGLQPFKLSSNKGGVAAIFLNKYVWYEEYPTTPSSFILNGF 437 
Tcas: SEHIQQFYDAAEWFVRHQDTETGGWPIPVKRKLASGFHDLQSGWYSAMGQGHAISVLSRAYHHSGGDVRYLQAALAGLKPFQVPSTKGGVLATFLNKYHWYEEYPTKPASFVLNGF 491 
Agam: SEHISHFYDAAEWLIRHQDPSTGGWPIPVRRKLGSGFGELARGWYSAMAQGHAISLLARAYYHSKGDKRYLRAALDGLKLFRIPSYQGGVLATFLGKYAWYEEYPTTPHSFVLNGF 467 
Apis: SDHISQFYAAAHWFNKHQDKESGGWINPVTRKISPVIKPLKPGWLSAMGQGQAISLLSRAFFHSGGNEMYLKTAHTALKPFKIPTKNGGVLSEFMNLHPWYDEYPTVPPIFILNGF 447 
Isca: SAHEAHFFDAADWFVRRQDD-AGGWPIKVTRRLSNGMLELEPGWYSAMAQGQAMSVLTRAFAATG-KRDYLDAALRAVGPFRIRSESRGVMTTFLGKFVWYEEYPTVPSSFVLNGF 413 
Spur: SLHMYHFYDAADWLVHHQDE-RGGWPIMVERILDDK-MSLSPGWYSSMAQGQAMSVLTRAYIKSR-RKKYIKAALHAARLFQIPSAQGGVLARFMDKYTWYEEYPTSPGSFVLNGF 556 
Skow: TAHMAHFYDAANWLLNNQDK-KGGWPIWITRILIDEMGELPPGWYSAMAQGHAMSVLVRAYRKSG-KPEYLKAALKATYPFNKLSSQGGVKAVFLDKYPWYEEYPTNPSSFVLNGF 484 
Nvec: SARLDFFMAAANWFVRNQDK-NGGWPITVKRKIMEGV-EMAPGWYSAMAQGQAMSLLTRAYYHTN-NSVYLEAALKATSLFGVPANKGGVRAMFMDKYPWYEEYPTTPSLYVLNGF 415 
Cele: EQHSHAFYAAADWLVKNQND-RGGWSVPVERSIAERKLVLPPGWHSAMAQGHGISVLTRAFKHFN-DEKYLKSAAKALKLFKINSSDGGVRGEFFG-NIWYEEYPTTPGSFVLNGF 502 
Cbre: EQHLHAFKSAADWLAENQDV-KGGWAVPVERSIADRKLVLPPGWHSAMAQGHGISVLTRAFKHFD-DEKYLNSALKALELFKTNASDGGVRAEFFG-NVWYEEYPTTPGSFVLNGF 501 
Bmal: SAHLEHFLVAADWLTNNQDE-HGGWSVPVERSIADKRLILPAGWYSAMAQGHALSVLTRAYVVTN-DMKYFQGAKRALQLFKIKASKGGVLNELFG-HPWFEEYPTTPGTFVLNGF 452 
Hmag: EDHIAKFMAAADWLLYYQDD-QGGWKTNVSRIVIPEIR-TDAGWYSAMGQGQAISLLCRVYFYTK-DTKYLNSALRATHLFRIPSAKNGILAMLFDKYPWYEEYPTVPPLYVLNGF 483 
Tadh: SADKDFFIDAANWLVANQDR-SGGWPVSVSHKINKLTLTLKPGWYSAMAQGQAMSTLTRAFHLTK-EYKYLRTALLATKPFHIPASEGGVLATVFGTYKFYEEYPTKIPLLVLNGF 477 
                                                                                                                               
                                                                                                                               
                                                                                                                               
Mmus: MYSLIGLYDLKETA--GE-------TLGKEARSLYERGMESLKAMLPLYDTGSGTIYDLRHFML-GIAPNLARWDYHTTHINQLQLLSTIDESPIFKEFVKRWKSYLKGSRAKHN  618 
Hsap: MYSLIGLYDLKETA--GE-------KLGKEARSLYERGMESLKAMLPLYDTGSGTIYDLRHFML-GIAPNLARWDYHTTHINQLQLLSTIDESPVFKEFVKRWKSYLKGSRAKHN  617 
Btau: MYSLIGLYDLKETA--GE-------KLGKEARSLYERGMESLKAMLPLYDTGSGTIYDLRHFML-GIAPNLARWDYHTTHINQLQLLSTIDESPIFKEFVKRWKSYLKGSRAKHN  617 
Ggal: MYSLIGLYDLKETA--GE-------KLGKEARLLYERGMESLKAMLPLYDTGSGTIYDLRHFML-GTAPNLARWDYHTTHINQLQLLSTIDEAPIFKEFVRRWKSYLRGGRAKHN  605 
Xlae: IYALLGLHDLKETA--GE-------RQGKEARLLYERGIESLRAMLPLYDTGSGSIYDLRHFML-GTAPNLARWDYHTTHINQLQLLASVDGSPIFRDFIRRWKSYLRGGRAKHN  607 
DreA: IYSLIGLYDVAETA--GN-------KLGREAGILFSQGLESLKAMLPLFDTGSGTVYDLRHFTL-GVALNLARWDYHTTHINQLQLLASIDGAPIFRDHVKRWKTYLKGGRAKHN  585 
DreB: IYSLIGLFDLAQTA--GE-------KLGRDAGQLYSKGMESLKVMLPLYDTGSGTIYDLRHFIL-GTAPNLARWDYHTTHINQLQLLGTIDNSPIFRDSVKRWKSYLKGGRAKHN  585 
Tnig: IYSLLGLFDLTETA--GE-------KLGREARQLFSHGMESLKAMLPLFDTGSGSIYDLRHFML-GTAPNLARWDYHTTHINQLQLLASIDSSPIFRDVVKRWKNYLKGIRAKHN  568 
Gacu: IYSLLGLHDVSDTA--GE-------KLGREAGLLFARGMESLKAMLPLFDTGSGSIYDLRHFML-ATAPNLARWDYHTTHINQLQLLASIDNAPVFRDVVKRWKNYLKGIRAKHN  593 
BflA: IYSLIGLYDLKETA--PA-------QEGREAAELFEEGMRSLKAMMPLYDTGAGTVYDLRHFML-GIAPNIARWDYHTTHVNLLQLLVSIDPDPALAATLRRWVGYTKGRRAKHN  523 
BflB: IYSLIGLYDLKETA--PA-------QEGREAAELFEEGMRSLKAMMPLYDTGAGTVYDLRHFML-GIAPNIARWDYHTTHVNLLQLLVSIDPDPALAATLRRWVGYTKGRRAKHN  453 
Dmel: IYSLLGLYDLNSTA--PG-------KIAREAGKLFAQGMHSLKKMLLLFDTGSGTSYDLRHLSL-GVAPNLARWDYHATHVNQLLLLATIDSDPLIAQTAERWKGYMFGRRAKHN  614 
Amel: IYSLIGLYDLKSIA--AG-------KDAEEASRLFNQGMTSLKNMLTLYDTGSGTTYDLRHFTL-KTAPNLARWDYHSTHINQLLLLNSIDNDSIFTTTAERWIGYMNGKRAAHN  542 
Tcas: IYSLLGLYDLMTIA--PP-------GQADEAEFLFREGMISLKGMLLFYDMGSVTSYDLRHVTL-GVAPNLARWDYHATHINQLLLLSTIENEPLFAQTAERWIGYMAGKRAAHN  596 
Agam: IYSLLGLYDLNSTA--PA-------NQSNEAAVLFEQGMASLKKMLLLYDTGSGTSYDLRHFTL-GIAPNLARWDYHATHVNQLLLLATIDPDPLISQTAERWKNYMVGKRAPHN  572 
Apis: MYSLIGLYDLFSLAPNGS-------EVSQEAHSLWKQGMTSLKNLLPLFDMGSRSAYDLRHVTL-DIAPNIARWDYHATHINQLLLLATLDNATVIQTTAKRWIGYMNGARASHN  554 
Isca: IYSLFGLYDLKSTC--GE---GSSEELCRDAGKLFADGMVSLKRMLPLFDTGSGTVYDLRHFSL-GVAPNLARWDYHTTHINQLLYLGTIDDDPVFGATAERWVQYMKGKRAPHN  522 
Spur: IYSMIGLYDVLSVA--DV-------EESRESRRLYDEGMVSLKAMLLLFDMGTGTLYDLRHLAL-GKAPNVARWDYHATHISQLQLLASIDPDPIFKETVARWIGYTKGKRARHN  661 
Skow: IYSLIGLYDLMMTA--SD-------EDRVEAERLYREGLTSLKALLPLYDTGSGTVYDLRHITT-GVAPKLARWDYHTTHISQLQLLSSIEKNSLFQNTLERWIEYMKGKRAKHN  589 
Nvec: IYSLVGLHDLTLAA---------P-KK-TEAKAFFDDGMKSLKALLLMFDAGSGTFYDLRHVSM-RAPPNLARWDYHTLHVSLLHFISGIDSDRVVKDTAVRWTGYTKGKRAKHN  518 
Cele: LYSLIGLYDLSQLELMIDENDETMRAKIQEAQELYSAGVRSLKQLLPLYDTGSGTIYDLRHVAL-GTAPNLARWDYHAVHVYLLKWIAGIEKDEVLSKTADRWIGYAYGKRAKHN  616 
Cbre: LYSLIGLYDLSKLESLN----SEHNSKIQEAKELYSTGIQSLKQLLPLYDTGSGTIYDLRHVAL-GSAPNLARWDYHAVHVYLLKWIANLEKDDFLSKTADRWIGYAYGKRAKHN  611 
Bmal: LYSLIGLYDFAQIS--------NSHDSDNDSAALFSAGLESLRIFLPLFDTGSGTFYDLRHLGL-KTAPNLARWDYHSVHIYLLKWLYIITKDEFFNVTANRWVSYATGHRAKHN  558 
Hmag: IYSLFGLYDLLNIA--SS-------KDAAEAQYLFYQGMNSLETVLPLFDNGHGSFYDLRHISIPGSMPNRARWQYHRVHIEQLHAIVELTKNSVVNRTLQRWIGYGWGILAKHN  589 
Tadh: IYSLFGLYDLKSAV--ED---VNAHNITSDAAELYRDGIRTLKNLLPLYDAGSDTFYDLRHVVI-KAEPIIARSTYHALHISQLLHIDTIEEDPLFARIAKRWMEYMNGGRANHN  586 
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Figure 6 – Multiple sequence alignment animal D-glucuronyl C5-epimerases; conserved residues putatively 
involved in heparin binding (grey shading) or residues that could be involved in catalysis (black shading). 
Putative N-glycosylation sites are indicated with asterisks (below sequence). The start positions of all made 
truncations are indicated as triangles. Secondary structure predictions are indicated as cylinders (α-helices) and 
arrows (β-strands). Abbreviations: Mmus: Mus musculus (mouse); Hsap: Homo sapiens (human); Btau: Bos 
taurus (cow); Ggal: Gallus gallus (chicken); Xlae Xenopus laevis (frog); DreA: Danio rerio isoform A (zebrafish); 
DreB: Danio rerio isoform B (zebrafish); Tnig: Tetraodon nigroviridis (pufferfish); Gacu: Gasterosteus aculeatus 
(three spined stickleback); BflA: Branchiostoma floridae isoform A (lancelet fish); BflB: Branchiostoma floridae 
isoform B (lancelet fish); Dmel: Drosophila melanogaster (fruit fly); Amel: Apis mellifera (honey bee); Tcas: 
Tribolium castaneum (red flour beetle); Agam: Anopheles gambiae (malaria mousquito); Apis: Acyrthosiphon 
pisum (pea aphid); Isca: Ixodes scapularis (black-legged tick); Spur: Strongylocentrotus purpuratus (purple sea 
urchin); Skow: Saccoglossus kowalevskii (Acorn worm); Nvec: Nematostella vectensis (starlet sea anemone); 
Cele: Caenorhabditis elegans (nematode); Cbre: Caenorhabditis brenneri (nematode); Bmal: Brugia malayi 
(filarial roundworm); Hmag: Hydra magnipapillata (freshwater polyp hydra); Tadh: Trichoplax adhaerens 
(Placozoa).  
 
Catalytic residues | Experimental proof suggests the C5-epimerization reaction to proceed 
via the abstraction and re-addition of the proton at the C5-atom (Chapter 1). This requires 
catalytic residues acting as a proton acceptor and a proton donor. The re-added proton is 
not the C5-abstracted proton, but a proton from the medium (water). Likely there are at 
least two residues involved in catalysis in a two-base mechanism; one for deprotonation and 
one for reprotonation. 
While the mechanism of the heparan sulfate D-glucuronyl C5-epimerase still needs to 
be elucidated, molecular mechanisms have been proposed for the other hexuronyl C5-
epimerases. Dermatan sulfate D-glucuronyl C5-epimerase are believed to proceed via a β-
elimination via a 4,5-unsaturated hexuronic intermediate step (Pacheco et al., 2009), 
similarly as seen for heparinase cleavage. However, in contrast to the β-elimination step in 
lyase activity, the C5-epimerization is not finished at this intermediate, but instead the 
glycosidic linkage is restored and the C5-atom is reprotonated. Two histidine residues (His-
205 and His-450) are believed to act as general base and general acid in the reversible 
epimerization reaction. A third residue is tyrosine residue Tyr261 and is believed to be 
essential in mediating the β-elimination reaction. This is based on a equivalently positioned 
tyrosine in the structure of heparinase II (Shaya et al., 2006). 
A similar mechanism has been proposed for alginate D-mannuronan C5-epimerases 
(Jerga et al., 2006). However, structural data for AlgE4A suggests another mechanism, in 
which the glycosidic linkage remains intact (Rozeboom et al., 2008). This mechanism is 
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similar to the proposed mechanism of some polygalacturonic acid lyases (Charnock, 2002). 
Instead of β-elimination, the removal of the C5-proton leads to the formation of a carbanion, 
with a delocalized negative charge at the carboxyl-group. For the polygalacturonic acid 
lyases this negative charge is stabilized by the divalent cation Ca2+, but for the alginate C5-
epimerase the carboxylate group is likely to be protonated by two aspartate residues, 
enhancing stability and reactivity instead. A tyrosine residue (Tyr-149) acts as a general base, 
responsible for the C5-proton abstraction. To prevent lyase activity, the abstracted proton is 
removed from the active site to prevent donation of the proton to the glycosidic oxygen. The 
proposed general acid responsible for the reprotonation is a histide residue (His-154). 
Via which catalytic mechanism the heparan sulfate D-glucuronyl C5-epimerase acts is 
hard to predict. We propose two alternative mechanisms (Fig.7), based on the mechanisms 
of the other two hexuronyl C5-epimerases. A β-elimination reaction mechanism (Fig.7A) 
similar to dermatan sulfate D-glucuronyl C5-epimerase would require a general base (B:), a 
general acid (B:H) and a residue that facilitates the β-elimination (A:). A mechanism similar 
to that of the alginate C5-epimerase (Fig.7B) would also require a general base (B:), a general 
acid (B:H), but additionally needs a stabilizing factor. In lyases having such mechanism this 
stabilization generally is achieved via ionic interaction with the divalent cation Ca2+. 
However, we could not detect any calcium ion in the heparan sulfate D-glucuronyl C5-
epimerase (Chapter 4). This not necessary excluded the possibility of such mechanism, as 
also the alginate C5-epimerase lacks a calcium ion in the active site, so this stabilizing factor 
could be analogous to the alginate C5-epimerase. 
The catalytic mechanisms of either known hexuronic acid C5-epimerases have a 
highly conserved tyrosine and one or two histidines involved. Only few histidines and 
tyrosines are conserved in the family of heparan sulfate D-glucuronyl C5-epimerases (Fig.6). 
Especially promising are Tyr-168 and Tyr-222, since recent research by Li and co-workers 
indicated complete loss of activity upon substitution of these residues by alanine (Li et al., 
2010). Based on our multiple sequence alignment (Fig.6) we only propose a potential role in 
catalysis for Tyr-168 which is, in contrary to Tyr-222, completely conserved in both animal 
heparan sulfate D-glucuronyl C5-epimerase (Chapter 4) and RED-C5-epimerase (Chapter 3). 
No studies have been performed yet on the conserved C-terminal residues. Very 
promising are the C-terminal residues Tyr-561 and Tyr-579, since these residues also are 
completely conserved in all the prokaryotic sequences (Chapter 2). Additionally promising 
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are residues Tyr-501, His-580 and His-583 which are well-conserved in prokaryotes, and Tyr-
320, His-565, Tyr-609 and His-617. The latter four are not completely conserved in all 
prokaryotic sequences, however, they are conserved between MmC5 and RED-C5-epimerase 
(Chapter 3). Conserved residues potentially involved in heparin binding are in close 
proximity as well, especially when considering their spacial orientation based on secondary 
structure predictions (Supp. Fig. 1). All these conserved residues would be a great start for 
site directed mutagenesis studies. 
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Figure 7 – Possible catalytic mechanisms of the D-glucuronyl C5-epimerase; (A) β-elimination based 
mechanism. Upon proton abstraction a 4,5-unsaturated hexuronic acid is formed. Reprotonation of C5 results 
in reformation of the glycosidic linkage. An acidic amino acid “A” facilitates the breakage of the glycosidic bond. 
(B) Non-β-elimination based mechanism. The removal of the proton leads to the formation of a carbanion, with 
a delocalized negative charge at the carboxyl-group. This negative charge needs to be stabilized, here indicated 
by “S”. Reprotonation of the carbanion results in the reformation of a hexuronic acid.
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Enzyme structure of D-glucuronyl C5-epimerase 
To date, structural knowledge of heparan sulfate D-glucuronyl C5-epimerase is still lacking. 
In Chapter 4 of this thesis we have discussed secondary structure predictions of the murine 
heparan sulfate D-glucuronyl C5-epimerase. These secondary structure predictions indicate 
the C-terminus to be composed of seven α-helices, while the N-terminal domain has no 
significant homology to any known sequence. Based on predictions with PHYRE Protein Fold 
Recognition Server (http://www.sbg.bio.ic.ac.uk/phyre/; Kelley and Sternberg, 2009), these 
helices are likely to be arranged in an (incomplete) alpha/alpha toroid fold. This fold 
comprises up to seven alpha-hairpins being arranged in closed circular array. A topology 
diagram of the putative secondary structure organization of the murine heparan sulfate D-
glucuronyl C5-epimerase is provided in Figure 8. 
 
 
Figure 8 – Topology diagram of the seven predicted α-helices (cylinders) of heparan sulfate D-glucuronyl C5-
epimerase carboxy-terminus. 
 
Members that are proven to have an alpha/alpha toroid fold include glycosidases and lyases 
(e.g. the earlier mentioned polygalacturonic acid lyase (Charnock, 2002) and heparinase II). 
Also the 13 α-helices of the N-terminal domain of DS-epimerase 1 are predicted to adopt in 
an incomplete alpha/alpha toroid fold (Pacheco et al., 2009). Unfortunately, none of these 
known alpha/alpha toroid protein structures, nor any other structure in the Protein Data 
Bank (PDB), has sufficient homology with a heparan sulfate D-glucuronyl C5-epimerase to 
generate a reliable 3D-model. 
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Despite the lack of template structures with sufficient homology, we tried several methods 
of protein threading, scanning the C-terminal amino acid sequence (aa 400-618) of the 
heparan sulfate D-glucuronyl C5-epimerase against a database of solved structures (Table 2). 
 
Table 2 – Used protein threading methods to model the heparan sulfate D-glucuronyl C5-epimerase C-terminus 
Model Method Templates Website (Reference) 
Green Phyre 1gmx http://www.sbg.bio.ic.ac.uk/~phyre          
(Kelley and Sternberg, 2009) 
Blue hhPred / 
modeller 
3gt5, 3k7x, 2gz6, 
3pmm, 1gxm 
http://toolkit.tuebingen.mpg.de/hhpred      
(Sali et al., 1995; Söding et al., 2005) 
Red Itasser 2okx, 3k7x, 1gxm, 
1r76 
http://zhanglab.ccmb.med.umich.edu/I-TASSER           
(Zhang, 2008; Roy et al., 2010) 
Purple Robetta 2zbl http://robetta.bakerlab.org                             
(Chivian et al., 2003; Kim et al., 2004) 
 
Used template structures include (pectate) lyases, glycosyl hydrolases and N-
acetylglucosamine 2-epimerases (Table 3), all proteins with potential similar molecular 
mechanisms as a C5-epimerase. 
 
Table 3 – Used templates for protein threading 
Template Description Organism 
1gxm Pectate lyase Cellvibrio cellulosa 
1r75 Pectate lyase Azospirillum irakense 
2okx Rhamnosidase Bacillus Sp. 
2zbl Putative isomerase                                              
(similar to N-acetylglucosamine 2-epimerase) 
Salmonella enterica 
2gz6 N-acetylglucosamine 2-epimerase Anabaena Sp. 
3gt5 N-acetylglucosamine 2-epimerase Xylella fastidiosa 
3k7x Lin 0763 protein (glycosyl hydrolase fam76) Listeria innocua 
3pmm Possible member GH105 family 
(rhamnogalacturonyl hydrolase) 
Klebsiella pneumonia 
 
Interestingly, the generated models all show the predicted alpha/alpha toroid fold of the α-
helices with an RMSD < 5, making us confident that the C-terminus of heparan sulfate D-
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glucuronyl C5-epimerase can adopt a similar configuration. However, none of these 
generated models successfully passes quality checks (Z-scores ≤-2), and obviously, large 
deviation is seen for the coils linking the helices. Even though the exact orientation of the 
helices could not be determined, we propose a tentative model in Figure 9, indicating the 
seven predicted α-helices and the predicted alpha/alpha toroid fold.  
 
 
Figure 9 – Structure modelling of the heparan sulfate D-glucuronyl C5-epimerase carboxy-terminus. 
 
However, to get ultimate confirmation of the heparan sulfate D-glucuronyl C5-epimerase 
structure, a high resolution crystal structure is required. And although we have made many 
attempts to crystallize the bacterial candidate C5-epimerases RED-C5-epimerase and TTE-C5-
epimerase (Chapter 3), none of these trials have been successful thus far. 
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In conclusion 
We aimed to develop industrially applicable of the (murine) heparan sulfate D-glucuronyl C5-
epimerases, to be used in the chemo-enzymatic synthesis of highly defined heparin variants. 
The natural enzyme has some serious limitations in production and use, of which some have 
been overcome upon fusion to a solubilizing protein tag (MBP). Improvement in protein 
stability is still desirable, however requires an adequate method to assay protein activity. 
 We have tested a range of analytical methods to monitor D-glucuronyl C5-epimerase 
activity. Although not every method was equally successful, eventually we were able to 
show activity with both HPLC-PAD and the tritium labeled substrate method. However, for 
further protein optimization by means of directed evolution experiments, a medium to high-
throughput method is indispensable. Potential assays could be based on heparinase I in 
combination of 2-OST, or on an antibody against L-iduronic acid (e.g. HS4E4). A biosensor 
sensing L-iduronic acid also has great potential, but its development is expected to be an 
extensive and laborious project. 
 The lack of structural knowledge of the heparan sulfate D-glucuronyl C5-epimerase, 
makes it hard to predict via what mechanism the catalysis proceeds, let alone to predict 
mutations to improve protein characteristics. However, based on sequence analysis and 
secondary structure predictions we were able to identify different domains, of which the C-
terminus is most conserved. This domain is likely to consist of seven α-helices that is 
predicted to adopt an (incomplete) alpha/alpha toroid fold, a common fold in glycosyl 
hydrolases, lyases and the N-acetylglucosamine 2-epimerase. Conserved residues that might 
be involved in substrate binding and catalysis have been indicated. All this adds to the steady 
increase in knowledge on this key enzyme in heparin biosynthesis and brings us closer to the 
understanding and integration of this enzyme in novel heparin production methods. 
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Supplemantary Figure 1 – Helical wheel diagrams of the α-helices (murine heparan sulfate D-glucurnonyl C5-
epimerase) with conserved amino acid residues putatively involved in heparin binding (grey shading) or 
residues that could be involved in catalysis (black shading). 
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Samenvatting 
Het onderzoek beschreven in dit proefschrift is erop gericht om op biotechnologische wijze 
glycosaminoglycanen te kunnen produceren. Er is onderzoek gedaan naar een tweetal 
enzymen, beide betrokken in de biosynthese van twee industrieel relevante 
glycosaminoglycanen, genaamd hyaluronzuur en heparine. 
Hoofdstuk 1 geeft een algemene inleiding in een aantal van de meest voorkomende 
glycosaminoglycanen. Dit zijn biologisch actieve polysacchariden, bestaande uit repeterende 
disacchariden van een hexosamine gekoppeld aan hexuronzuur. De focus van dit hoofdstuk 
ligt met name op de biologische relevantie en de biosynthese van hyaluronzuur, heparine en 
heparine-achtige glycosaminoglycanen. Een gemeenschappelijk aspect binnen deze groep is 
dat ze allen zijn opgebouwd uit glucosamine en glucuronzuur/iduronzuur. Er wordt ingegaan 
op de relevantie van L-iduronzuur en de enzymatische omzetting (oftewel C5-epimerisatie) 
vanuit D-glucuronzuur. Deze omzetting wordt gekatalyseerd door het enzym D-glucuronyl 
C5-epimerase. Daarnaast wordt ingegaan op het feit dat heparan sulfaat D-glucuronyl C5-
epimerase een essentieel enzym is voor de biotechnologische productie van heparine. 
Heparan sulfaat D-glucuronyl C5-epimerases, zoals die in vivo voorkomen in mens en 
dier, blijken ongeschikt te zijn voor gebruik in een industrieel proces. Een potentieel 
alternatief voor deze eukaryote epimerases zijn D-glucuronyl C5-epimerases uit micro-
organismen. Hoofdstuk 2 geeft een overzicht van mogelijke prokaryote D-glucuronyl C5-
epimerases in prokaryoten. Er wordt een overzicht gegeven van micro-organismen waaruit 
glycosaminoglycanen en/of andere L-iduronzuur bevattende polysacchariden zijn geïsoleerd. 
De aanwezigheid van deze polysacchariden suggereert namelijk dat in vivo C5-epimerase 
activiteit aanwezig kan zijn. Het zoeken naar potentiële D-glucuronyl C5-epimerases 
kandidaten is gedaan met behulp van in silico screening methoden, waarbij het humane 
heparan sulfate D-glucuronyl C5-epimerases als query gebruikt is. Afsluitend wordt 
gespeculeerd en gediscussieerd over de mogelijke biologische implicaties van de gevonden 
kandidaat C5-epimerases. 
In hoofdstuk 3 zijn vervolgens vijf van deze beschreven prokaryote kandidaat C5-
epimerases geselecteerd en heterologisch tot expressie gebracht in Escherichia coli 
BL21(DE3). Alle vijf kandidaat C5-epimerases zijn succesvol tot expressie gebracht, waarbij 
een aantal bovendien voldoende zuiver verkregen zijn om kristallisatie-experimenten mee te 
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initiëren. In vitro omzetting van L-iduronzuur naar D-glucuronzuur is bevestigd voor de 
kandidaat C5-epimerase uit de bacterie Bermanella marisrubri sp. Red65, hetgeen het eerste 
experimentele bewijs is van D-glucuronyl C5-epimerase activiteit in een micro-organisme. 
Als een alternatieve aanpak, is er tevens getracht de muizen heparan sulfaat D-
glucuronyl C5-epimerase te optimaliseren voor toepassingen in biotechnologische 
processen. In hoofdstuk 4 staat beschreven hoe twee verschillende microbiële 
expressiesystemen zijn getest voor de heterologe productie van de muizen heparan sulfaat 
D-glucuronyl C5-epimerase, namelijk in Pichia pastoris en Escherichia coli. Het gebruik van 
de gist P. pastoris heeft geen succesvolle enzymproductie opgeleverd. Daarentegen 
resulteerde genexpressie in de bacterie E. coli wel in productie van grote hoeveelheden 
enzym. Het product bleek echter onoplosbaar en onbruikbaar te zijn. De oplosbaarheid van 
deze C5-epimerase is verbeterd door het enzym N-terminaal te fuseren met het “maltose 
binding protein” (MBP). Truncaties van de N-terminus zorgen voor een verdere toename van 
de oplosbaarheid. Deze N-terminale truncaties resulteren echter in verlies van de activiteit, 
ondanks dat de N-terminus van dit enzym slecht geconserveerd is. Significante activiteit is 
wel aangetoond bij het fusie-eiwit waar enkel het signaalpeptide van de C5-epimerase N-
terminus getrunceerd is. Dit bevestigd dat functioneel muizen heparan sulfaat D-glucuronyl 
C5-epimerase kan worden geproduceerd via heterologe genexpressie in E. coli. 
Net als de heparan sulfaat D-glucuronyl C5-epimerase, geeft ook het tweede enzym 
waaraan we gewerkt hebben oplosbaarheid problemen wanneer het geproduceerd wordt in 
E. coli. Hoofdstuk 5 beschrijft een vergelijkingsstudie voor de Pasteurella multosida 
hyaluronan synthase (PmHAS) productie in E. coli. PmHAS is in andere studies al succesvol 
tot expressie gebracht. Er bestaan echter nog limitaties voor optimale enzym productie, 
zuivering en stabiliteit. Derhalve worden twee verschillende PmHAS fusie-eiwitten 
vergeleken, ter verhelpen van deze bestaande limitaties. Er is aangetoond dat de PmHAS 
productie aanzienlijk verhoogd kan worden door een N-terminale fusie met “maltose 
binding protein”, zonder dat dit een negatief effect geeft op de specifieke activiteit van het 
enzym. 
In hoofdstuk 6 wordt een voorbeeld van enzym optimalisatie gegeven, door in plaats 
van het screenen van een grote mutantenbank, een zogenaamde “smart library design” te 
gebruiken. Hiervoor is een beperkte mutantenbank gemaakt van het Pyrococcus furiosus 
phosphoglucose isomerase (PfPGI). Mutaties zijn gebaseerd op voorspellingen, welke 
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gemaakt zijn met Comulator, een bio-informatica methode om gecorreleerde 
aminozuurresiduen te identificeren. De gecreëerde mutantenbank bevat PfPGI mutanten 
met aminozuur variaties voor het sterk gecorreleerde aminozuur paar Pro132 en Tyr133. 
Gebruikmakende van enzymkinetiek metingen is aangetoond dat voor deze mutanten een 
correlatie bestaat tussen de aanwezigheid van een specifiek animozuur paar, en verhoogde 
phosphoglucose isomerase activiteit. We hypothetiseren dat deze verandering in activiteit 
het gevolg zijn van subtiele veranderingen in de eiwitstructuur, met als gevolg 
veranderingen in de metaal-coördinatie in het PfPGI. Om meer inzicht te krijgen in de exacte 
veranderingen zijn er eiwitkristallisaties opgezet. Meerdere verkregen eiwitkristallen worden 
momenteel uitgewerkt en onderzocht. 
Afsluitend worden alle eerdere hoofdstukken samengevat en bediscussieerd in 
hoofdstuk 7. Hierbij worden drie bottlenecks aangeven die opgelost dienen te worden, 
voordat een succesvolle implementatie van deze enzymen in een industrieel proces kan 
worden bewerkstelligd. Naast de behaalde resultaten worden additionele wegen besproken 
om de genoemde enzymen verder te optimaliseren. Bovendien worden verscheidene 
geteste assay methoden, geschikt om de epimerisatie van D-glucuronzuur aan te tonen, 
bediscussieerd om hun bruikbaarheid. Ook wordt er gespeculeerd over welke aminozuur 
residuen mogelijk een cruciale rol hebben in de D-glucuronyl C5-epimerase en worden de 
mogelijkheden binnen eiwitstructuur / vouwing besproken. 
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